Professional Documents
Culture Documents
MGD
MGD
NAVIGATION
Top right corner of book
Contents
Takes you to the table of contents. Click on the page numbers to
go to the chapter of interest.
Index
Takes you to the index. Click on the page numbers for the term
of interest.
Back
Takes you to the last page you were looking at. It is like the back
arrow button on an internet browser.
Up arrow
Takes you to the previous page.
Down arrow
Takes you to the next page.
You can also change pages using the scroll wheel on your mouse
or the Page Up and Page Down keys.
Bookmarks panel to the left of book
Click the plus sign (+) next to the bookmark to expand it, then
click on your topic of interest.
Back Index Contents
How to use this ebook (cont.)
Links
Any text formatted like this is an active link.
Most links take you to another part of the book.
Some are hyperlinks that connect you to a website (a link on a
reference title goes to its PubMed abstract). To return to this
book, click the back arrow on your internet browser.
Searching the book
Enter Ctrl F to open the Find function in the top right corner of
the window.
Request for comment on guidelines
We welcome your comments. See contact information.
Back Index Contents
Management Guidelines
Developmental Disability
Back Index Contents
Available from Terapeutic Guidelines Limited (TGL):
eTG complete
eTG complete is TGLs core product, designed for use on
computers and available online or on CD. It has the latest
version of all topics published by TGL, including several
that are only published electronically. eTG complete also
provides references, links to other independent information
and patient information sheets (for download).
miniTG
miniTG is the portable (ofine) version of eTG complete,
for use on mobile phones and handheld devices.
Print titles
Terapeutic Guidelines: Analgesic
Terapeutic Guidelines: Antibiotic
Terapeutic Guidelines: Cardiovascular
Terapeutic Guidelines: Dermatology
Terapeutic Guidelines: Endocrinology
Terapeutic Guidelines: Gastrointestinal
Terapeutic Guidelines: Neurology
Terapeutic Guidelines: Oral and Dental
Terapeutic Guidelines: Palliative Care
Terapeutic Guidelines: Psychotropic
Terapeutic Guidelines: Respiratory
Terapeutic Guidelines: Rheumatology
Terapeutic Guidelines: Toxicology and Wilderness
Terapeutic Guidelines: Ulcer and Wound Management
Management Guidelines: Developmental Disability
Back Index Contents
Management Guidelines
Version 3, 2012
Developmental Disability
Therapeutic Guidelines Limited, Melbourne
Back Index Contents
Copyright 2012 Terapeutic Guidelines Limited
All rights reserved. Apart from any fair dealing for the purpose
of private study, criticism or review as permitted under the
Copyright Act 1968, no part of this publication may be
reproduced, stored in a retrieval system, scanned or transmitted
in any form without the permission of the copyright owner.
Suggested citation:
Terapeutic Guidelines Limited. Management guidelines:
developmental disability. Version 3. Melbourne: Terapeutic
Guidelines Limited; 2012.
First published 1999
Version 2 2005
Version 3 2012
Publisher and distributor:
Terapeutic Guidelines Limited
Ground Floor, 473 Victoria Street
West Melbourne, Victoria 3003
Australia
Telephone +61 3 9329 1566
Telephone 1800 061 260 (within Australia)
Facsimile +61 3 9326 5632
Email sales@tg.org.au
Website <www.tg.org.au>
ISBN 978-0-9808253-5-0
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
viii
Contents
How to use this ebook .....................................................................ii
Tables and boxes ...............................................................................x
How Management Guidelines: Developmental
Disability, version 3 was prepared ............................................... xii
Contributors ...................................................................................xiv
Acknowledgments ...................................................................... xviii
Endorsements .................................................................................xx
Board of directors of TGL ............................................................xxi
Chapters
Developmental disability and health care .....................................1
Te doctor as advocate ..................................................................10
Communicating with a person with developmental
disability ...........................................................................................15
General practice consultation .......................................................29
Legal concerns ................................................................................38
Informing parents of their childs disability ................................50
Assessing developmental delay and disability ............................57
Managing a child with developmental disability .......................70
Managing an adolescent with developmental disability ...........79
Adult health care ............................................................................95
Aged care .......................................................................................112
Womens health .............................................................................130
Mens health ...................................................................................142
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
ix
Preventive health care and health promotion ..........................145
Challenging behaviour: assessment and management ............148
Challenging behaviour: drugs ....................................................165
Psychiatric disorders: assessment ...............................................175
Psychiatric disorders: management ...........................................187
Epilepsy and seizures ...................................................................210
Nutritional disorders....................................................................220
Dysphagia ......................................................................................230
Oral health .....................................................................................240
Sexual expression .........................................................................244
Angelman syndrome ....................................................................250
Autism spectrum disorder ..........................................................255
Cerebral palsy ...............................................................................266
Down syndrome ...........................................................................283
Fetal alcohol syndrome ................................................................295
Fragile X syndrome ......................................................................301
Neurofbromatosis type 1 ............................................................314
Noonan syndrome ........................................................................321
Prader-Willi syndrome ................................................................326
Rett syndrome ...............................................................................338
Tuberous sclerosis ........................................................................344
Williams syndrome ......................................................................350
Disability resources ......................................................................355
Appendices
Index ..............................................................................................364
Request for comment on guidelines ..........................................374
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
x
Tables and boxes
Tables
Table 1. Causes of developmental disability ...............................60
Table 2. Normal development in children ..................................61
Table 3. Manifestations of developmental delay .........................62
Table 4. Features of history when establishing cause and
developmental pattern of a disability ............................64
Table 5. Useful referrals when assessing developmental
delay and disability ..........................................................67
Table 6. Interventions to minimise developmental problems ..72
Table 7. Checklist of health and social concerns in an
adolescent with developmental disability .....................81
Table 8. Pubertal disorders associated with developmental
disability or other conditions .........................................84
Table 9. Health care checklist for an adult with
developmental disability .................................................97
Table 10. Diferential diagnosis of functional decline
in Down syndrome ......................................................121
Table 11. Checklist for assessing and managing challenging
behaviour ......................................................................153
Table 12. Questions to guide a history of challenging
behaviour ......................................................................155
Table13. Individualised data sheet for monitoring
challenging behaviour (example) ..............................159
Table 14. Risk factors for psychiatric disorder in people
with developmental disability ....................................176
Back Index Contents
Table 15. Observable features of depression in people with
developmental disability .............................................182
Table 16. Observable features of hypomania and mania in
people with developmental disability ........................184
Table 17. Clinical characteristics of Angelman syndrome ......252
Table 18. Recommended health monitoring for children
with Down syndrome ..................................................292
Table 19. Diagnosis of tuberous sclerosis ..................................345
Boxes
Box 1. Information needed when assessing a person with
developmental disability ...................................................33
Box 2. Common conditions in older people with
developmental disability .................................................115
Box 3. Questions before prescribing psychotropic drugs
to manage challenging behaviour ..................................166
Box 4. Investigations to consider in psychiatric assessment
of a person with developmental disability ....................177
Box 5. Obtaining collateral information in psychiatric
assessment of a person with developmental
disability ............................................................................178
Box 6. History of presenting complaint in psychiatric
assessment of a person with developmental
disability ............................................................................179
Box 7. Key points when using psychotropic drugs in a
person with developmental disability ...........................192
Box 8. Indicators of Lennox Gastaut syndrome .......................213
Box 9. Decision-making framework for assessing and
managing a person with dysphagia ...............................238
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xi
Back Index Contents
How Management
Guidelines: Developmental
Disability, version 3 was
prepared
Management Guidelines: Developmental Disability, version 3
(DDG3) has been prepared in a diferent way from other
Terapeutic Guidelines Limited (TGL) titles (see eTG complete
for a description of that process).
A TGL editor, Dr Susie Rogers, was responsible for managing
this project and editing the book.
Professor Nick Lennox, from the Queensland Centre for
Intellectual and Developmental Disability, was a consultant. At
the start of the project he gave advice on appropriate reviewers
for each chapter in the book. During the project he answered
questions specifc to developmental disability from TGL staf.
Te Medical Advisor at TGL, Professor Robert Moulds, and the
Editorial Director, Ms Jenny Johnstone, held regular meetings
with Dr Rogers to discuss progress and resolve any problems
that arose.
At the start of this project, Dr Rogers edited each chapter to
make DDG3 more concise and minimise duplication between
chapters. She did not review the content.
Each of the 36 chapters in the book was reviewed by an expert
on that topic. Some chapters had two reviewers who worked
together. Twenty-nine experts contributed. Many chapters had
diferent reviewers from the last version of the book (DDG2),
which was published in 2005.
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xii
Back Index Contents
Reviewers were asked to bring the chapter content up to date,
to provide references to support their changes, and to focus
on what information would be most helpful to a general
practitioner. TGL decided that when treatment of a person with
developmental disability was the same as for a person without
disability, the reader would be directed to eTG complete. Tis
means the reader always has the most up-to-date advice on that
topic.
In a collaboration between the relevant expert and Dr Rogers,
each chapter was reviewed and re-edited at least twice (usually
several times). At the end of this process, all reviewers were sent
the draf manuscript for comment. Decisions on whether to
incorporate reviewers comments in the fnal manuscript were
made by TGL staf in consultation with Professor Lennox.
Relevant peak organisations and centres were invited to endorse
the manuscript.
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xiii
Back Index Contents
Contributors
Professor Nick Lennox (contributor and expert advisor)
Queensland Centre for Intellectual and Developmental
Disability, School of Medicine, Te University of Queensland,
Brisbane, Queensland
Dr Helen Boocock
Director, Oral Health, Clinical Education & Training
Queensland, Brisbane, Queensland
Winthrop Research Professor Carol Bower
Telethon Institute for Child Health Research, Centre for Child
Health Research, The University of Western Australia, West
Perth, Western Australia
Dr Mary Burbidge
Clinical Director (retired July 2012), Centre for Developmental
Disability Health Victoria, Monash University, Notting Hill,
Victoria
Dr Jonathan Cohen
Fragile X Alliance Inc, North Caulfeld, Victoria
Adjunct Senior Research Fellow, Centre for Developmental
Disability Health Victoria, Monash University, Notting Hill,
Victoria
Dr Ivana Dojcinov
Specialist trainee in psychiatry of intellectual disabilities, Welsh
Centre for Learning Disabilities, Cardiff University, Cardiff,
Wales, UK
Dr Seeta Durvasula
Medical Lecturer in Developmental Disabilities, Centre for
Disability Studies, Sydney Medical School, University of
Sydney, Camperdown, New South Wales
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xiv
Back Index Contents
Dr Gillian Eastgate
Senior Lecturer/General Practitioner, Queensland Centre for
Intellectual and Developmental Disability, School of Medicine,
Te University of Queensland, Brisbane, Queensland
Dr Catherine Franklin
Consultant Psychiatrist, Queensland Centre for Intellectual
and Developmental Disability, School of Medicine, Te
University of Queensland, Brisbane, Queensland
Ms Julie Gibson
Clinical Coordinator, Queensland Centre for Intellectual and
Developmental Disability, School of Medicine, Te University
of Queensland, Brisbane, Queensland
Dr Sonia Grover
Royal Childrens Hospital, Parkville, Victoria
Dr Bronwyn Hemsley
Senior Lecturer (Speech Pathology), Te University of
Newcastle, Callaghan, New South Wales
Ms Jenny Johnstone
Editorial Director, Terapeutic Guidelines Limited, Melbourne,
Victoria
Professor Mike Kerr
Professor Learning Disability Psychiatry, Welsh Centre for
Learning Disabilities, Cardif University, Cardif, Wales, UK
Dr Margo Lane
Senior Lecturer, School of Medicine, The University of
Queensland, Ipswich, Queensland
General Practitioner, Queensland Centre for Intellectual and
Developmental Disability, School of Medicine, Te University
of Queensland, Brisbane, Queensland
Clinical A/Professor Helen Leonard
Head, Child Disability Research, Telethon Institute for Child
Health Research, West Perth, Western Australia
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xv
Back Index Contents
Professor Robert Moulds
Medical Advisor, Therapeutic Guidelines Limited, Melbourne,
Victoria
Professor Kathryn North
Douglas Burrows Professor of Paediatrics, Faculty of
Medicine, The University of Sydney, New South Wales
Head, Institute for Neuroscience and Muscle Research, The
Childrens Hospital at Westmead, Westmead, New South Wales
Professor Gregory OBrien
Senior Staff Specialist, Mental Health Assessment and
Outreach Team, Wacol, Queensland
Emeritus Professor, Northumbria University, UK
Dr Colleen OLeary
Centre for Population Health Research, Curtin Health
Innovation Research Institute, Curtin University, Perth,
Western Australia
Ms Dianne Pendergast
Former National Chairperson, Australian Guardianship and
Administration Council and former Adult Guardian
(Queensland)
Chairperson, Elder Law Committee, Queensland Law Society
and Barrister, Queensland
Professor Dinah Reddihough
Consultant Paediatrician, Royal Childrens Hospital and
Department of Paediatrics, The University of Melbourne,
Parkville, Victoria
Professor Nicole Rinehart
Clinical Psychology Centre, School of Psychology and
Psychiatry, Monash University, Notting Hill, Victoria
Clinical Psychologist, Melbourne Childrens Clinic,
Camberwell, Victoria
Dr Susie Rogers
Editor, Therapeutic Guidelines Limited, Melbourne, Victoria
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xvi
Back Index Contents
Dr Margaret Rowell
Consultant Paediatrician, Developmental Medicine, Royal
Childrens Hospital, Parkville, Victoria
Mr Jim Simpson
Senior Advocate, New South Wales Council for Intellectual
Disability, Surry Hills, New South Wales
Dr Jacqueline Small
Senior Staff Specialist, Disability Specialist Unit, Sydney
Childrens Hospital Network (Westmead), Burwood, New
South Wales
Clinical Lecturer, The Childrens Hospital at Westmead
Clinical School, The University of Sydney, New South Wales
Clinical Professor Bronwyn Stuckey
Keogh Institute for Medical Research, Sir Charles Gairdner
Hospital, Nedlands, Western Australia
Ms Miriam Taylor Gomez
Education Coordinator, Queensland Centre for Intellectual and
Developmental Disability, School of Medicine, University of
Queensland, Brisbane, Queensland
Dr Jane Tracy
Education Director, Centre for Developmental Disability
Health Victoria, Monash University, Notting Hill, Victoria
A/Professor Julian Trollor
Chair, Intellectual Disability Mental Health, School of
Psychiatry and Head, Department of Developmental Disability
Neuropsychiatry, University of New South Wales, New South
Wales
Dr Madonna Tucker
Psychologist, Brisbane, Queensland
All contributors have stated that they have complied with
Therapeutic Guidelines Limited policy on confict of interest.
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xvii
Back Index Contents
Acknowledgments
Colleagues who have contributed to this manuscript are acknow-
ledged below. Versions 1 and 2 of Management Guidelines:
Developmental Disability formed the basis for Version 3.
Additional contributor to current version
Dr David Mowat
Senior Staf Specialist and Clinical Geneticist, Sydney
Childrens Hospital, Randwick, New South Wales
Contributors to previous versions
Dr S Balandin (version 1)
Dr H Beange (versions 1, 2)
Professor S Berkovic (version 1)
Ms S Brady (version 1)
Ms J Butler (versions 1, 2)
Ms A Buzio (version 1)
Dr B Chenoweth (version 1)
Dr A Churchyard (version 2)
Mr J Cockerill (version 2)
Dr N Cooling (version 2)
Dr J Curran (version 1)
Dr M Cuskelly (version 2)
Dr J Davis (version 1)
A/Professor R Davis (versions 1, 2)
Ms J Diggens (versions 1, 2)
Ms N Edwards (version 2)
Dr P Graves (versions 1, 2)
Dr D Harley (version 2)
Dr D Henderson (version 2)
Dr T Iacono (version 2)
A/Professor N Kerse (versions 1, 2)
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xviii
Back Index Contents
Dr P King (version 2)
Mr F Lambrick (version 2)
Dr J Marshall (version 2)
Dr J Maxwell (version 2)
Ms J McDowell (version 2)
Dr A McElduf (version 2)
Dr C Mohr (version 2)
Dr A Nielsen (version 2)
Dr M Nugent (version 2)
Ms W OConnor (version 1)
Dr D Palmer (versions 1, 2)
Ms N Paul (version 1)
Professor D Ravine (version 2)
Ms L Stewart (version 2)
Professor B Tonge (versions 1, 2)
Dr J Torr (version 2)
Dr S Trumble (version 1)
Dr P White (version 2)
Dr M Winshaw (version 1)
Evaluation network
Terapeutic Guidelines Limited (TGL) thanks its evaluation
network of over 200users who provide feedback on use of the
guidelines in clinical practice. TGL also thanks those who have
provided feedback directly or through the request for comment
at the end of the book.
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xix
Back Index Contents
Endorsements
Australian Association of Developmental Disability Medicine
Australasian Society for Intellectual Disability
Centre for Developmental Disability Health Victoria
Centre for Disability Studies, Te University of Sydney
National Council on Intellectual Disability
Queensland Centre for Intellectual and Developmental Disability
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xx
Back Index Contents
Board of directors of TGL
Mr RS Kneebone (chairman)
Albert Park, Victoria
Dr JS Dowden
Yarralumla, Australian Capital Territory
Professor PP Glasziou
Robina, Queensland
Mr MJ Harvey
Sandringham, Victoria
Professor MR Kidd
Potts Point, New South Wales
Professor JE Marley
New Lambton Heights, New South Wales
Dr CD Mitchell
*
Ballina, New South Wales
Dr JG Primrose
Farrer, Australian Capital Territory
Professor JWG Tiller
Melbourne, Victoria
Chief executive ofcer of TGL
Dr SM Phillips
Williamstown, Victoria
Nominees of the following organisations:
* The Royal Australian College of General Practitioners
Victorian Medical Postgraduate Foundation Inc.
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
xxi
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Developmental disability and health care 1
Developmental disability
and health care
Management Guidelines: Developmental Disability aims to help
medical practitioners care for people with developmental dis-
ability. In particular, general practitioners (GPs) are central to
care of these people. Te guidelines cover a broad rangefrom
birth to old age, from assessment to long-term management, and
from general health concerns to those specifc for syndromes.
Management Guidelines: Developmental Disability is also relevant
to a broader readership. Input from a range of medical and non-
medical professions is usually required when responding to
the health needs of people with developmental disability. Most
importantly, the person with disability, their families and other
support people need to be involved. Te guidelines have been
written so they are accessible to people who are not professional
health care workers.
As well as medical information, this book discusses the social,
developmental and environmental concerns common to all
people with developmental disability. Many health concerns
are managed as for people without disability. In this situation
the reader is directed to eTGcomplete for advice. Management
Guidelines: Developmental Disability highlights areas where
management difers from that of the general population.
DEFINITIONS
Important terms used in this book are defned below.
Developmental disability
Developmental disabilities are those that relate to diferences in
neurologically based functions that have their onset before birth
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Developmental disability and health care 2
or during childhood, and are associated with signifcant long-
term difculties.
*
While most people with developmental disability have
intellectual disability, some do not. For example, cerebral palsy
and autism spectrum disorder are developmental disabilities, but
not all people with these disorders have intellectual disability.
Intellectual disability
Intellectual disability is a disability characterized by signifcant
limitations both in intellectual functioning and in adaptive
behavior, which covers many everyday social and practical skills.
Tis disability originates before the age of 18.
A screening
program is only efective if the child identifed to have problems
with their development can access intervention. GPs and early
childhood nurses tend to be the main professionals involved in
developmental screening and referral for further assessment or
intervention.
For a person to be diagnosed with developmental disability, the
disability must be present before they are 18years old. However,
sometimes an adult with a disability might not see their
doctor regularly, or lives a relatively secluded life with elderly
parents. It is possible they have not had a formal diagnosis of
developmental disability. Tey may not have received the help
that might have enabled them to develop more independence
skills. Also, they may have health conditions that have not been
identifed. Reasons for presenting to their GP might include
decline in functional status.
Te childs developmental trajectory is important. Signs of
developmental regression are indicators for urgent detailed
paediatric assessmentthis should include assessment for
neurological or metabolic conditions. At any age, if the person
cant perform established skills or develops new challenging
behaviours, a thorough functional and medical assessment is
warranted.
CAUSES OF DEVELOPMENTAL DELAY AND
DISABILITY
Most developmental disabilities are due to factors that are oper-
ative before the onset of labour, particularly chromosomal and
other genetic abnormalities. Tese can cause subtle abnormal-
ities of brain development or function that may not be readily
*
Advice on selecting the most appropriate paediatric developmental screening
instrument.
and
the Developmental Behaviour Checklist.
Integrate other resources and assessments
Sometimes the person with developmental disability has had
challenging behaviours for much of their life. Other professionals
have probably assessed them. Tese assessments (eg from
schools, speech pathologists, psychologists, paediatricians) can
be useful to the clinician.
Services for people with developmental disability may include
behavioural support teams for assessing and treating challenging
behaviours. Tese teams ofen use applied behaviour analysis
(ABA) methodology. ABA methodology uses observational
*
Aman MG, Singh NN. Aberrant behavior checklist: ABC. New York, NY: Slosson
Educational Publications; 1986
McAtee M, Carr EG, Schulte C, Dunlap G. A contextual assessment inventory for
problem behavior initial development. J Posit Behav Interv 2004;6(3):14865 (a copy
of the inventory is in the appendix to the article)
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: assessment and management 160
and experimental strategies to identify a function or cause that
reinforces the behaviour. Te information is used to develop a
behaviour intervention plan.
Te intervention strategies may target fve areas:
ecological or setting event (setting where the behaviour takes
place)
immediate antecedent event (event immediately before the
behaviour)
response of support people to the behaviour, and skill training
for the person with developmental disability (if their lack of
certain skills is contributing to their display of challenging
behaviour)
consequences of the behaviour
emergency procedures.
Behavioural support teams ofen recognise that medical
assessment is needed. Tey may initiate a medical referral to a
GP or psychiatrist, to assess if there is an underlying undiagnosed
medical or mental health problem. Te support team can change
the environment of the person with developmental disability, to
alter the exhibition of challenging behaviours. If necessary, they
can also support any medical or psychiatric intervention needed
by the person to decrease their challenging behaviour.
Te information from the behavioural support team needs to be
integrated with the clinicians information.
Review and plan intervention
Te clinician can review their completed medical and psychiatric
assessment of the person with developmental disability and the
available information. On the basis of this review they can make
a diferential diagnosis that identifes the most likely cause of
the persons challenging behaviour. Tey can also identify the
factors that contribute to it.
Te clinician should document the following:
description of the challenging behaviour
support persons concerns
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: assessment and management 161
safety concerns
medical and psychiatric problems
objective measures of the behaviour.
Te clinician should also know what organisations provide
services for the person with developmental disability. With
all this information, they can discuss and formulate the most
efective management strategies and referral options. When
making these decisions, factors to be considered include:
potential benefts and harms of each option
availability of resources
long- and short-term efects on the person with developmental
disability.
Manage and refer
Options for managing the person with developmental disability
and challenging behaviour include:
referral to appropriate practitioners and service providers
education and skill development
environmental modifcations
improving communication.
In some situations the clinician may take the lead role in
managing the person with developmental disability. For example,
if the underlying cause of the challenging behaviour is mainly
medical, it might be appropriate for the medical practitioner to
take the lead role. Similarly, if the behaviour is mainly learnt,
a behavioural support team or psychologist may have the lead
role.
In general, assessment of more specialised medical and
psychiatric problems requires referral to an appropriate
specialist. Common general practice problems (eg depression,
dysmenorrhoea) can be managed by the GP. Resources to
manage challenging behaviours vary, depending on local
support services and their confguration.
In certain situations, drugs may be considered necessary to treat
challenging behaviour.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: assessment and management 162
Whatever the management strategy, good communication
between the professionals and service providers involved is
important for a thorough assessment and efective management.
Environment
It is essential that people live in an environment that supports
them. To maintain their mental health, all people need an
environment with:
appropriate living conditions
vocational opportunities
supportive social networks
meaningful leisure time.
Common problems for people with developmental disability
are:
overstimulating or understimulating environments
confusing or inconsistent communication
social isolation
being placed in demanding situations
unrealistic expectations of their abilities.
Te person with developmental disability is likely to respond
best to appropriate modifcations to their environment, thus
avoiding medication. For example, people with a strong need
for a predictable environment respond well to structure and
consistency. A person with disability who does not like living
with, or being with, certain room-mates or staf, would beneft
from diferent living arrangements. Teir clinician can advocate
for this.
Several strategies may help support people to minimise
challenging behaviour. Tese include:
coordinated management of all the support people working
with a person with developmental disability (a consistent
approach helps all concerned)
respite care for the person with developmental disability and
their support people
attention to the health needs and lifestyle concerns of support
people
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: assessment and management 163
education for support people, so:
their expectations of the person with developmental
disability are realistic
they are familiar (and comply) with legislation (when
appropriate)
they have strategies to manage their stress.
Education and skill development
It may be helpful for the person with disability to learn more
skills for coping with their environment. Learning new skills can
increase their integration into society and is also benefcial for
their self-esteem and capacity to cope.
One example is learning to interact more appropriately with
others, by increasing their social skills. Another example is
learning how to wait, by teaching the person how to amuse
themselves while they wait. Tey could learn leisure skills (like
puzzles) or how to work their CD or MP3 player to listen to
music.
Communication
Communication can be improved by referring the person with
developmental disability and their friends, family or other
support people (including staf) to a specialist (eg speech
pathologist, psychologist). Tey can advise on communication
strategies and augmentative and alternative communication
techniques (eg signing, visual diary). See communicating with a
person with developmental disability.
Monitor and review
Afer identifying the cause of the challenging behaviour and
establishing a management plan, it is important to review
the persons progress regularly. Continuing data collection
is desirable. Te persons response to the intervention, and
observations over time, might suggest a new diagnosis and a
more efective strategy.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: assessment and management 164
REFERENCES AND FURTHER READING
Aman MG, Singh NN. Aberrant behavior checklist: ABC. New York, NY: Slosson Educational
Publications; 1986.
Davis R, Radler G. Behaviour intervention. Aust Fam Physician 1993;22(8):1457-60, 62,
64.
Davis R, Thurecht R. Care planning and case conferencing. Building effective multi-
disciplinary teams. Aust Fam Physician 2001;30(1):78-81.
Donnellan AM. Progress without punishment: effective approaches for learners with
behavior problems. New York: Teachers College Press; 1988.
Emerson E, Cummings R, Barrett S, Hughes H, McCool C, Toogood A. Challenging
behaviour and community services 2. Who are the people who challenge services? J Brit
Inst Ment Handicap 1988;16(1):16-9.
Gourash LF. Assessing and managing medical factors. In: Barrett RP, editor. Severe
behavior disorders in the mentally retarded: nondrug approaches to treatment. New York:
Plenum Press; 1986.
Kansas Institute for Positive Behavior Support. Functional behavioral assessment interview
form [156 KB]. Lawrence, KS: KIPBS; accessed May 2012.
Lucyshyn JM, Albin RW. Comprehensive support to families of children with disabilities
and behavior problems: keeping it friendly. In: Singer GHS, Powers L, editors. Families,
disability, and empowerment: active coping skills and strategies for family interventions.
Baltimore: Brooks; 1993. p.365-407.
McAtee M, Carr EG, Schulte C, Dunlap G. A contextual assessment inventory for problem
behavior initial development. J Posit Behav Interv 2004;6(3):148-65.
Murtagh J. A safe diagnostic strategy. In: John Murtaghs general practice. 5th ed. North
Ryde, NSW: McGraw-Hill Education; 2011. p.150-7.
Oberlander TF, Symons FJ. Pain in children and adults with developmental disabilities.
Baltimore, Md.; London: Paul H. Brookes Pub.; 2006.
OBrien G. Behavioural phenotypes in adulthood. In: Understanding Intellectual Disability &
Health [website]. London: St Georges, University of London; 2003.
ONeill RE. Functional assessment and program development for problem behavior: a
practical handbook. 2nd ed. Pacic Grove; London: Brooks/Cole Pub.; 1997.
Richdale A, Francis A, Gavidia-Payne S, Cotton S. Stress, behaviour, and sleep problems in
children with an intellectual disability. J Intellect Dev Disabil 2000;25(2):147-61.
Ryan R, Sunada K. Medical evaluation of persons with mental retardation referred for
psychiatric assessment. Gen Hosp Psychiatry 1997;19(4):274-80.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 165
Challenging behaviour:
drugs
Sometimes psychotropic drugs are used to manage challenging
behaviour in people with developmental disability. Medical
practitioners are ofen asked to make decisions about initiating,
changing or continuing psychotropic drugs in this setting. Tis
practice has a limited evidence base. Also, ethical concerns arise
when drugs are used to treat behaviour that is underpinned by
environmental (rather than biological) factors. Many people
with developmental disability are on high doses of drugs and/or
multiple drugs, sometimes without a clear rationale.
Challenging behaviour has many causes. Before considering the
use of psychotropic drugs as part of the management plan, the
cause of the persons behaviour should be determined and treated
where possible (see the chapter on assessing and managing
challenging behaviour). Te one possible exception is an acute
situation when the person or others are at physical risk from the
behaviour. Emergency treatment may be needed (see safety and
behavioural emergencies). Te cause of their behaviour should
still be investigated.
CHOOSING WHETHER TO PRESCRIBE DRUGS
Before deciding whether to prescribe a psychotropic drug to
manage challenging behaviour in a person with developmental
disability, the questions in Box 3 should be considered.
Drugs may themselves cause or aggravate challenging behaviour.
Reducing or stopping some drugs may have a positive outcome.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 166
Box 3. Questions before prescribing psychotropic
drugs to manage challenging behaviour
1. Is the person (or are others) at risk of injury from the behaviour? (see
safety, aggression)
2. Have the potential causes of the behaviour been assessed?
3. What is the hypothesis for the cause of the behaviour?
4. What interventions have been tried? What were their outcomes?
5. Does the behaviour warrant treatment with drugs without a clear
psychiatric or medical diagnosis?
6. Is there a drug that may help this person?
7. Do the benets outweigh the harms of prescribing this drug?
8. How can the efcacy and adverse effects of the drug be monitored?
Sometimes drug treatment may be considered appropriate
for a person with developmental disability, even though their
challenging behaviour lacks a traditional psychiatric or medical
diagnosis. In general, drugs may be justifed if the persons
behaviour is:
persistent over time
pervasive across situations
frequent
severe in another way, because it:
may cause injury to them or others
compromises their health
distresses them
causes breakdown of residential and day placement
restricts their activities and community access.
It is always necessary to obtain consent to treatment. If the
person lacks capacity to provide consent, a substitute decision-
maker may need to provide consent on their behalf. Diferent
arrangements may apply in diferent states. See contact details
for the guardianship authorities.
Certain psychotropic drugs may be helpful for particular
problem behaviours. Some may help the person make better use
of a nonpharmacological approach (eg by lifing their mood or
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 167
reducing their agitation, so they can apply relaxation techniques
better). However, due to their sedative efect, psychotropic drugs
may also interfere with new learning. Tis may compromise
other treatments.
Longer term use of psychotropic drugs to manage challenging
behaviour requires regular monitoring for efcacy and adverse
efects. Monitoring drugs such as lithium can be a problem.
DRUG TREATMENT PLAN
Afer exploring the questions in Box 3, the clinician may
consider drugs to be appropriate for the person with challenging
behaviour. Tey should prepare a treatment plan following the
steps below. Te person with developmental disability (where
possible), their family and other support people should be
consulted.
First, in relation to the challenging behaviour, the clinician
should:
defne the target behaviour and outline techniques for
measuring it
take a reliable baseline measure
formulate a hypothesis for its cause
develop a treatment rationale (this may include reducing or
ceasing current psychotropic medication).
When selecting a drug, the clinician should:
assess the best available evidence for its efect on the target
behaviour
ensure it is the best choice for the person
ensure its potential benefts outweigh its potential harms.
See precautions to consider before prescribing psychotropic
drugs.
Clear treatment outcomes need to be defned. It is important to
have sufcient resources to monitor the:
frequency and severity of the persons behaviour
efcacy and adverse efects of the drug.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 168
A regular review process should be developed, based on pre-
determined outcomes. Tis must be agreed to by all parties
involved in the decision to treat.
Te person must be informed of the potential benefts and
adverse efects of the drug. Consent to the treatment is needed.
When treating people with developmental disability, start any drug
at a low dose and slowly increase it.
Drug treatment should start with a low dose. A general principle
when prescribing drugs for people with developmental disability
is to start low and go slow. It may be prudent to start some
people on half the usual recommended dose. Te patient should
be reviewed before any dose increases. Te aim is to use the
lowest efective dose of the drug. Continuing treatment with the
drug should be based on its:
efect on the persons target behaviour
adverse efects.
Finally, the review process should be ongoing.
Assessing the efcacy of a particular drug is a dynamic process.
It depends on the accuracy and reliability of the defnition of
the behaviour and the observation techniques. In many cases, a
clinician may not be able to satisfy all the steps above. A harm
beneft analysis determines how to proceed in this situation.
Te clinician may need to engage a psychiatrist, psychologist or
(preferably) a multidisciplinary team skilled in this area.
BEHAVIOURAL EMERGENCIES
Te following information about people with developmental
disability should be read in conjunction with Behavioural
emergencies in eTGcomplete.
In a behavioural emergency, the person with developmental
disability usually settles spontaneously. Sometimes an emergency
is triggered by an unfamiliar environment in frightening
circumstances (eg at hospital admission). It is important to
consider the situation from the persons point of view, and make
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 169
eforts to ease their anxiety and fear. Te best course of action
may be to make sure they are safe and wait for them to settle.
Sometimes the level of danger is such that a tranquillising drug is
needed. Tere is a scant evidence base for safe doses of drugs for
managing this situation in people with developmental disability.
Te upper limits of doses of sedating drugs recommended in
eTGcomplete could be excessive for some of these people.
Upper limit doses of sedating drugs can be dangerous for people
with developmental disability.
Respiratory complications (including aspiration pneumonia) are
the main cause of premature death in people with developmental
disability. When the person is sedated, it is mandatory that
nursing or medical professionals monitor their vital signs
and protect their airway. Tis may mean the person has to be
transferred to hospital.
Afer the person settles, the clinician should reassess the situation
and look for a cause for their behaviour.
SELF-DIRECTED BEHAVIOUR AND OUTWARD
BEHAVIOUR
It is helpful to recognise whether a persons problem behaviour
is directed primarily towards themselves (ie self-directed) or
others (ie outward).
Self-directed behaviour
Common types of self-directed behaviour that may merit drug
treatment include self-injury and stereotyped behaviour.
Self-injury
Self-injury in people with developmental disability can be
relatively harmless hitting and scratching. However, it ranges
through to injuries that cause major physical damage or even
death. Tis behaviour is resistant to behavioural management
programs. When it is severe, it may be treated with drugs.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 170
Antipsychotic drugs may reduce stereotyped behaviour that
causes self-injury, primarily by their anxiolytic efect (see also
eTGcomplete).
One theory for continuing self-injury is that it induces
endogenous opioids or beta endorphins. Tese modulate pain
and induce a feeling of euphoria. Naltrexone is a narcotic
antagonist, and should only be used in patients with serious
compulsive nonvolitional self-injury.
Stereotyped behaviour
Stereotyped behaviours are repetitive motor acts with no
adaptive function. Tey are highly idiosyncratic and fxed in
form in each case. Actions such as rocking the body, hand-
fapping or head-rolling are common examples among people
with developmental disability. Many studies have shown that
antipsychotic drugs (in particular, low-dose risperidone)
decrease stereotyped behaviour (see also eTGcomplete).
Outward behaviour
Common types of outward behaviour that may merit drug
treatment include aggression and agitation.
Aggression
Aggressive behaviours include physical violence, verbal threats
and abuse and property destruction. Psychiatric disorders (eg
mania) need to be considered as a cause.
Sometimes drugs may be needed to manage aggressive behaviour
in a person with developmental disability. For example, when
there is:
continuing risk to the person and those around them
refractoriness to behaviour management and other
nonpharmacological programs or strategies.
Diminishing the persons tendency to aggressive behaviours
may allow environmental and behavioural interventions to be
more efective.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 171
Acts of aggression are ofen intermittent, resulting from poor
impulse control when provoked. Increasing the doses of the
persons regular medication is not usually efective. Short-term
tranquillisation may be more appropriate. Here, the usual order
of preference for drugs is:
selective serotonin reuptake inhibitors
antipsychotics
carbamazepine and sodium valproate (for their efect on
mood)
other drugs (eg beta blockers, lithium).
Selective serotonin reuptake inhibitors
Depression is common in people with developmental disability,
and may present as irritable mood and associated aggressive
behaviours. Te diagnosis is ofen missed.
Selective serotonin reuptake inhibitors (SSRIs) have been shown
to moderate aggressive behaviour, sometimes in people without
proven depressive symptoms. Te efcacy of SSRIs results from
both their antidepressant and anxiolytic efects. As SSRIs are
well tolerated and have relatively few adverse efects, a trial
may be worthwhile. People with developmental disability are
more prone to certain common adverse efects of SSRIs than
the general population. Tey may become agitated or manic.
Also, SSRIs reduce the seizure threshold, and this is a problem
in a population in which epilepsy is common. It is advised to
commence therapy at half the standard recommended dose,
with half-dose increments.
Antipsychotic drugs (anxiolytic major tranquillisers)
When antipsychotic drugs are used to treat challenging behaviour,
most ofen it is to take advantage of their anxiolytic efect. All
types of antipsychotic drugs (frst- and second-generation) have
been used to diminish aggressive behaviours. Te choice of
drug depends on its adverse efect profle. People with disability
ofen have obesity, constipation, poor oral health and mobility
problems. It is preferable not to give them drugs that make these
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 172
problems worse. Even at low doses, antipsychotic drugs can
cause functional impairment through their sedative efect.
In the absence of frank mental illness, risperidone is the most
common antipsychotic drug used to diminish aggression. Its
advantage is a pronounced anxiolytic efect at low dose (0.5 to
1mgdaily), and it is available as a tablet, liquid or soluble wafer.
Carbamazepine and sodium valproate
Te evidence base for using carbamazepine and sodium valproate
for aggression is limited, but they are widely used. Teir use has
increased since their recognition as mood stabilisers. Dosing is
related to clinical response rather than to serum concentrations.
For further information, see the advice on treating mania
(acute) in eTGcomplete.
Other drugs
Beta blockers (eg propranolol) have been shown to moderate
aggressive behaviour, particularly explosiveaggressive episodes.
Tey are less likely to cause sedation than other drugs.
Beta blockers are contraindicated in people with asthma or
severe peripheral vascular disease.
Moderation of aggressive behaviour by lithium has a strong
evidence base. However, its narrow therapeutic range and the
need for regular blood tests (to monitor its serum concentration)
ofen limit its use in this population. It is a long-term therapy.
Lithium may be considered when aggression is associated
with autistic tendencies and occurs with hyperactivity. For
further information, see the advice on treating mania (acute) in
eTGcomplete.
Some patients need to reach a serum lithium concentration of
0.8to 1mmol/L before showing a response.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 173
Agitation
Sometimes a persons agitation and restlessness may be
misinterpreted. Importantly, it may be an adverse efect (eg
akathisia) of an antipsychotic drug they are taking.
Selective serotonin reuptake inhibitors and antipsychotic drugs
SSRIs or antipsychotic drugs may be used to treat agitation
when there is good evidence of underlying anxiety. No clear
evidence indicates which drugs are preferable, but in severe cases
most clinicians would use antipsychotic drugs. For appropriate
doses, see eTGcomplete.
Other drugs
Clomipramine has been shown to be efective when the
persons agitated and restless behaviour resembles obsessive
compulsive disorder. Even in such cases its use is limited,
and most clinicians would choose an SSRI as treatment.
Frequently clomipramine has anticholinergic adverse efects
(eg sweating, hot fushes, tachycardia) that may distress the
person. Drowsiness, confusion and disorientation may also be
a problem. For appropriate doses, see the advice on obsessive
compulsive disorder in eTGcomplete.
Lithium therapy is long term. It should only be considered for
agitation afer the failure of less intrusive therapies. Treatment is
the same as for aggression.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Challenging behaviour: drugs 174
REFERENCES AND FURTHER READING
Expert Consensus Guideline Series: Treatment of psychiatric and behavioral problems in
mental retardation. Am J Ment Retard 2000;105(3):159-226.
Baumeister AA, Todd ME, Sevin JA. Efcacy and specicity of pharmacological therapies
for behavioral disorders in persons with mental retardation. Clin Neuropharmacol
1993;16(4):271-94.
Bouras N, editor. Psychiatric and behaviour disorders in developmental disabilities and
mental retardation. Cambridge: Cambridge University Press; 1999.
Fraser WI, Kerr M, editors. Seminars in the psychiatry of learning disabilities. 2nd ed.
London: Gaskell; 2003.
Khreim I, Mikkelsen E. Anxiety disorders in adults with mental retardation. Psychiatr Ann
1997;27(3):175-81.
Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in
the mentally retarded. Psychopharmacol Bull 1989;25(3):372-5.
OBrien G. Pharmacological interventions. In: OBrien G, editor. Behavioural phenotypes in
clinical practice. London: Mac Keith; 2002.
OBrien G. Psychopharmacology in women with learning disabilities. In: Kohen D, editor.
Oxford textbook of women and mental health. Oxford: Oxford University Press; 2010.
OBrien G, Pearson J, Berney T, Barnard L. Measuring behaviour in developmental disability:
a review of existing schedules. Dev Med Child Neurol Suppl 2001;87:1-72.
Tyrer P, Oliver-Africano PC, Ahmed Z, Bouras N, Cooray S, Deb S, et al. Risperidone,
haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients
with intellectual disability: a randomised controlled trial. Lancet 2008;371(9606):57-63.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 175
Psychiatric disorders:
assessment
Psychiatric disorders are two to three times more common
in people with intellectual disability. Estimates of prevalence
vary widely, according to the sample selection, defnition of
psychiatric disorder, diagnostic criteria and the clinicians
skill and experience. A number of factors make people with
developmental disability more vulnerable to psychiatric illness
(see Table 14). Tese factors may also precipitate episodes of
illness or complicate the clinical picture.
DIAGNOSTIC CRITERIA
In people with mild disability and good communication skills,
psychiatric disorders present as in the general population.
Standard diagnostic criteria (eg DSM-IV-TR, ICD-10) can
generally be applied. Tese criteria rely on a person being able
to report subjective experiences verbally. Tey are not valid
in more severe intellectual disability and/or communication
impairment. Tey also do not take into account the behavioural
manifestations or atypical features of psychiatric disorder in
people with developmental disability.
Diagnostic criteria have been adapted for use in developmental
disability. Te Diagnostic ManualIntellectual Disability (DM-
ID)
*
relates to DSM-IV. Te Diagnostic criteria for psychiatric
disorders for use with adults with learning disabilities/mental
retardation (DC-LD)
relates to ICD-10.
*
Fletcher RJ, National Association for the Dually Diagnosed, American Psychiatric Associ-
ation, editors. DM-ID: diagnostic manual-intellectual disability: a clinical guide for diagnosis
of mental disorders in persons with intellectual disability. Kingston, NY: NADD Press; 2007.
Royal College of Psychiatrists. DC-LD: diagnostic criteria for psychiatric disorders for
use with adults with learning disabilities/mental retardation. London: Royal College of
Psychiatrists; 2001.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 176
Table 14. Risk factors for psychiatric disorder in
people with developmental disability
biological
underlying neurodevelopmental brain abnormalities
genetic disorders/behavioural phenotypes (eg fragile X
syndrome/social anxiety, Down syndrome/depression,
velocardiofacial syndrome/psychotic illness)
family history of psychiatric disorder
epilepsy
other comorbid medical conditions (eg hypothyroidism)
drugs (eg corticosteroids, beta blockers, adverse effects of
psychotropic drugs)
psychological
impaired cognitive skills
underdeveloped coping strategies
less control over life circumstances
vulnerability to repeated losses or separations
communication impairments
impaired acquisition of social, recreational and
interpersonal skills
low self-esteem from failure, rejection and physical
differences
social
higher risk of physical, sexual and emotional abuse and
neglect
lack of social support, social isolation
adverse life events (including abuse)
rejection, stigmatisation, discrimination
conict at home, disability group home, workplace or day
placement
carer stress
ASSESSMENT
Conducting a psychiatric assessment for a person with develop-
mental disability can be challenging. However, identifying and
appropriately treating psychiatric illness can profoundly improve
their level of functioning and quality of life.
Some challenges in assessment arise from intellectual or
communication difculties. Other challenges include referral
bias and a lack of specialist services and training in the area.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 177
Referrals are ofen initiated by a third party, and this can involve
referral bias. It is more likely for a person with challenging
behaviours to be referred than someone who is quietly depressed.
In approaching the psychiatric assessment of the person with
developmental disability, it is helpful to consider some basic
principles:
allow extra timeseveral sessions may be needed
tailor questions and communication style (see the chapter on
communicating with a person with developmental disability
perform physical examination and investigations as indicated
(see Box 4)
remember that epilepsy is a common comorbid condition
(see the chapter on epilepsy)
try to obtain collateral information from someone who has
known the person well for a number of years (see Box 5)
interview the patient on their own, if at all possible.
Box 4. Investigations to consider in psychiatric
assessment of a person with developmental
disability
In the absence of focal signs or symptoms, basic screening tests in the
psychiatric assessment of a person with developmental disability include:
blood tests (full blood count, urea and electrolyte concentrations, liver
biochemistry, thyroid function tests)
urine microscopy, culture and sensitivity
Depending on presenting signs and symptoms, consider:
head scan (computerised tomography [CT] or magnetic resonance imaging
[MRI])
electroencephalogram (EEG), if any suspicion of epilepsy
plain abdominal X-ray, to exclude constipation
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 178
Box 5. Obtaining collateral information in psychiatric
assessment of a person with developmental
disability
Be alert to potential inuences on the quality and relevance of collateral
history, such as the:
extent of stress in those supporting the person with developmental
disability
professional background and experience of the referrer
referrers attitude towards, and knowledge of, the person
Maximise accurate collateral history by:
acknowledging that sources of collateral history may not have all the facts,
and may need help to identify the most relevant information
using monitoring charts to document relevant aspects of the persons
health (see ongoing data collection)
encouraging support people to identify someone to attend the
appointment who knows the person well
History taking
A full psychiatric assessment includes a comprehensive bio-
psychosocial history and mental state examination. When there
is limited time for assessment, focusing on obtaining a clear
history of the presenting complaint aids the diagnostic process
(see a broad outline of the basic areas to cover in Box 6).
Other important areas of inquiry include:
past medical and psychiatric assessments (including cause of
the disability, diagnosis of autism spectrum disorder)
family history of intellectual disability, autism spectrum
disorder or psychiatric illness
temperament and personality
level of functioning, previous education
developmental history (including attachments, losses, abuse,
accommodation moves).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 179
Box 6. History of presenting complaint in psychiatric
assessment of a person with developmental
disability
Establish why the person with developmental disability has been referred,
and by whom
Obtain as clear a picture as possible of the persons functioning and
behaviour in the past (eg 2 years, 5 years ago) compared with the present
Ask about:
usual activities, level of function and enjoyment
changes in sleep, appetite, attention/concentration
mood changes, irritability, agitation
general or specic anxieties, xed routines/rituals
thoughts or talk of death/dying, hurting self or others
hearing voices (nature and content, see hallucinations)
new or unusual beliefs or habits
ANXIETY AND ASSOCIATED DISORDERS
Anxiety is frequent in people with developmental disability, as
a symptom or as a psychiatric disorder. High levels of anxiety
may cause agitation, increased repetitive behaviours or even
aggression. Excess anxiety is ofen associated with autism
spectrum disorder. Organic and medical factors (eg cafeine
intoxication, hyperthyroidism) must be excluded as a cause.
Also see management and further discussion in eTGcomplete.
Generalised anxiety disorder and panic disorder
Te anxiety and worry associated with generalised anxiety
disorder may be expressed in people with developmental
disability as fear and doubts about the present, the future,
personal health and the welfare of signifcant others. Associated
features include repetitive questioning, restlessness, agitation,
aggression and sleep and concentration problems. Panic attacks
may occur. If they are frequent, a separate diagnosis of panic
disorder may be warranted.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 180
Obsessive compulsive disorder
Obsessive compulsive disorder may present in a person with
mild developmental disability as recurring, intrusive and
distressing thoughts (obsessions) associated with anxiety. Tese
may lead to repetitive acts (compulsions) to allay the fears
and consequences associated with the obsessions. However, in
people with more severe developmental disability, obsessions
are usually less prominent. Compulsions alone may be the
predominant symptom. It may also be difcult to distinguish
between compulsions and the stereotypic and ritualistic
behaviours of autism spectrum disorder.
Phobic disorders
Simple phobias are common in people with developmental
disability. If they cause signifcant disturbance in function,
desensitisation procedures may be needed.
Social phobia can be difcult to diagnose. Many of its
manifestations overlap with the features of autism spectrum
disorder. Tey may also result from the lower level of education
and underdeveloped social skills related to the persons
developmental disability.
MOOD DISORDERS
Mood disorders (ie depression, bipolar disorder or mixed
episodes) in people with developmental disability are discussed
below. Also see management.
Depression
A diagnosis of depression requires at least 2weeks of depressed
mood, loss of interest or pleasure and associated symptoms.
People with mild/moderate intellectual disability may express a
wish to die and even attempt suicide. People with greater degrees
of intellectual disability may not be able to tell others they are
feeling depressed.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 181
A 28-year-old woman with a history of minor skin picking
presents with severe self-injury over the last 2 months. She
has open wounds on her arms and legs. During this time
she has been irritable and unhappy, and has been found
crying in her room. She hits staff when they try to help her
onto the bus in the morning. She needs encouragement
to help with the evening chores. She picks at her food.
She goes to her room rather than watch her favourite
television shows with her housemates. She no longer joins
in conversations, and shrugs when staff try to talk with her.
Night staff have sometimes found her sitting alone in the
lounge room in the dark.
Table 15 documents common observable features of depression
in people with developmental disability, including irritable
mood. Other disorders (eg hypomania) may also present with
irritable mood. To avoid confusion with them, additional
indicators of depression need to be identifed (eg loss of interest
or pleasure).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Psychiatric disorders: assessment 182
Table 15. Observable features of depression in
people with developmental disability
Behaviour Observable features
depressed mood tearful
appearing sad
smiling less or not at all
laughing less or not at all
irritable mood short tempered
verbally aggressive
physically aggressive (including damaging property)
loss of interest
or pleasure
refusing to, or needing prompting to, participate in
routine activities
no longer watching or enjoying favourite TV shows
unable to be cheered up
increased anxiety seeking reassurance
questioning repetitively
increasing repetitive behaviours
associated features spending more time alone
talking to, or interacting with, others less
losing skills
no longer completing tasks
showing self-injurious behaviour
biological symptoms changing sleep pattern
getting up during the night
getting up early
difcult to wake up in the morning
eating more or less
losing or gaining weight
showing psychomotor agitation or retardation
baseline
exaggeration of pre-
existing behaviours
*
A weight for height chart is available in attachment 1 (Nutrition and swallowing risk
checklist) to the nutrition and swallowing policy of the New South Wales Department of
Family and Community Services Ageing, Disability and Home Care.
Bhaumik S, Watson JM, Thorp CF, Tyrer F, McGrother CW. Body mass index in adults
with intellectual disability: distribution, associations and service implications: a
population-based prevalence study. J Intellect Disabil Res 2008;52(Pt 4):287-98.
Beange H, Gale L, Stewart L. Project renourish: a dietary intervention to improve
nutritional status in people with multiple disabilities. Aust NZ J Dev Disabil 1995;20(3):
165-74.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 222
Being underweight is the manifestation of short-term or long-
term undernutrition. If a person with developmental disability
is chronically underweight, this may be mistakenly ascribed to
their disability. While it is common for a person with severe
disability to be underweight, it is not necessarily normal,
and warrants assessment. Being underweight may be due to
dysphagia with reduced food intake. Also, psychiatric conditions
(eg depression) or behavioural disorders may cause reduced or
inconsistent appetite.
Investigate any person who is chronically underweight.
Failure to meet growth expectations (failure to thrive) may
occur in children with developmental disability. A child with a
provisional diagnosis of failure to thrive should be referred to a
paediatrician. Tey may need further investigation by specialist
services, particularly paediatric dysphagia assessment services.
Consequences
Being chronically underweight should not be ignored in any
person, because it has major implications for their health.
Consequences of being underweight may include:
compromised immunity, with increased susceptibility to
infections
reduced respiratory muscle function
decreased energy, so less participation in education, work
and social activities
impaired learning (in children)
reduced quality of life.
Dysphagia has additional consequences.
Assessment
A multidisciplinary approach is ofen needed to assess a person
with developmental disability suspected of being underweight.
Te frst step is to establish the persons weight and height, and
then calculate their BMI. Te height of some people cannot
be measured accurately, so their BMI cannot be calculated.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 223
However, a marked decrease in subcutaneous fat indicates the
person is signifcantly underweight. Serial weight measure-
ments can be an important tool when assessing underweight
and weight loss, as well as monitoring efcacy of therapy. Other
measures include waist circumference or skinfold thickness.
It is also important for the persons GP to:
look for the cause of underweight (eg dysphagia, malab-
sorption, depression, malignancy)
check for associated clinical problems or complications (eg
aspiration, dehydration, gastro-oesophageal refux disease,
constipation, anaemia, specifc micronutrient defciencies,
acute or chronic infection due to reduced immunity).
Te next step is referral to a:
dietitian, to assess the persons kilojoule intake and nutri-
tional status
speech pathologist (if the person is suspected to have
dysphagia) to:
assess their ability to swallow, eat and drink
advise whether additional investigations are needed
physiotherapist and an occupational therapist, to assess and
manage the persons seating (eg positioning, support), eating
techniques, equipment and need for assistance.
As part of the assessment, the concerns and priorities of many
people need to be consideredthe person with developmental
disability, family members, other support people and allied
health professionals.
Management
If no clinical reason for being underweight is found, it can
be assumed that the person with developmental disability is
malnourished. Malnutrition can be insidious in onset and long
term in nature. It may appear resistant to obvious remedies
such as ofering more food. Sometimes family members or
other support people feel that nothing can be done. However,
malnutrition is usually reversible with careful attention to what
and how the person eats and drinks.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 224
Strategies
As for assessment, management needs a multidisciplinary
approach. Te same health professionals may be involved, such
as a:
dietitian, to prepare a nutrition care plan for renourishment
that may include:
calorie supplementation (commercial products may be
used, but common foods [eg milk] are ofen the basis of
supplementation)
modifed food textures
vitamin and mineral supplements
speech pathologist, to provide advice to the person with
disability and the person helping them at mealtimes
(especially if the person with disability has dysphagia) on:
eating and drinking techniques and strategies
correct positioning
food and fuid textures
occupational therapist or seating specialist, for:
advice on functional skills in eating and drinking
advice on the type and level of assistance required
seating modifcation
advice about seating systems, to improve the persons
positioning and increase their safety and comfort during
mealtimes.
If the person has associated conditions or complications, it may
be necessary to consult a:
gastroenterologist (eg to treat gastro-oesophageal refux
disease, constipation)
respiratory physician (eg to treat respiratory infections).
People who are severely underweight and malnourished ofen
have compromised immunity. Many also have dysphagia and
aspiration. Combined with reduced mobility, this increases their
risk of infection. It is important to ensure their immunisations
are up to date, including infuenza and pneumococcal vaccines
if indicated (see Te Australian Immunisation Handbook).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 225
Te persons nutritional status should be monitored and re-
viewed regularly. Te management plan can be modifed as
needed. All stakeholders must be involved in the management
plan to ensure its success.
Enteral nutrition
If initial management is unsuccessful, and the poor nutritional
status of the person with developmental disability continues,
enteral tube feeding should be considered (see eTG complete).
Any decision to commence this should involve the person, their
family and other support people, and relevant specialists (eg
dietitian, speech pathologist, gastroenterologist). A decision-
making framework may be helpful so the clinical assessments,
options for management and views of all these people are
considered. Tis may be particularly useful when people have
conficting views (see Box 9).
OVERWEIGHT AND OBESITY
Overweight and obesity are generally more common in people
with developmental disability than in the general population.
Te prevalence cited in the literature varies widely, according to
the population studied. However, most studies agree that rates of
obesity (and overweight, to some extent) are signifcantly higher
in women with intellectual disability. Some studies also show
higher rates of obesity in men with intellectual disability.
Most studies show that the people with developmental disability
most at risk of overweight and obesity are:
women
people living in community settings (eg independently, with
families, in disability group homes)
people with less severe levels of disability
people with Down syndrome.
Insufcient physical activity is a major factor in overweight and
obesity. People with developmental disability have higher rates
of physical inactivity and lower cardiovascular ftness than the
general population.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 226
Overweight and obesity are not inevitable in people with
developmental disability. Tey are usually the result of excessive
consumption of energy dense foods and low levels of physical
activity. Terefore overweight and obesity are amenable to the
usual strategies for prevention or treatment. Tis is also true in
people who have a biological basis to their obesity (eg Prader-
Willi syndrome).
Te guidelines for preventing, assessing and managing over-
weight and obesity in adults and children with developmental
disability are the same as for others in the community. Some
modifcations are needed to cater for their cognitive and/or
physical impairments. If a persons accurate height cannot be
determined, other measures (eg waist circumference, skinfold
thickness) can be used. Te persons level of physical activity
(including incidental activity) needs to be estimated. Steps
should be taken to overcome any barriers to participation in
physical activity.
People with developmental disability are as susceptible to
the complications of overweight and obesity as others in the
population. For detailed discussion of overweight and obesity,
see eTGcomplete.
Managing healthy eating and weight in people
with developmental disability
Te goals of the person with developmental disability must be
considered when promoting healthy eating and a healthy weight.
Several factors specifc to this population can be challenging.
Tese include:
inadequate knowledge of nutrition in some support people
who provide the persons food
unhealthy or restricted food choices being made by some
people with developmental disability who access food
independently
inconsistent intervention across diferent support settings
physical disability (this may restrict the persons level of
physical activity)
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 227
commonly used drugs that induce weight gain (eg some
psychotropic drugs, antiepileptic drugs).
Attitudes of family and other support people
Most people with developmental disability rely on family
members or other support people for their access to food
or physical activitythese people may have inadequate
understanding of healthy nutrition and the persons nutritional
needs. For example, they may:
not see the persons overweight and obesity as a problem
use food to:
encourage appropriate behaviour
minimise unwanted behaviour
provide comfort
provide a diversion
allow the person unlimited access to food
not realise they need to limit portion sizes if the person has
low levels of physical activity.
Food choices
When the person with developmental disability lives in a
community setting, the food preferences and nutritional require-
ments of fellow residents may infuence the types of food given.
Some people with developmental disability are more physically
mobile and independent. Tey can access food independently
(inside and outside the home), but their food choices may not
always be healthy. If the person also has intellectual disability,
their cognitive limitations may make it more difcult to
implement educational and behavioural changes.
Inconsistent intervention
Te promotion of healthy eating and exercise for a person with
developmental disability may be difcult for their support
workers and family members. Ofen the intervention needs to
be applied consistently in many settings (eg disability group
home, family home, day program, respite care, social activities)
to be successful.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 228
When the person lives in a disability group home:
diferent shifs and high turnover of residential staf can lead
to inconsistent and sometimes ad hoc decisions about food
shopping and meals
if stafng levels are inadequate or inconsistent, this may
reduce the support available for the person to take part in
physical activity.
Helpful strategies
Te following strategies can promote weight management in a
person with developmental disability:
Include family members and key support people when
devising management plans.
Get advice from a dietitian on:
the persons diet
food shopping lists and meal plans for the entire
household.
Ensure a consistent eating plan is implemented in all
settings (eg disability group home, day program).
Where appropriate, consider referring the person for
behaviour support to help monitor and change eating
behaviours.
Encourage group-based physical activities, so everyone in
the household can participate.
Where possible, consider alternative drugs that are less
likely to cause weight gain.
VITAMIN AND MINERAL DEFICIENCIES
Folate, iron and micronutrient defciencies may occur in people
with undernutrition (eg from dysphagia). It is important to
test for these defciencies and correct them if necessary. People
with gastro-oesophageal refux disease with oesophagitis are
especially at risk of iron defciency due to blood loss. VitaminD
defciency is prevalent in people with developmental disability,
due to a combination of factors (eg limited sun exposure, use
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Nutritional disorders 229
of some antiepileptic drugs that interfere with vitamin D me-
tabolism). People at risk of defciency should have their serum
25-hydroxy vitamin D concentration measured and be given
vitaminD supplements if indicated.
Vitamin and mineral defciencies and their treatment (including
information on vitamin D and calcium supplements) are dis-
cussed in eTGcomplete.
REFERENCES AND FURTHER READING
Australian Technical Advisory Group on Immunisation. The Australian immunisation
handbook. 9th ed. Canberra: NHMRC; 2008.
Beange H, Gale L, Stewart L. Project renourish: a dietary intervention to improve nutritional
status in people with multiple disabilities. Aust NZ J Dev Disabil 1995;20(3):165-74.
Bhaumik S, Watson JM, Thorp CF, Tyrer F, McGrother CW. Body mass index in adults
with intellectual disability: distribution, associations and service implications: a population-
based prevalence study. J Intellect Disabil Res 2008;52(Pt 4):287-98.
Emerson E. Underweight, obesity and exercise among adults with intellectual disabilities
in supported accommodation in Northern England. J Intellect Disabil Res 2005;49(Pt
2):134-43.
Hove O. Weight survey on adult persons with mental retardation living in the community.
Res Dev Disabil 2004;25(1):9-17.
National Health and Medical Research Council. Dietary guidelines for Australian adults.
Canberra: Commonwealth of Australia; 2003.
NSW Family and Community Services Ageing Disability and Home Care. Health care policy
and procedures: attachment 08. Physical activity chart [checklist]. Sydney: NSW ADHC;
2010.
NSW Family and Community Services Ageing Disability and Home Care. Nutrition resouces
[various]. Sydney: NSW ADHC.
Robertson J, Emerson E, Gregory N, Hatton C, Turner S, Kessissoglou S, et al. Lifestyle
related risk factors for poor health in residential settings for people with intellectual
disabilities. Res Dev Disabil 2000;21(6):469-86.
Temple VA, Walkley JW. Physical activity of adults with intellectual disability. J Intellect Dev
Disabil 2003;28(4):342-53.
Vanlint S, Nugent M, Durvasula S. Vitamin D and people with intellectual disability. Aust
Fam Physician 2008;37(5):348-51.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 230
Dysphagia
Dysphagia (difculty swallowing) is common in people with
developmental disability. It has been estimated that its prevalence
in adults with multiple disabilities is as high as 76%. People
with severe physical disability secondary to cerebral palsy are
much more likely to have difculty swallowing and, possibly,
malnutrition. Infants diagnosed with, or at risk of, cerebral palsy
or intellectual disability (eg extremely low birthweight infants)
may be at risk of feeding difculties.
Dysphagia is a condition that afects:
several body functions and structures
activity and participation (eg eating and drinking; attendance
at work; preparation of meals; informal associations with
others; participation in ceremonies, religious events and
recreation and leisure).
*
In turn, the efect of dysphagia on the life of a person with
developmental disability is infuenced by environmental factors.
Tese include:
foods, products and technology
family, support people and service providers.
Te interaction of all these efects should be considered in
assessing and managing dysphagia in a person with develop-
mental disability.
Consequences of dysphagia can include:
death from choking
aspiration (inhaling food or fuid into the lungs) and its
complications (see below)
nutritional compromise (malnutrition and dehydration)
*
World Health Organization. International classication of functioning, disability and
health. Geneva: World Health Organization; 2001.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 231
changes to usual patterns of oral intake
social isolation and a negative efect on psychosocial health
(eg depression, anxiety related to coughing or choking)
reduced quality of life.
Complications of aspiration related to dysphagia include
pneumonia, recurrent respiratory illness, wheezing and night-
time coughing. Some of these may be masked by, or mistaken
for, symptoms of asthma. Aspiration pneumonia is one of the
most common causes of death in people with developmental
disability. Eating and drinking without appropriate dietary and/
or positioning modifcations may be life-threatening (see advice
on minimising these risks).
Developmental disabilities may be considered stable conditions,
but some functional changes related to ageing must be
considered in the management of dysphagia. For example, the
swallowing skills of some people with developmental disability
deteriorate afer the age of 30 years. It is important to review
their swallowing ability and oral intake regularly.
PRESENTATION
A person with dysphagia and/or aspiration may present with
one or more of the following symptoms:
coughing or choking on food, fuid or saliva
drooling or poor saliva control
difculty chewing or swallowing food, fuids, drugs or saliva
(food or fuid falls out of the mouth)
taking a long time to eat
eating and drinking less (eg early satiety; food avoidance,
refusal or restricted range)
fatigue afer eating or drinking
disruption to normal sensations of hunger and satiety
being underweight or losing weight
lung involvement:
chronic wheezing
recurrent chest infections.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 232
Many symptoms of dysphagia can be observed by the person
with dysphagia (or their support person) during mealtimes
or when administering drugs. However, the absence of some
symptoms does not mean there is no dysphagia. For example,
some people with reduced sensation, or a weak or inefective
cough refex, may not cough even if they aspirate food, fuid or
saliva. Silent aspiration (aspiration without triggering a cough
refex) is common in people with cerebral palsy. It might only
be detected by specifc investigations. If a persons physical
presentation suggests that dysphagia is present or suspected,
a full assessment by a speech pathologist and other relevant
professionals is indicated.
ASSESSMENT
A screening for dysphagia can be performed using a checklist
*
by
the persons general practitioner (GP), family member or other
support person. Following a positive screening, a comprehensive
multidisciplinary dysphagia assessment is indicated so informed
decisions can be made about interventions (see Box 9). Tis
may involve a number of professionals and may require clinical
and additional investigations. Gathering information from the
person with disability, family members and/or other support
people should be part of the assessment.
Dysphagia afects a persons health and quality of life. A person
with developmental disability and dysphagia may have difculty
communicating by speech and have complex communication
needs. It is important that they have a way to communicate.
Tey need to be included to the level of their understanding and
capacity in the dysphagia assessment and decisions that afect
their mealtimes.
A speech pathologist can be consulted to:
determine if a person vulnerable to poor communication
might beneft from:
*
A nutrition and swallowing risk checklist is available as attachment 1 to the nutrition
and swallowing policy of the New South Wales Department of Family and Community
Services Ageing, Disability and Home Care.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 233
an augmentative or alternative communication (AAC)
system
other communication supports
update or redesign the persons existing form of AAC for use
during the assessment and throughout management.
Clinical assessment
Te role of a GP in working with the person with developmental
disability and dysphagia is to:
assess the persons clinical presentation
refer to other members of the multidisciplinary team.
Te GPs assessment should include an investigation of:
the primary clinical condition underlying the dysphagia
any associated conditions afecting the persons dysphagia (eg
respiratory compromise, gastro-oesophageal refux disease,
malnutrition, oral health problems)
current drug treatment (some drugs may afect the persons
ability to swallow)
family and social dynamics afecting the persons oral intake
factors associated with quality of life that are related to the
persons dysphagia or management.
Referral to a respiratory physician or gastroenterologist may
be needed for further assessment of the persons respiratory or
gastrointestinal status, respectively.
If the GP detects signs or symptoms of dysphagia, they can refer
the person to a speech pathologist for a full clinical assessment
of dysphagia and mealtimes. Within a multidisciplinary team,
the speech pathologist has several roles. Tese include to:
make clinical observations on the process of swallowing and
symptoms of dysphagia
advise the GP and other professionals on additional invest-
igations needed, so they can make appropriate referrals
advise on ongoing mealtime management and give reasons
for recommendations
advise on any therapeutic interventions to improve the
persons function in eating and drinking
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 234
advise if the person needs any communication supports or
AAC systems.
Te GP may also refer the person to a dietitian, to assess
nutritional status and any need for nutritional rehabilitation.
Cerebral palsy and other physical disabilities may afect a
persons ability to maintain an upright posture or appropriate
head positioning when swallowing (eg at mealtimes or other
times of oral intake). Poor posture, or inadequate seating or
head support while eating, may contribute to dysphagia and can
increase the risk of aspiration. People with physical disability
may need a customised seating system for:
optimal positioning during mealtimes
clinical assessment or additional investigation of dysphagia
and dietary intake.
Terefore it is important to consider the persons seating
and positioning, and make appropriate referrals (eg to an
occupational therapist and physiotherapist) if needed.
Investigations
Te person with dysphagia may require additional investigations
such as:
videofuoroscopy of the swallow (modifed barium swallow)
fbreoptic endoscopic examination of the gastro-oesophageal
tract.
Tese investigations can be used to:
identify the level, degree and type of dysphagia
determine the level and degree of aspiration and any factors
in the swallow that contribute to aspiration
assess the efect of positioning and other therapeutic strategies
that might help the swallow or reduce the risk or occurrence
of aspiration.
Other investigations may include radiology of the chest and tests
to assess nutritional status (eg iron studies, full blood count,
liver biochemistry, vitaminB
12
and folate concentrations, body
composition studies).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 235
MANAGEMENT
Te GP should maintain an overall awareness of the persons
dysphagia in relation to other areas of their general health and
wellbeing.
Some interventions for dysphagia can reduce the risk of choking
or aspiration pneumonia and increase the efciency of oral
intake. Tey include:
modifying food or fuid consistencies according to the
persons difculty in swallowing
training support people to modify food and fuids
altering food quantities, meal timing or pacing of oral intake
teaching the person specifc swallowing techniques to protect
the airway.
Interventions to help the persons swallow include:
oromotor therapy designed to improve movement of the
mouth, lips, tongue and cheeks
specialised food utensils (eg cups, spoons, plates and bowls)
designed to increase independence or promote a more
efcient swallow
prompts to promote a safe swallow (eg cough, swallow again,
chin down)
training for support staf on techniques to help the person
eat.
Te person with dysphagia who is underweight or has difculty
maintaining adequate food intake may beneft from nutritional
rehabilitation and/or enteral tube feeding.
People with physical disability may need a customised seating
system to help them stay upright when eating or drinking.
Health problems related to the persons dysphagia (eg gastro-
oesophageal refux disease, efect of drugs, oral health) also need
to be managed. Drugs that might afect swallowing may need to
be reviewed (see next page).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 236
Drugs and dysphagia
A number of drugs exacerbate dysphagia by:
reducing saliva fow (eg anticholinergic drugs)
causing nausea
afecting neuromotor control of the swallow (eg sedatives,
psychotropic and antiepileptic drugs).
Interactions between drugs can make dysphagia symptoms
worse and interfere with absorption of nutrients from food.
Dysphagia can also afect how a person takes drugs. If it
stops them from taking an oral drug in solid form, alternative
formulations must be considered (eg liquid, suppository, patch).
Saliva control
Poor saliva control or drooling can be a symptom of difculty
in swallowing, and has important social efects. It afects 10%
to 37% of people with cerebral palsy and a signifcant number
of people with other developmental disabilities. A range of
surgical, medical and behavioural interventions is used for saliva
management, with varying success. Interventions may include
referral for behaviour modifcation and biofeedback, oromotor
therapy, drug therapy and surgery.
Oral health
Poor oral health results in increased numbers of bacteria in the
oral area. Tis has been implicated as a signifcant factor in the
development of aspiration pneumonia in elderly people who
inhale food or fuids. Terefore, it is important that a person
with dysphagia and developmental disability maintains optimal
oral health through implementation of an oral health care plan.
Dental or gum infections must be treated promptly to reduce
the risk of the person developing respiratory illness related to
dysphagia and aspiration. See also the chapter on oral health.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 237
Enteral nutrition
Enteral tube feeding should be considered if the person
with dysphagia cannot get adequate nourishment, despite a
reasonable trial of a nutrition care plan. A percutaneous tube
into the stomach should be considered if prolonged enteral
nutrition is likely (ie longer than 4 to 6 weeks). Gastrostomy
tube insertion may be combined with a fundoplication to reduce
gastro-oesophageal refux and aspiration. As a person who has
had both procedures may still aspirate their saliva, it is important
to maintain correct posture and positioning at mealtimes.
Decision-making framework
An ethical decision-making framework (Box 9) is helpful when
assessing and managing dysphagia in people with developmental
disability. Tis framework considers more than the body
structure and the function of swallowing. It guides physicians
in weighing up the facts about the persons dysphagia with the
potential harms and benefts of all treatment options.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 238
Box 9. Decision-making framework for assessing and
managing a person with dysphagia*
Identication
What is the problem?
Who are the people involved? Consider the person, family members,
guardian, other support people, health professionals, advocate
Who can give consent?
Assessment
Include clinical assessments (eg speech pathologist, dietitian, respiratory
physician, gastroenterologist, occupational therapist) and investigations, as
required
Swallowing
Nutrition
Associated medical conditions
Complications
Seating
Communication
Quality of life of the individual, family, other support people
Assess the options for management
What are the options?
What are the benets and harms of each option?
What are the ethical and legal implications of each option?
Who and what does each option involve in practical terms?
Make a decision about management
Consider the values, beliefs and attitudes of all involved in the process
Take a collaborative approach and choose an option
Obtain consent
If people cant agree, look for a way to resolve this (eg conciliation,
independent assessment or [as a last resort] application to the Guardianship
Tribunal)
Implementation
Develop a plan to implement the chosen option
Implement the plan
Monitor, review and amend the plan as appropriate
* See attachment 2 (Decisions about nutrition) to the nutrition and swallowing policy
of the New South Wales Department of Family and Community Services Ageing,
Disability and Home Care.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Dysphagia 239
REFERENCES AND FURTHER READING
Dysphagia [journal]. New York: Springer-Verlag.
Balandin S, Hemsley B, Hanley L, Sheppard JJ. Understanding mealtime changes for
adults with cerebral palsy and the implications for support services. J Intellect Dev Disabil
2009;34(3):197-206.
Feinberg M. The effects of medication on swallowing. In: Sonies BC, editor. Dysphagia: a
continuum of care. Gaithersburg, MD: Aspen Publishers; 1997. p.107-20.
Hemsley B, Balandin S. Disability, dysphagia, and complex communication needs: making
room for communication in ethical decisions about dysphagia. Adv Speech Lang Pathol
2003;5(2):125-9.
Kaatzke-McDonald M. Dysphagia, disability, and icebergs: a discussion. Adv Speech Lang
Pathol 2003;5(2):131-5.
Langmore SE, Terpenning MS, Schork A, Chen Y, Murray JT, Lopatin D, et al. Predictors of
aspiration pneumonia: how important is dysphagia? Dysphagia 1998;13(2):69-81.
Nunn JH. Drooling: review of the literature and proposals for management. J Oral Rehabil
2000;27(9):735-43.
Rosenthal S, Sheppard JJ, Lotze M. Dysphagia and the child with developmental
disabilities: medical, clinical and family interventions. San Diego (CA): Singular Publishing
Group; 1995.
Sonies BC. Dysphagia: a continuum of care. Gaithersburg, MD: Aspen; 1996.
Sullivan PB, Lambert B, Rose M, Ford-Adams M, Johnson A, Grifths P. Prevalence and
severity of feeding and nutritional problems in children with neurological impairment:
Oxford Feeding Study. Dev Med Child Neurol 2000;42(10):674-80.
Threats TT. Use of the ICF in dysphagia management. Semin Speech Lang 2007;28(4):323-
33.
Weir KA, McMahon S, Taylor S, Chang AB. Oropharyngeal aspiration and silent aspiration
in children. Chest 2011;140(3):589-97.
World Health Organization. International classication of functioning, disability and health.
Geneva: World Health Organization; 2001.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Oral health 240
Oral health
Te efect of oral health on general health has been well
documented. Poor oral health increases the risk of aspiration
pneumonia and complicates the management of diabetes. Also,
oral health afects nutritional status.
Factors that increase the risk of dental disease in people with
developmental disability include:
inadequate plaque removal
reliance on support people for oral care (may be complicated
by challenging behaviour)
diet (may include frequent small meals and drinks that are
high in sugars and other carbohydrates)
poor oral clearance of foods (food debris lef around the
teeth)
drug-induced dry mouth (xerostomia)
increased incidence of gastro-oesophageal refux disease.
Patient fear can hinder optimal dental care. When examining
the mouth of a person with developmental disability, using their
toothbrush (instead of a spatula) may help. Some people are
sufciently traumatised by oral examinations that they need a
sedative or general anaesthetic for work to be performed.
ORAL CARE
Efective cleaning of teeth is important to minimise dental
caries and periodontal disease. Most people with developmental
disability need some help to clean their teeth. Toothbrushing is
a complex process that requires fne motor skills and planning.
If a toothbrush is used incorrectly, it can cause trauma to the
sof tissues of the mouth. It is natural to resist toothbrushing if it
has caused pain. People with developmental disability may show
challenging behaviours during toothbrushing.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Oral health 241
Brushing another persons teeth can be a complex task. Support
people need to be taught how to brush peoples teeth efectively
without causing discomfort.
Most people with developmental disability need some help to
clean their teeth.
Interdental cleaning is ofen difcult for people with develop-
mental disability. Again, support people may be taught how to
help.
DENTAL CARIES
Saliva prevents tooth decay by washing away food debris and
remineralising teeth. People with developmental disability are
ofen taking drugs that may cause a dry mouth (eg tricyclic
antidepressant and anticholinergic drugs). Tis increases their
risk of dental decay.
Strategies to reduce the incidence of tooth decay include:
advising people with dry mouth to use high-dose fuoride
toothpaste
teaching people with developmental disability (and their
support people) to brush teeth with fuoride toothpaste twice
a day
discouraging frequent consumption of high-carbohydrate
snacks and sugary drinks
providing healthy snacks (eg cheese, nuts, raw vegetables)
providing alternative sweet foods (eg confectionery sweet-
ened with xylitol, in moderate quantities to avoid osmotic
diarrhoea)
promoting frequent drinking of water between (and with)
meals, and in place of sugary or acidic drinks
providing saliva substitutes for people with dry mouth
(replacing missing enzymes eg lactoperoxidase, lactoferrin
and lysozyme)
encouraging interdental cleaning (including using dental
foss) where possible.
For a detailed discussion of dental caries, see eTGcomplete.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Oral health 242
DENTAL EROSION
Gastro-oesophageal refux disease (GORD) introduces stomach
acid into the mouth at regular intervals. Te acid erodes the
teeth, leaving them hypersensitive. Te degree and pattern of
tooth wear may be the frst indicators that a person sufers from
GORD. Te management of tooth wear is complex. In severe
cases, the teeth need restoration using an overlay technique
(expensive and complex). Early diagnosis of GORD is essential
to avoid this.
PERIODONTAL DISEASE
Failure to clean teeth efectively results in periodontal disease
(gum disease), which can lead to halitosis, dental caries and
tooth loss.
People with Down syndrome are more susceptible than the
general population to periodontal disease, due to a reduced
immunologic response caused by neutropenia. Torough
toothbrushing and interdental cleaning is essential.
Periodontal disease is discussed in detail in eTGcomplete.
DENTAL MALOCCLUSION
People with developmental disability have an increased
incidence of oromotor dysfunction, which in turn increases the
likelihood of dental malocclusion. Orthodontic treatment may
be appropriate. For the best result, this should commence when
secondary (adult) teeth are developing (ie between the ages of
6 to 12 years). During this time, children with developmental
disability should be examined regularly by an oral health
professional. If necessary, interceptive care to reduce the degree
of malocclusion can be provided. Conventional orthodontics
may not be possible for people with challenging behaviours.
RESOURCES
Resources on oral health for people with developmental
disability, their families, support people and professionals are
listed on the next page.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Oral health 243
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Dental Health Services Victoria
Resources for people with disabilities, health professionals and
carers to help people with disability to manage their oral health
British Society for Disability and Oral Health
Society for all interested in the oral health of people with
disability
International Association for Disability and Oral Health
(iADH)
Association working with the community, health professionals
and social or service organisations to improve the oral health
and quality of life of people with special needs
REFERENCES AND FURTHER READING
Holland TJ, OMullane DM. The organisation of dental care for groups of mentally handi-
capped persons. Community Dent Health 1990;7(3):285-93.
Kuo LC, Polson AM, Kang T. Associations between periodontal diseases and systemic
diseases: a review of the inter-relationships and interactions with diabetes, respiratory
diseases, cardiovascular diseases and osteoporosis. Public Health 2008;122(4):417-33.
Mustapha IZ, Debrey S, Oladubu M, Ugarte R. Markers of systemic bacterial exposure
in periodontal disease and cardiovascular disease risk: a systematic review and meta-
analysis. J Periodontol 2007;78(12):2289-302.
National Institute of Dental and Craniofacial Research. Developmental disabilities and oral
health [web page]. Bethesda, MD: NIDCR, National Institutes of Health (NIH); accessed
June 2012.
Nunn JH, editor. Disability and oral care. London: FDI World Dental Press; 2000.
Sullivan WF, Heng J, Cameron D, Lunsky Y, Cheetham T, Hennen B, et al. Consensus
guidelines for primary health care of adults with developmental disabilities. Can Fam
Physician 2006;52(11):1410-8.
Waldman BH, editor. Abstracts in developmental dentistry [web page]. Prospect, KY:
American Academy of Developmental Medicine and Dentistry; accessed June 2012.
Williams RC, Barnett AH, Claffey N, Davis M, Gadsby R, Kellett M, et al. The potential
impact of periodontal disease on general health: a consensus view. Curr Med Res Opin
2008;24(6):1635-43.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 244
Sexual expression
People with developmental disability have the same range of
sexual desires and expression as the rest of the community.
However, they may have limited life experiences and limited
social opportunities to learn about sexuality. People with
developmental disability can be assisted to develop their sexual
expression to its full potential.
When a person with developmental disability becomes sexually
active, their parents or other support people may be anxious.
Tis anxiety about the risks and the vulnerability of the person
may not be warranted. Each case needs to be assessed on its
merits.
People with developmental disability and those supporting them
need:
appropriate and accessible information on sexuality
advice on how the person can incorporate this part of their
identity into their daily life.
General practitioners have a substantial role as educators. Te
appropriate approach varies with the needs of each person with
developmental disability. It is important to:
consider what treatment or counselling they would be given
if they did not have a disability
be aware of myths and stereotypes about the sexuality of
people with developmental disability
consider the underlying cause of any form of sexual ex-
pression that is problematic.
FACTORS AFFECTING SEXUAL EXPRESSION
Adolescence or early adulthood is the time when a persons
awareness and expression of their sexuality develops. See sexual
expression in an adolescent with developmental disability.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 245
INAPPROPRIATE SEXUAL BEHAVIOUR
Inappropriate sexual behaviour in a person with developmental
disability may be due to a lack of knowledge or experience. If
a person masturbates in public, it may be because they dont
understand the diference between public and private places.
Inappropriate sexual behaviour may also be related to the
persons disability. For example, if a person has repetitive and
obsessive behaviour, this may afect how they express their
sexuality. Inappropriate sexual behaviour may also be an
expression of:
a medical condition (eg the discomfort of a urinary tract
infection or chronic constipation)
boredom or a lack of meaningful activity.
When counselling a person with inappropriate sexual behaviour:
exclude any underlying medical and/or psychiatric causes
consider the underlying cause of their disability and its
associated problems
encourage ongoing education in all aspects of human rela-
tions and sexuality
consider whether they have sufcient meaningful activities
encourage them to seek opportunities to develop worthwhile
and meaningful relationships (including sexual relationships)
with others.
If appropriate, the person should be referred for behaviour
management and education.
MASTURBATION
Masturbation is a normal and natural experience for men and
women of all ages. Sometimes masturbation may not in itself be
a sexual act. It may simply be a form of sensory stimulation that
is readily accessible and usually pleasurable. Masturbation at the
appropriate time and place can be acceptable behaviour.
Acceptable behaviour when a person with developmental
disability wants to masturbate can be encouraged by:
redirecting them to their room when appropriate
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 246
ensuring they have privacy
ensuring age-appropriate access to erotic materials (eg
magazines, posters, pictures)
providing appropriate education and opportunities to explore
this aspect of their sexual development
teaching socially acceptable rules of sexual behaviour (eg
masturbation is an activity that occurs in a private place
[such as a bedroom], any bodily fuids should be cleaned up
[logical consequences])
educating support people (if necessary) about socially
acceptable behaviour.
Parents and other support people may become concerned
when they think the person with developmental disability is
masturbating too ofen. Te reason for masturbating should be
sought if it is causing physical injury or signifcantly afecting
the persons daily life. Usually there is no medical cause. Ofen,
frequent masturbation is an expression of boredom and the
absence of other meaningful and enjoyable activities.
Te frequency of masturbation can be afected by changing
environmental factors. For example, support people may
fnd that redirecting the person to other activities is the most
appropriate strategy.
Anal masturbation
Some people derive sexual pleasure from anal masturbation,
and sometimes this is associated with faecal smearing. A person
who chooses to masturbate this way is likely to continue, despite
how others feel about it. Terefore it is important to teach them
to be responsible in this practice.
Responsible anal masturbation practices include:
not smearing faeces
practising good hygiene before and afer masturbation
ensuring foreign objects and sex toys used during
masturbation are unbreakable, have smooth surfaces and can
be retrieved
masturbating in private.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 247
HOMOSEXUALITY
Homosexuality does not appear to be more or less frequent
in people with developmental disability than in the rest of the
population. However, many older people with developmental
disability have spent long periods in institutions, usually in
same-sex units. Teir sexual experiences may have been limited
to same-sex activity through lack of opportunity, rather than as
a sexual preference.
People with developmental disability need opportunities to so-
cialise and experience a range of relationships so they can realise
their sexual preferences. Safe sex practices should be encouraged.
CONTRACEPTION
Providing contraception to a person with developmental dis-
ability removes the fear of an unwanted pregnancy. However, it
does not diminish their vulnerability to sexual abuse, exploitation
or sexually transmissible infections (STIs).
When considering contraception, the persons needs should be
assessed from the least restrictive point of view. Te decision
should not be based on what is easier for parents or other
support people. Te views of the person with developmental
disability should be explored, by talking with them if possible.
Teir ability to give informed consent to sexual contact or a
relationship also needs to be assessed.
Advice on contraception should always include:
the rights and responsibilities of being sexually active
protective behaviour strategies, such as teaching a person
about:
their body parts
how to sense their feelings
knowing when they dont feel safe, and how to talk about
it with someone they trust
safe sex practices (eg safe touching, using condoms to avoid
STIs)
the right to say no.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 248
Te practitioner may consider informing parents or other
support people about:
appropriate medical review (timing and type)
potential adverse efects of the chosen form of contraception.
See contraceptive choices for women.
Boys and men should be given explicit explanations about the
correct use of condoms. Teir understanding of this information
should be checked carefully. Tis is essential, so they have the
information they need to protect themselves and their partner.
PREVENTIVE HEALTH CARE
Preventive health screening for people with developmental
disability is the same as for the rest of the population (see
Table 9). It should never be assumed that a person with develop-
mental disability is not having sexual intercourse. Regardless
of the perceptions of family and other support people, they
need education about STIsthis should be appropriate to their
learning level.
RESOURCES
Te following websites have information on sexual health,
education and contraception.
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Centre for Developmental Disability Health Victoria
Family Planning Queensland (disability services and
resources)
HealthInsite
Sexual Health and Family Planning Australia
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Sexual expression 249
REFERENCES AND FURTHER READING
Cambridge P, Carnaby S, McCarthy M. Responding to masturbation in supporting sexuality
and challenging behaviour in services for people with learning disabilities a practice and
research overview. J Learn Disabil 2003;7(3):251-66.
Eastgate G. Sexual health for people with intellectual disability. Salud Publica Mex 2008;50
Suppl 2:s255-9.
Hamilton CA. Now Id like to sleep with Rachael: researching sexuality support in a service
agency group home. Disabil Soc 2009;24(3):303-15.
Healy E, McGuire BE, Evans DS, Carley SN. Sexuality and personal relationships for people
with an intellectual disability. Part I: service-user perspectives. J Intellect Disabil Res
2009;53(11):905-12.
Higgins D. Sexuality, human rights and safety for people with disabilities: the challenge of
intersecting identities 1. Sex Relation Ther 2010;25(3):245-57.
Hingsburger D, Tough S. Healthy sexuality: attitudes, systems, and policies. Res Pract
Persons Severe Disabl 2002;27(1):8-17.
Rissel CE, Richters J, Grulich AE, de Visser RO, Smith AM. Sex in Australia: selected
characteristics of regular sexual relationships. Aust N Z J Public Health 2003;27(2):124-
30.
Stinson J, Christian LA, Dotson LA. Overcoming barriers to the sexual expression of women
with developmental disabilities. Res Pract Persons Severe Disabl 2002;27(1):18-26.
Swango-Wilson A. Caregiver perceptions and implications for sex education for individuals
with intellectual and developmental disabilities. Sex Disabil 2008;26(3):167-74.
Taylor Gomez M. The S words: sexuality, sensuality, sexual expression and people with
intellectual disability. Sex Disabil 2012;30(2):237-45.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Angelman syndrome 250
Angelman syndrome
Angelman syndrome is a severe neurodevelopmental disorder
associated with intellectual disability. It also features severe
speech impairment, gait ataxia and tremulousness of the limbs.
People with Angelman syndrome have distinctive behaviour
with an inappropriate happy afect, which includes frequent
laughing, smiling and excitability. Microcephaly and seizures
are common.
Te epidemiology of Angelman syndrome has only been studied
in relatively small populations. Te estimated prevalence varies
with the method used, and ranges from 1in52000 to 1in10000
births. In Western Australia, the estimated prevalence is approxi-
mately 1in21 000 births.
*
CAUSE
Angelman syndrome is caused by several genetic mechanisms
involving chromosome15. Tese include:
a deletion of the 15q11.2-q13 critical region (60%to 75%)
a mutation in the ubiquitin-protein ligase E3A (UBE3A) gene
(10%)
paternal uniparental disomy (2%to 5%)
an imprinting defect (2%to 5%).
Te risk of recurrence varies according to the type of mutation.
*
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report
of the idEA database: intellectual disability in Western Australia. Perth, WA: Telethon
Institute for Child Health Research; 2004.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Angelman syndrome 251
DIAGNOSIS
Diagnosis of Angelman syndrome is challenging, and based
on the clinical characteristics in Table 17. It usually requires
evaluation by a clinician (eg developmental paediatrician,
clinical geneticist) who is familiar with the nuances of this
syndrome. Clinical diagnosis is difcult in the frst 2to 3years
of life. Conditions with a similar presentation include Rett
syndrome, Lennox Gastaut syndrome, autism spectrum disorder
and nonspecifc cerebral palsy.
In about 90% of cases, clinical diagnosis can be confrmed by
genetic testing.
CLINICAL CHARACTERISTICS
Te developmental history of people with Angelman syndrome
reveals:
normal antenatal and birth history
normal head circumference at birth
no major birth defects
developmental delay by 6to 12months of age that is ongoing,
but not accompanied by regression.
Investigations show:
normal metabolic, haematological and chemical laboratory
profles
normal brain structure.
Table 17 lists the characteristics of Angelman syndrome and
their chance of being present in afected people.
Children with Angelman syndrome can acquire some simple
skills associated with daily living, but not enough to live in-
dependently. By adulthood, about 80% are toilet-trained by day.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Angelman syndrome 252
Table 17. Clinical characteristics of Angelman
syndrome
*
Present in 100%
of cases
Present in at least
80% of cases
Present in 20% to
80% of cases
severe developmental
delay
speech impairment
(minimal or no use of
words)
movement or balance
disorder
distinctive behavioural
phenotype
frequent laughter
excitability
hand-apping
hyperactivity
microcephaly (absolute
or relative) by the age
of 2 years
seizures (onset usually
before the age of
3 years)
abnormal
electroencephalogram
(pattern characteristic
of this syndrome)
at occiput
occipital grooves
deep-set eyes
feeding problems/
hypotonia during infancy
prominent jaw
wide mouth, widely
spaced teeth
frequent drooling
protruding tongue
tongue thrusting
excessive chewing/
mouthing behaviours
strabismus
hypopigmented skin
fair to blond hair
hyperactive lower limb
deep tendon reexes
(often difcult to assess)
uplifted exed arm
position, especially when
walking
wide-based gait
increased sensitivity to
heat
sleep disturbances
(improve with age)
fascination with water
abnormal food-related
behaviours
obesity
scoliosis
constipation
* Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, et al.
Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med
Genet A 2006;140(5):413-8.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Angelman syndrome 253
MANAGEMENT
Managing a person with Angelman syndrome includes estab-
lishing the diagnosis, particularly because it gives parents:
an explanation for their childs disability
access to the benefts of a support association.
Conditions that need to be managed include:
seizures
gastrointestinal problems (eg gastro-oesophageal refux,
constipation)
orthopaedic problems (eg subluxed or pronated ankles)
hyperactive behaviour
sleep problems
obesity.
Arranging respite care is also important.
Children may beneft from physiotherapy and occupational and
speech therapy.
RESOURCES
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Te Angelman Syndrome Association provides information and
support for parents, professionals and other interested people.
Angelman Syndrome Association
Telephone (02) 9520 5857
A multidisciplinary Angelman syndrome clinic is located in
Sydney, New South Wales.
Te Angelman Syndrome Clinic
Developmental Assessment Service
PO Box 90, Kogarah NSW 2217
Telephone (02) 8566 1222 or 1300 721 770
Email AngelmanClinic@sesiahs.health.nsw.gov.au
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Angelman syndrome 254
REFERENCES AND FURTHER READING
Bonanni P, Gobbo A, Nappi S, Moret O, Nogarol A, Santin M, et al. Functioning and
disability in patients with Angelman syndrome: utility of the international classication of
functioning disability and health, children and youth adaptation framework. Disabil Rehabil
2009;31 Suppl 1:S121-7.
Clayton-Smith J, Pembrey ME. Angelman syndrome. J Med Genet 1992;29(6):412-5.
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report of the
idEA database: intellectual disability in Western Australia. Perth, WA: Telethon Institute for
Child Health Research; 2004.
Petersen MB, Brondum-Nielsen K, Hansen LK, Wulff K. Clinical, cytogenetic, and molecular
diagnosis of Angelman syndrome: estimated prevalence rate in a Danish county. Am J Med
Genet 1995;60(3):261-2.
Tan WH, Bacino CA, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, et al.
Angelman syndrome: Mutations inuence features in early childhood. Am J Med Genet A
2011;155A(1):81-90.
Thomson AK, Glasson EJ, Bittles AH. A long-term population-based clinical and morbidity
prole of Angelman syndrome in Western Australia: 1953-2003. Disabil Rehabil 2006;
28(5):299-305.
Van Buggenhout G, Fryns JP. Angelman syndrome (AS, MIM 105830). Eur J Hum Genet
2009;17(11):1367-73.
Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, et al.
Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A
2006;140(5):413-8.
Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome.
Genet Med 2010;12(7):385-95.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 255
Autism spectrum disorder
Autism spectrum disorder is a group of lifelong neurodevelop-
mental disabilities with onset before the age of 3 years (see
characteristics of the spectrum). Clinically the disorder has a
range of overlapping presentations. Te three most common
types are:
autistic disorder
Asperger disorder
atypical autism (pervasive developmental disorder not
otherwise specifed [PDDNOS]).
Other pervasive developmental disorders include Rett syndrome
and childhood disintegrative disorder.
Autism spectrum disorder is an abnormality of brain develop-
ment and function. It is likely to have multiple causes. Twin
studies strongly support genetic factors as a cause. A medical
condition (eg tuberous sclerosis) may be associated in 10%
to 37% of cases. Tere is no evidence to support theories that
autism is caused by environmental factors (eg immunisations)
or parenting style.
Autistic disorder has a prevalence of about 0.8 to 1 in 1000.
Te prevalence of Asperger disorder is likely to be higher, with
estimates as high as 3in 1000. Te prevalence of atypical autism
is not known, but is estimated to be 1in 1000. In Australia, on
average, 1in 160children aged 6to 12years old has an autism
spectrum disorder.
*
More children with autism spectrum
disorder are presenting for services. Tis may refect an increase
in incidence, but is more likely due to improved case-fnding.
*
Australian Advisory Board on Autism Spectrum Disorders. The prevalence of autism in
Australia: can it be established from existing data? Frenchs Forrest, NSW: Australian
Advisory Board on Autism Spectrum Disorders; 2007.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 256
Children with autism spectrum disorder do not grow out of
it, but their symptoms change and ofen improve with age. If
they develop epilepsy in adolescence, this can compromise
their progress. Outcome depends on IQ and the development
of language abilities and social skills. Te best outcomes are
seen in people with an IQ in the normal range who have spoken
language by the age of 5years.
CHARACTERISTICS
Autism spectrum disorder is associated with a core triad of:
impaired social interaction and development
impaired verbal and nonverbal communication
repetitive, stereotyped and restricted behaviour.
Asperger disorder difers from autistic disorder in that:
children with Asperger disorder do not have impaired early
communication and play
children with Asperger disorder do not have a language delay
Asperger disorder is not associated with intellectual disabil-
ity or defcits in nonsocial adaptive function.
General practitioners (GPs) can watch out for the following
characteristics that may indicate autism spectrum disorder. For
example, the child who:
does not babble, point or make meaningful gestures by the
age of 1year
does not speak single words by the age of 16months
does not combine two words by the age of 2years other than
by echolalia
does not respond to their name
loses language or social skills at any age.
Impaired social interaction
Impaired social interaction can present in a person with autism
spectrum disorder in a variety of ways, as described on the next
page.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 257
Typically, people with classic autism may:
be aloof and fail to develop friendships
be socially passive (while tolerating social approaches)
be awkward, avoidant or indiferent with eye contact (unless
eye contact has been taught)
have markedly impaired use of nonverbal behaviours to
regulate social interaction (eg gestures and facial expression)
lack spontaneity in seeking to share enjoyment with others.
People with high-functioning autism (ie with normal intelli-
gence) or Asperger disorder are likely to:
seek peoples company, but may have difculty engaging in
two-way social interactions
have stilted, one-sided or repetitive social interactions
be unable to understand social rules (eg make socially
embarrassing comments unintentionally)
have impaired understanding of the motivations, perspective
or feelings of others.
Te proposed DSM-V category for autism spectrum disorder
is a diagnosis closer to classic autism. If accepted, it may result
in poorer detection of children currently being diagnosed with
Asperger disorder.
Impaired communication and play
Te development and qualitative use of communication
may be impaired in a person with autism spectrum disorder.
Consequences include:
delay in (or lack of) speech development, without a compen-
satory form of communication (eg gesture, mime)
signifcant difculty initiating and sustaining a conversation
stereotyped or idiosyncratic use of language
lack of imitation of others.
Te play of a child with autism spectrum disorder lacks the
variety or make-believe that is appropriate to their developmental
level.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 258
Restricted, repetitive and stereotyped interests
and behaviours
Te interests and behaviours of a person with autism spectrum
disorder are ofen restricted, repetitive and stereotyped.
Examples are:
interests that are excessively narrow, intense or unusual
adherence to rigid routines
intolerance of change
stereotyped/repetitive motor mannerisms (eg hand-fapping)
persistent preoccupation with parts of objects.
AUTISTIC DISORDER, ASPERGER DISORDER
AND ATYPICAL AUTISM
Autistic disorder is the best-known disorder in the autism
spectrum, and is sometimes called classical, Kanner or
childhood autism. It is more common in males than females
(3:1). People with autistic disorder have the core triad of impaired
social interaction, impaired communication and repetitive,
stereotyped behaviour. 70% of people with autistic disorder
have intellectual disability. Te remaining 30%, with an IQ in the
normal range, are sometimes called high functioning. Despite
this, they ofen have major difculty functioning independently.
On intelligence testing their profle may be uneven, with
advanced visuomotor skills but delayed verbal performance.
Asperger disorder is also more common in males than females
(13:1), but it may be underdiagnosed in females. Diagnosis is
based on impaired social interaction and restricted, repetitive
and stereotyped interests and behaviours. Language is not
signifcantly delayed, but its social use is subtly impaired. Tis
is ofen disabling because it leads to teasing and social isolation.
People with Asperger disorder have normal or borderline
intellectual ability, as classifed by DSM-IV criteria.
*
*
American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical
manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric
Association; 2000.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 259
On psychological assessments they may have better verbal skills
than nonverbal skills. Other typical characteristics are:
clumsiness
concrete pedantic speech
lack of common sense
normal (or even precocious) speech development
intolerance of change
anxiety.
People with Asperger disorder ofen want friendships, but lack
the skills to make and maintain them.
Atypical autism is also known as pervasive developmental
disorder not otherwise specifed (PDDNOS). Tis diagnostic
grouping is used when core autistic behaviours are present
but the criteria for autistic disorder are not fully met. Reasons
for not meeting these criteria include late age of onset or
symptomatology that is atypical or subthreshold.
COMMON ASSOCIATED CONDITIONS
Certain conditions are common in association with autism
spectrum disorder. Te main neurological comorbidities
are epilepsy, fne and gross motor impairments and sleep
disturbances. Epilepsy is common in people with autism
spectrum disorder, and can develop at any age.
Many people with autism spectrum disorder also have unusual
sensory responses. Tese include:
sensitivity (or aversion) to certain sounds or tactile sensations
intolerance of certain foods
fascination with spinning objects or lights.
Emotional and behavioural problems are common in autism
spectrum disorder, afecting more than 50% of people.
Depression, anxiety disorders and schizophrenia and related
psychoses may emerge during adolescence and continue into
adulthood. See assessment and management of psychiatric
disorders.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 260
People with autistic disorder form afectionate attachments to
those they know well, and experience sadness and grief afer loss
or bereavement. Particularly in childhood, they may develop
behavioural problems (eg angry outbursts, self-injury, feeding
difculties or fads, sleep disorders, hyperactivity). Anxiety
may underlie many of these problemsit may be due to poor
communication skills, overstimulation or lack of predictability
in the persons environment.
DIAGNOSIS
Accurate diagnosis of autism spectrum disorder is important.
Parents ofen suspect that their child is diferent. Trough
assessment, they can understand their childs needs and strengths
better. Early diagnosis maximises learning opportunities.
Trough the Helping Children with Autism program, specifc
Medicare items may apply for specialist and multidisciplinary
assessment and therapy.
Diagnosis of autism spectrum disorder requires specialist team
skills.
Diagnosis in adulthood is more difcult. However, previously
undiagnosed adults without signifcant intellectual disability
ofen fnd a diagnostic assessment is helpful. It explains their life
experience and gives them access to support (eg a student with
Asperger disorder may beneft from educational help to study
efectively).
A discussion of the diagnostic process is available from Autism
Victoria.
MANAGEMENT
Autism spectrum disorder should be managed with a multimodal
program of targeted and structured educational and behavioural
interventions. If indicated, these may be supplemented with
pharmacotherapy. Management should include training in
educational, behavioural and social skills and communication.
Tis should be tailored to the persons intellectual ability,
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 261
language ability, age and needs. Psychoeducational support for
parents and siblings, together with an individual management
program, produces a better outcome. No one approach to
intervention and treatment can be applied to all people with
autism spectrum disorder.
Early behavioural management
Training in behavioural management and skills by a
multidisciplinary team (eg psychologists, speech pathologists
and occupational therapists) produces better outcomes for
children with autism spectrum disorder. Behavioural approaches
may involve promoting competent behaviours and reducing
difcult or antisocial behaviours. Antecedents and consequences
of the target behaviours need to be identifed.
A range of behavioural techniques is appropriate for people with
autism spectrum disorder. It includes positive reinforcement,
verbal and nonverbal prompting and behavioural chaining
(ie setting small goal steps to slowly teach the child a new
behaviour). Evidence suggests Applied Behaviour Analysis
(ABA) improves cognitive skills in preschool children. However,
ABA programs are time-consuming and a fnancial burden
for families. Other approaches include the treatment and
education of autistic and related communication handicapped
children (TEACCH) program, sensory integration therapy and
augmentative communication.
Other interventions
Other educational and behavioural interventions that contribute
to better adjustment to autism spectrum disorder include:
augmenting communication by visual means (eg picture
communication books, diaries, rule books)
managing sensory-induced stress
improving coordination by sensory integration and motor
interventions, prescribed by an occupational therapist or
physiotherapist
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 262
reducing anxiety (eg relaxation exercises, environmental
modifcation, martial arts)
modelling appropriate sequences of behaviour using Social
Stories or personalised picture and text stories of daily or
special events (eg Bill goes to school on the bus).
Parents of children with autism spectrum disorder (more so
than for any other disability) ofen have mental health problems,
resulting from the stress of caring for their child. Parent
education and skills training in managing autistic behaviours
improves outcomes for the family and child.
Drug therapy
Behavioural, educational and social approaches are the main
treatments for autism spectrum disorder. Using psychotropic
drugs to reduce the severity of some symptoms may be
considered if:
behavioural therapy and environmental modifcation have
failed
the benefts of drug therapy outweigh the harms.
Specialist psychiatric consultation is needed. For discussion of
pharmacological management in autism spectrum disorder, see
eTGcomplete.
ROLE OF THE GENERAL PRACTITIONER
Te GP has an important role in managing a person with autism
spectrum disorder. Tey can:
identify autism spectrum disorder as early as possible
initiate referral for assessment
improve the quality of the persons medical care (eg by
adapting their clinical approach, taking into account the
persons social, communicative and behavioural patterns).
Te GP can also help the persons family. Tey can:
support the family during, and afer, diagnosis (eg help them
to access information and services)
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 263
address the needs of family members (eg parental grief, stress
or depression; efect on siblings)
reassure parents that the:
cause of their childs autism spectrum disorder is outside
their control, and they need not feel guilty
condition can be improved by specifc behaviour
interventions.
RESOURCES
Te following services can be helpful for people with autism
spectrum disorder and their families:
children up to the age of 6years: early intervention services
school-age children: school psychological services, special-
ist autism services, government disability services, and
relevant medical services (eg paediatric, psychiatric)
adults: autism-specifc serviceswhen the person also has
intellectual disability, they can access disability services.
Services for eligible children may be accessed through the
Helping Children with Autism program, Australian Govern-
ment Department of Health and Ageing.
Other services include respite care, home help, and social
skills and work preparation courses for adolescents and young
adults. Information is available from local government disability
services and local autism or Asperger disorder organisations.
Fact sheets
Fact sheets on many aspects of autism spectrum disorder are
available from the Autism Secondary Consultation and Training
Strategy (ACT-NOW), Monash University, Victoria.
State autism associations
State autism associations provide information and support for
parents, professionals and other interested people.
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 264
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Australian Capital Territory
Autism Asperger ACT
Telephone (02) 6176 0514
New South Wales
Autism Spectrum Australia (Aspect)
Telephone (02) 8977 8300
Northern Territory
Autism Northern Territory
Telephone (08) 8948 4424
Queensland
Autism Queensland
Telephone (07) 3273 0000
South Australia
Autism SA
Telephone (08) 8379 6976
Tasmania
Autism Tasmania
Telephone 1300 288 476
Victoria
Amaze
Telephone 1300 308 699
Western Australia
Autism Association of Western Australia
Telephone (08) 9489 8900
REFERENCES AND FURTHER READING
American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical
manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric
Association; 2000.
Australian Advisory Board on Autism Spectrum Disorders. The prevalence of autism in
Australia: can it be established from existing data? Frenchs Forrest, NSW: Australian
Advisory Board on Autism Spectrum Disorders; 2007.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Autism spectrum disorder 265
Autism spectrum conditions. In: Lindsay P, editor. Care of the adult with intellectual dis-
ability in primary care. London: Radcliffe; 2011. p.210-15.
Brereton AV, Tonge BJ. Pre-schoolers with autism: an education and skills training pro-
gramme for parents: a manual for parents. London: Jessica Kingsley; 2005.
Brereton AV, Tonge BJ. Pre-schoolers with autism: an education and skills training pro-
gramme for parents: manual for clinicians. London: Jessica Kingsley; 2005.
Campbell M, Schopler E, Cueva JE, Hallin A. Treatment of autistic disorder. J Am Acad
Child Adolesc Psychiatry 1996;35(2):134-43.
Carr J. Helping your handicapped child. 2nd ed. Harmondsworth (Middlesex): Penguin
Books; 1995.
Gillberg C. Clinical child neuropsychiatry. Cambridge: Cambridge University Press; 1995.
Maski KP, Jeste SS, Spence SJ. Common neurological co-morbidities in autism spectrum
disorders. Curr Opin Pediatr 2011;23(6):609-15.
Maurice C, Green G, Luce SC. Behavioral intervention for young children with autism: a
manual for parents and professionals. Austin, Tex.: Pro-Ed.; 1996.
McPartland JC, Reichow B, Volkmar FR. Sensitivity and specicity of proposed DSM-
5 diagnostic criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry
2012;51(4):368-83.
Prior M. Is there an increase in the prevalence of autism spectrum disorders? J Paediatr
Child Health 2003;39(2):81-2.
Schopler E. Parent survival manual: a guide to crisis resolution in autism and related
developmental disorders. New York: Plenum Press; 1995.
Tonge B, Brereton A, Kiomall M, Mackinnon A, King N, Rinehart N. Effects on parental mental
health of an education and skills training program for parents of young children with autism:
a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2006;45(5):561-9.
Tonge BJ. Autism: time for a national approach to early assessment and management.
Med J Aust 1996;165(5):244-5.
Volkmar FR, Klin A. Autism and pervasive developmental disorders. In: Gelder MG, Lopez-
Ibor JJ, Andreasen N, editors. New Oxford textbook of psychiatry. Oxford: Oxford University
Press; 2000. p.1723-34.
Werry JS, Aman MG, editors. Practitioners guide to psychoactive drugs for children and
adolescents. New York, NY: Plenum Medical Book Co; 1993.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Cerebral palsy 266
Cerebral palsy
Cerebral palsy describes a group of developmental disorders
of movement and posture causing activity restriction or
disability, that are attributed to disturbances occurring in the
fetal or infant brain. Te motor impairment may be accom-
panied by a seizure disorder and by impairment of sensation,
cognition, communication and/or behaviour and by secondary
musculoskeletal problems.
*
It has a prevalence of 2.0to 2.5per
1000 live births. Most people with cerebral palsy live into
adulthood, and many live into old age.
As cerebral palsy is caused by a diference in development of, or
injury to, the developing brain, it is nonprogressive. However,
people with cerebral palsy experience changes in function
throughout their lives. Tese may result from:
changes in relative length of muscles and bones during
periods of rapid growth
contractures, joint subluxation, dislocation or deterioration
(arthritis)
the efects of medications
the efects of physical or mental ill health.
Te physical wear and tear on the musculoskeletal system, in
some cases compounded by chronic ill health, takes its toll. Tis
means that people with cerebral palsy may begin to experience
the efects of ageing as early as their late twenties or early thirties.
*
Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the
denition and classication of cerebral palsy April 2006. Dev Med Child Neurol Suppl
2007;49(suppl. 109):8-14.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Cerebral palsy 267
CAUSE
Te term cerebral palsy describes a movement disorder, but
gives no information about the cause of the motor impairment.
Cerebral palsy has diverse risk factors (eg low birthweight
and prematurity) and causes. It may result from events in the
prenatal, perinatal or postneonatal period. Whenever possible,
the cause should be established. In a considerable proportion of
cases it remains unknown.
Information about the cause of cerebral palsy is helpful for
families and a foundation for accurate genetic counselling.
A brain scan (by magnetic resonance imaging) should be
performed if the cause is not apparent. Investigations such as
urinary metabolic screening and chromosome analysis may
elucidate rare causes.
Prenatal events are responsible for approximately 75% of cases
of cerebral palsy. Known causes include congenital intrauterine
infection (eg rubella, cytomegalovirus, toxoplasmosis), vascular
events (eg middle cerebral artery occlusion) and malformations
(eg cortical dysplasias).
Perinatal asphyxia accounts for only 8% to 10% of cases of
cerebral palsy. It may be the result of antepartum haemorrhage
or other placental or cord problems. Neonatal problems (eg
severe hypoglycaemia, untreated jaundice) may also cause
cerebral palsy.
Postneonatal events account for about 10% of cases of cerebral
palsy. Known causes include:
accidental injury (eg hypoxic events [such as near-drowning
accidents], head trauma [such as from motor vehicle
accidents])
nonaccidental injury, resulting in head injury
severe brain infections (eg meningitis).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Cerebral palsy 268
CLASSIFICATION
Cerebral palsy may be classifed according to the:
type of motor disorder (eg spasticity, dyskinesia, ataxia,
mixed)
distribution of the motor disorder (eg hemiplegia, diplegia,
quadriplegia)
severity of the efect of the motor disorder on function.
Spasticity is the most common type of motor disorder (about
70% of cases). Te increased muscle tone has a characteristic
clasp-knife quality. Clinical features include impaired control of
voluntary movement, and ofen there is underlying weakness.
Contractures may result.
Dyskinesia (dystonia or athetosis) usually afects the whole body
(including all four limbs), and generally results from damage
to the basal ganglia. It is characterised by variable muscle tone
and involuntary movements. Dystonia is the term for sustained
muscle contractions that frequently cause twisting or repetitive
movements or abnormal postures. Athetosis refers to slow
writhing movements involving the distal parts of the limbs.
Ataxia is a disorder of balance associated with damage to the
cerebellum. Unsteadiness, tremor and hypotonia may be present.
A mixture of more than one type of motor disorder is common,
particularly the combination of spasticity and dystonia.
Te severity of the motor disorder is best described by the Gross
Motor Function Classifcation System (GMFCS), a fve level
grading system based on functional abilities.
*
Overseas
estimates and recent research indicate that these fgures are
probably an underestimate.
CAUSE
Prenatal alcohol exposure increases the risk to the fetus
throughout pregnancy. Tere is no safe time for a pregnant
woman to consume alcohol. However, not all children exposed
to alcohol in utero are afected, or are afected to the same extent.
FAS occurs when the child is exposed to alcohol during the frst
8weeks of embryogenesis.
*
Bower C, Rudy E, Callaghan A, Quick J, Cosgrove P, Nassar N. Report of the birth
defects registry of Western Australia 19802008. Subiaco, WA: King Edward Memorial
Hospital; 2009.
Bower C, Silva D, Henderson TR, Ryan A, Rudy E. Ascertainment of birth defects:
the effect on completeness of adding a new source of data. J Paediatr Child Health
2000;36(6):5746.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fetal alcohol syndrome 296
Te mothers alcohol consumption may be:
chronic heavy daily
frequent heavy intermittent (at least 5drinks per occasion at
least once a week [ie binge drinking]).
Exposure to alcohol later in pregnancy may afect prenatal and
postnatal growth and cause neurodevelopmental disorders. Low
levels of prenatal alcohol exposure appear to be low risk. However,
a safe threshold of prenatal alcohol consumption has not been
established. Research indicates the risk increases with 3 to 4
standard drinks per occasion, consumed once or twice a week.
Te risk of FAS is increased by factors related to:
genetics
low socioeconomic status (eg environmental pollutants, poor
nutrition, smoking, psychological stress, physical abuse).
FAS is more common in some minority racial groups, but
there is no evidence this is due to biological factorsdrinking
patterns, quantity of alcohol consumed and factors relating to
low socioeconomic status are thought to contribute. An older
maternal age (30 years and over) has also been associated
with increased risk of FAS in the child. However, this may be
confounded by drinking alcohol for longer, rather than being an
efect of age per se.
DIAGNOSIS
Tree key features are present in FAS:
growth retardation:
height and/or weight are lower than normal (at or below
the 10th percentile)
characteristic facial features:
smooth ridge between the nose and upper lip
thin upper lip
short distance between the inner and outer corners of the
eyes, giving the eyes a wide-spaced appearance
central nervous system anomalies or dysfunction:
structural (eg head smaller than normal, structural
changes on brain scans)
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fetal alcohol syndrome 297
neurologic (eg poor coordination, poor muscle control)
functional (eg signifcant developmental delay or low
IQ; problems with executive functions, motor function,
attention, social skills).
If a person has abnormalities in each of these key features, most
other syndromes can be excluded.
Diagnostic features can change with age. Facial features are easiest
to distinguish during infancy and early preschool years, but a
characteristic dysmorphic pattern continues into adolescence.
FAS causes difculties in many areas of executive functioning
and social skills, and these may be present in early childhood.
Problems in central nervous system function ofen lead to
maladaptive behaviour and psychiatric disorders.
Prenatal alcohol exposure can have a negative efect on the
central nervous system without producing the characteristic
facial features of FAS. Tis is classifed as alcohol-related
neurodevelopmental disorder (ARND).
*
ARND includes a
range of disabilities, such as:
problems in behaviour, emotion, self-regulation and mood
poor motor, adaptive and executive functioning.
MANAGEMENT
One aspect of managing FAS is its prevention, and the other is
caring for the person who has it. Once a mother has a child with
FASD, it is likely that subsequent ofspring will be afected unless
the mother abstains from alcohol.
Prevention
Preventing FASD requires:
early identifcation of women who drink during pregnancy:
a helpful questionnaire is the WHO Alcohol Use Disorders
Identifcation Test (AUDIT)
GPs can use the short AUDIT-C (3 questions) initially,
then complete the full AUDIT (10questions) if required
*
A consensus statement [217KB] on recognising alcohol-related neurodevelopmental
disorder (ARND) in primary health care of children has been released by the Interagency
Coordinating Committee on Fetal Alcohol Spectrum Disorders.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fetal alcohol syndrome 298
the T-ACE questionnaire can be used to identify alcohol
dependence
intervention to help pregnant women to stop drinking alcohol
or, when this is not possible, to help them to drink less
intervention to prevent further alcohol-exposed pregnancies
(eg reduce harmful alcohol consumption by nonpregnant
women of childbearing age, promote efective use of
contraception by women who continue to drink heavily)
referral to appropriate alcohol services (to modify maternal
drinking behaviour) and supportive social services.
Te National Health and Medical Research Council Australian
guidelines state For women who are pregnant or planning a
pregnancy, not drinking is the safest option.
Caring for people with fetal alcohol spectrum
disorder
Early diagnosis of FASD is important, enabling early intervention
and prevention of secondary disabilities.
When a child is suspected of having a FASD, their management
involves:
confrming the diagnosis with a paediatrician
monitoring:
growth and development
hearing (sensorineural and conductive)
behaviour and mental health
referring for early intervention for identifed problems,
preferably to services with expertise in FASD (there is
limited scientifc evidence for specifc interventions, but
some evidence supports training in social skills and attention
processes)
preventing secondary disabilities (eg unemployment,
inappropriate sexual behaviour, criminal activity, disrupted
schooling)
supporting the childs family (eg promoting a stable home
environment, advising parents on strategies to promote child
and family functioning and manage problem behaviours).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fetal alcohol syndrome 299
RESOURCES
Te following websites have information on preventing, diag-
nosing and managing FASD.
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Fetal Alcohol Spectrum Disorder Model of Care
Western Australia Department of Health
National Organisation for Fetal Alcohol Syndrome and
Related Disorders (NOFASARD)
Telethon Institute for Child Health Research
Perth, Western Australia
REFERENCES AND FURTHER READING
Astley SJ, Clarren SK. Diagnosing the full spectrum of fetal alcohol-exposed individuals:
introducing the 4-digit diagnostic code. Alcohol Alcohol 2000;35(4):400-10.
Bower C, Rudy E, Callaghan A, Quick J, Cosgrove P, Nassar N. Report of the birth defects
registry of Western Australia 1980-2008. Subiaco, WA: King Edward Memorial Hospital;
2009.
Bower C, Silva D, Henderson TR, Ryan A, Rudy E. Ascertainment of birth defects: the effect
on completeness of adding a new source of data. J Paediatr Child Health 2000;36(6):
574-6.
Chang G. Alcohol-screening instruments for pregnant women. Alcohol Res Health 2001;
25(3):204-9.
Chudley AE, Conry J, Cook JL, Loock C, Rosales T, LeBlanc N. Fetal alcohol spectrum
disorder: Canadian guidelines for diagnosis. CMAJ 2005;172(5 Suppl):S1-S21.
Floyd RL, Sobell M, Velasquez MM, Ingersoll K, Nettleman M, Sobell L, et al. Preventing
alcohol-exposed pregnancies: a randomized controlled trial. Am J Prev Med 2007;32(1):
1-10.
Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD).
Consensus statement on recognizing alcohol-related neurodevelopmental disorder in
primary health care of children. Rockville, MD: ICCFASD; 2011. [217KB]
May PA, Gossage JP, Kalberg WO, Robinson LK, Buckley D, Manning M, et al. Prevalence
and epidemiologic characteristics of FASD from various research methods with an
emphasis on recent in-school studies. Dev Disabil Res Rev 2009;15(3):176-92.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fetal alcohol syndrome 300
National Health and Medical Research Council. Australian guidelines to reduce health risks
from drinking alcohol. Canberra: NHMRC; 2009.
OLeary CM, Bower C. Guidelines for pregnancy: Whats an acceptable risk, and how is the
evidence (nally) shaping up? Drug Alcohol Rev 2011;31(2):170-83.
Streissguth AP, Bookstein FL, Barr HM, Sampson PD, OMalley K, Young JK. Risk factors
for adverse life outcomes in fetal alcohol syndrome and fetal alcohol effects. J Dev Behav
Pediatr 2004;25(4):228-38.
Western Australian Department of Health. Fetal alcohol spectrum disorder model of care.
Perth: Health Networks Branch, Department of Health; 2010.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 301
Fragile X syndrome
Fragile X syndrome is the most common known inherited cause
of developmental disability. It has a range of presentations, and
has developmental, physical, behavioural and emotional efects.
Although caused by a mutation on the X chromosome, it has
signifcant clinical efects in males and females.
CAUSE
Fragile X syndrome results from a mutation at the fragile X
mental retardation 1 (FMR1) gene on the long arm of the
X chromosome. When cultured in a folate-free medium, the
afected site has a gap on karyotyping and looks pinched or
fragile.
Te FMR1 gene makes a protein, FMR1 protein (FMRP).
FMRPs function is important for normal neurological develop-
ment. Most people have a normal trinucleotide (cytosine-
guanine-guanine [CGG]) repeat sequence of 6 to 45, with an
average of 30repeats. Te mutation is an expansion in the size
of this repeating sequence. Expansion only occurs when the
FMR1 gene is passed to a female fetus. When there are more
than 200 nucleotide repeats (known as a full mutation), the
FMR1 gene methylates and switches of production of FMRP.
People with a smaller expansion of 50to200 nucleotide repeats
are said to have a premutation.
Fragile X syndrome occurs in approximately 1in3600 people in
the general population. Te premutation is more commonit
occurs in approximately 1in130 to 1in250 females and 1in250
to 1in800 males.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 302
Pattern of inheritance
Both males and females can pass the premutation or full
mutation for fragile X syndrome on to their children.
A woman with fragile X syndrome full mutation has a 50%
chance of passing this on to her son or daughter.
A woman with fragile X syndrome premutation also has a
50% chance of passing the gene on to her son or daughter.
Te risk of the gene expanding to a full mutation is 50%
overall, and increases with the number of repeats.
A man with fragile X syndrome premutation passes it on
to his daughters without it changing in size. His sons only
receive his Ychromosome, so cant inherit the gene.
A person identifed to have fragile X syndrome has inherited it
from their mother. Te mother carries either a premutation or
a full mutation. Many people from the extended family across
generations are likely to carry the gene and may be afected.
However, in at least 30% of new cases of fragile X syndrome
there is no known family history.
PRESENTATION
Typical features of fragile X syndrome vary in severity, and may
not always be present (see the guidelines for testing).
Full mutation of the fragile X gene
Te full mutation of the fragile X gene has developmental,
physical, behavioural and emotional efects on a person.
Females may appear less afected than males, because one of
their Xchromosomes is normal.
Developmental effects
Children with fragile X syndrome ofen appear normal, and at
an early age their developmental delay may only be mild. Tis
means diagnosis is ofen delayed.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 303
Fragile X syndrome can result in:
intellectual disability (IQ less than70):
afecting most males and 30% to 50% of females
ranging from mild to severe, with most people in the mild
to moderate range
global developmental delay, including:
speech, language and communication difculties
poor fne and gross motor coordination
specifc learning difculties.
Behavioural and emotional characteristics
Te physical and developmental signs of fragile X syndrome
may be subtle or overlooked. As a result, the behavioural
and emotional phenotype of fragile X syndrome is ofen the
presenting feature. Tis includes:
anxiety and associated disorders (prominent; includes
panic disorder, social anxiety disorder, generalised anxiety
disorder)
attention defcit hyperactivity disorder (ADHD)
autism spectrum disorder (30% of people):
includes social avoidance and anxiety (see above), poor
eye contact/gaze aversion, resistance to change, stereotypic
behaviours, distinctive hand mannerisms (hand- and
wrist-biting, hand-fapping), preoccupation with objects,
echolalia, sensory defensiveness (aversion to touch, loud
noises, bright lights and strong smells)
mood disorders (eg tendency to outbursts of anger and
aggression, especially in postpubertal males).
Physical characteristics
Up to 80% of males and some females with fragile X syndrome
have large or prominent ears, a long face and/or macro-
orchidism. In addition to a long face, afected people may have
a high broad forehead, high arched palate and protruding lower
jaw (mandibular prognathism). Te facial features may be less
prominent in women, particularly those without intellectual
disability.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 304
Medical conditions
Up to 20% of people with fragile X syndrome have epilepsy
(usually tonic-clonic or complex partial seizures).
An elastin disorder associated with fragile X syndrome is
thought to explain:
vision problems (strabismus, errors of refraction)
recurrent ear infections
heart problems (mitral valve prolapse, aortic root dilation)
orthopaedic problems (particularly fat feet [pes planus],
hyperextensible joints, sunken chest [pectus excavatum],
scoliosis, congenital hip dislocation).
Premutation of the fragile X gene (fragile X
syndrome carriers)
People who carry the premutation for fragile X syndrome
generally have a normal IQ. However, some display characteristics
of the full mutation in a milder version, including physical
features (eg large ears) and hand-fapping. Other presenting
problems include learning difculties, ADHD, autism spectrum
disorder, executive function defcits and anxiety and mood
disorders. Te practitioner should enquire about these features.
Approximately 20% of females carrying the premutation for
fragile X syndrome have been shown to have fragile X premature
ovarian insufciency (FXPOI). Tis is much higher than the
incidence in the general population (1% of females). It may be
signifcant for females who want to have children. In addition
to receiving genetic counselling, they may need counselling on
other topics, such as whether to:
start their families at a younger age
use in vitro fertilisation technologies.
Fragile X tremor ataxia syndrome (FXTAS) is a degenerative
neurological disorder described in older people with the
premutation. It has been shown in approximately 40% of ageing
male carriers and 8% to 16% of female carriers older than
50 years. Suspicions may be raised when any person over the
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 305
age of 50 years presents with tremor, ataxia, cognitive decline
and deterioration similar to Parkinsons disease. Appropriate
management is to:
ask if they have a family history of fragile X syndrome or
developmental delay
refer them for neurological opinion, regardless of their family
history.
Magnetic resonance imaging may confrm typical brain lesions
in the middle cerebellar peduncles and adjacent white matter.
Pharmacological management can help.
TESTING
Testing for fragile X syndrome using DNA studies is sensitive
and specifc. It also reliably detects carriers of the premutation.
Te request should specify DNA studies for fragile X syn-
drome. General practitioners (GPs) can refer the person with
suspected fragile X syndrome directly or via a specialist for
testing.
DNA studies are necessary to conrm a diagnosis of fragile X
syndrome.
Occasionally, people with other syndromes or disabilities
(eg Down syndrome, cerebral palsy, Pierre Robin syndrome,
Prader-Willi syndrome) have concomitant fragile X syndrome.
If there is reason to suspect this, the person should be tested for
fragile X.
Chromosome analysis by karyotyping has largely been
superseded by comparative genomic hybridisation (CGH)
array (genome-wide microarray). CGH array detects almost
all known genetic causes of developmental delay, with the
exception of fragile X syndrome. Requests for both genome-
wide microarray and DNA studies for fragile X syndrome are
needed when investigating developmental delay.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 306
Who should be tested for fragile X syndrome?
International guidelines suggest any person with signifcant
developmental delay should be tested for fragile X syndrome.
*
Te Human Genetics Society Of Australasia recommend fragile
X testing for people with:
intelligence problems (ranging from learning disabilities to
severe intellectual disability)
social and emotional problems (eg aggression, shyness)
autism spectrum disorder
ADHD
developmental delay
speech and language problems
clinical indications suggesting fragile X premature ovarian
insufciency (FXPOI)
clinical indications suggesting fragile X tremor ataxia syn-
drome (FXTAS)
family history of a fragile X premutation or full mutation.
Specifc Medicare items may apply for fragile X testing.
Antenatal screening for fragile X is being performed more
frequently. Pregnant women and women planning to become
pregnant can be ofered testing if they have cause for concern.
Tis may be followed by referral for genetic counselling, if
needed.
Detecting fragile X syndrome allows families to make informed
decisions about family planning.
If a person tests positive for the fragile X mutation or premutation,
other family members may be afected. Teir family should be
referred for genetic counselling. Tis is important, to allow
families to make informed decisions about family planning. If
the afected person is male, genetic testing focuses on his mother
and her relatives. Nonafected brothers may carry premutations.
It is more common for the premutation to have been inherited
from the maternal grandfather than the maternal grandmother.
*
Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing.
Genet Med 2005;7(8):5847.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 307
Following up family members for testing is known as cascade
testing. Tis needs to be done assiduously, and the family GP
can ensure it happens.
MANAGEMENT
Managing a person with fragile X syndrome involves supporting
the family, coordinating appropriate interventions, and being
alert to conditions that are associated with this syndrome.
Family support and information
See advice on informing parents of their childs disability
(whatever the age of their child). An important part of the
clinicians role is to ofer hope and a positive outlook. All people
have a valuable place in society. People with fragile X syndrome
have many strengths that need to be recognised. Families
cope better when given sufcient information and support. In
addition to genetic counselling, they may need grief and anger
counselling.
Te demands and stresses on the family of a person with fragile X
syndrome can be great, especially if the person has problem
behaviours. Families should be treated with an understanding
of the difculties they may face. Tey should also be respected
for their ability to manage what may be an extremely difcult
situation.
Te family may need help from a community or social worker:
for personal support
to access fnancial assistance (eg applying for pensions and
disability allowances).
Information on fragile X syndrome may be obtained from
genetic counsellors and developmental paediatricians. A range
of medical and educational resources for parents and pro-
fessionals is available.
Intervention
Specifc treatment and intervention strategies (eg educational,
behavioural, pharmacological, medical) are available for people
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 308
with fragile X syndrome. Applying these strategies involves
multiple professionals and parents and other support people.
Early intervention is essential for an optimal outcome for
children with fragile X syndrome. Although most males and
some females require lifelong supervision, many people achieve
functional life skills.
Te GP can ensure that people with fragile X syndrome
are referred for appropriate assessment, intervention and
management. It is essential to refer these people to practitioners
familiar with managing fragile X syndrome. Efective
management may include speech and language therapy, special
education, occupational therapy and clinical and educational
psychology. Referral to a developmental paediatrician and/or a
psychiatric unit may also be appropriate.
See general advice on managing a child with developmental
disability (including services for the child and family).
Conditions associated with fragile X syndrome
A range of conditions is associated with fragile X syndrome,
including:
anxiety and hyperarousal
sensory defensiveness
attention problems
autism spectrum disorder
aggression and mood disorders
epilepsy and seizure disorders
connective tissue disorders.
Regular review is recommended to detect and manage them.
Medical practitioners can coordinate pharmacological and
behavioural management.
With appropriate use of medications, the child with fragile X
syndrome can remain within their community. Tere are no
controlled studies on using psychotropic drugs in the fragile X
syndrome population. However, these drugs are widely used,
and some less rigorous studies support their use.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 309
Anxiety and hyperarousal
Anxiety and hyperarousal are major features of fragile X
syndrome. People with fragile X syndrome ofen satisfy the
DSM-IV criteria for diagnosis of anxiety and associated disorders
(eg generalised anxiety, panic and social phobia disorders).
Treatment for the behavioural components of hyperarousal
includes a sensory diet, visual cues to transitions or change, and
appropriate distractors. Most people respond well to:
selective serotonin reuptake inhibitors
serotonin and noradrenaline reuptake inhibitors
second-generation antipsychotic drugs
clonidine
carbamazepine and sodium valproate (for their efect on
mood).
For further information on these drugs, see eTGcomplete.
Sensory defensiveness
Sensory defensiveness is an overly sensitive response to touch,
smell, sound, sight and taste. Tis leads to hyperarousal. Sensory
defensiveness in a person with fragile X syndrome needs
behavioural management. Otherwise, it may interfere with their
ability to take part in learning or social situations. Occupational
therapists can develop a sensory diet (eg appropriate stimulatory
or calming activities) for the person, to modify their responses
to sensory overload. Te aim of therapy is for the person to have
strategies for responding to the changes and challenges of daily
living.
Attention problems
Te clinician should formally assess the person with fragile X
syndrome for attention disorders (with or without hyperactivity),
as these are common. Behavioural management includes a
sensory diet. It works best in conjunction with drug therapy.
Treatment with dexamphetamine or methylphenidate (see eTG
complete) can be of great beneft, and results in improvement in
60%to 80% of people.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 310
Aggression or agitation
Aggression or agitation in people with fragile X syndrome tends
to be more common afer the onset of puberty, and requires
behavioural intervention (see the chapter on assessing and
managing challenging behaviour. Pharmacological intervention
is also useful. Aggressive behaviour is almost always associated
with underlying anxiety and hyperarousal, and usually follows a
triggering event.
Epilepsy and seizure disorders
Epilepsy and seizure disorders are commonly associated with
fragile X syndrome. For diagnosis and treatment, see the chapter
on epilepsy and eTG complete. Carbamazepine or sodium
valproate are ofen used in fragileX syndrome, perhaps because
of their additional efect on behaviour.
Mood disorders
Mood disorders occur in people with fragile X syndrome,
especially afer the onset of puberty. Depression may develop as
the person gains insight into their condition, or independently
of this. For advice on treatment, see mood disorders and
eTGcomplete.
SCHOOLING
Education is one of a childs most important needs. Good
educational outcomes can be achieved for children with fragile X
syndrome. Ideally the child attends a mainstream school and
interacts with their peers, while following their own (modifed)
syllabus. Regular meetings between educators, parents and
all others involved in the childs care are necessary, to defne
appropriate goals and monitor progress.
Te academic difculties of people with fragile X syndrome are
due to:
poor short-term memory
difculty with auditory processing
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 311
difculty with abstract concepts
poor attention span
difculty with initiation.
At the same time, these people have many strengths (see below).
Tese can be used to optimise their learning and the acquisition
of life skills.
MAXIMISING STRENGTHS
People with fragile X syndrome generally exhibit many strengths,
such as:
a marvellous sense of humour
a socially engaging nature
strong imitation skills
excellent visual skills and visual memory
intense interests.
People with fragile X syndrome are strong visual learners who do
well with pictures and logos. In particular, they learn well using
interactive multimedia computer programs. Teir imitation
skills and good long-term memory are put to advantage in
drama. Tey perform best with concrete relevant tasks (eg
shopping, cooking).
In general, people with fragile X syndrome thrive in an
environment that:
is highly structured and follows routines
prepares them for any changes in routine or environment
has written and visual schedules for the days activities
has minimal auditory and visual distractions
uses maximum visual input (eg pictures, drama)
uses calculators and computers (with interactive multimedia)
as teaching tools.
RESOURCES
Fragile X organisations provide information and support for
parents, professionals and other interested people.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 312
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Fragile X Alliance Inc
Telephone (03) 9528 1910
Te Fragile X Association of Australia
Telephone 1300 394 636
National Fragile X Foundation (USA)
Another source of information is Genetics in family medicine:
the Australian handbook for general practitioners. [Canberra]:
Biotechnology Australia; 2007 (see section on fragile X syn-
drome and other causes of developmental delay).
REFERENCES AND FURTHER READING
Braden M. Fragile - handle with care. Revised ed. Colorado Springs: Spectra Publishing
Co. Inc; 2000.
Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr
2009;56:165-86.
Genetics Education in Medicine (GEM) Consortium. Fragile X syndrome and other causes
of developmental delay. In: Genetics in family medicine: the Australian handbook for
general practitioners. [Canberra]: Biotechnology Australia; 2007.
Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al.
Advances in the treatment of fragile X syndrome. Pediatrics 2009;123(1):378-90.
Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: Diagnosis, treatment and
research. 3rd ed. Baltimore (MD): John Hopkins University Press; 2002.
Hersh JH, Saul RA. Health supervision for children with fragile X syndrome. Pediatrics
2011;127(5):994-1006.
Human Genetics Society of Australasia. Best practice fragile X testing and analysis guide-
lines for Australasian laboratories. Sydney: HGSA; 2012. [250 KB]
Metcalfe S, Cohen J. Fragile X syndrome: clinical and molecular aspects. Version 2. [CD
ROM]. [Parkville]: University of Melbourne and Murdoch Childrens Research Institute;
2009.
Nunn KP, Dey C, editors. The clinicians guide to psychotropic prescribing children and
adolescents. Newcastle, NSW: Child & Adolescent Mental Health Statewide Network
CAMHSNET; 2003.
Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing.
Genet Med 2005;7(8):584-7.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Fragile X syndrome 313
Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000;
97(3):189-94.
Tranfaglia MR. A medication guide for fragile X syndrome. 4th ed. Newburyport (MA):
FRAXA Research Foundation; 2009.
Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments
in autism. Neurother 2010;7(3):264-74.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 314
Neurobromatosis type 1
Neurofbromatosis type 1 (NF1) is a tumour predisposition
syndrome with an estimated frequency of about 1 in 3000.
Inheritance is autosomal dominant. NF1 is classifed as a
neurocutaneous disorder. However, it has many clinical
manifestations that can afect most organs of the body, including
the skin, eyes and bony skeleton. Most symptoms of NF1
arise from local pressure exerted by nonmalignant tumours
(neurofbromas), particularly in the central and peripheral
nervous systems.
Common clinical features include:
multiple caf au lait spots (nearly all patients)
axillary and inguinal freckling (80% of patients)
multiple cutaneous and subcutaneous neurofbromas (more
than 95% of patients by adulthood)
superfcial and internal plexiform neurofbromas (50% of
patients)
benign iris hamartomas (Lisch nodules; nearly all patients
older than 20years).
Learning disabilities are common (up to 50% of patients), and
range from subtle to severe. Children with neurofbromatosis are
at increased risk of attention defcit disordersabout40% have
attention defcit hyperactivity disorder (ADHD). See further
discussion of the clinical features of NF1.
Neurofbromatosis type2 (NF2) is also a tumour predisposition
disorder with autosomal dominant inheritance, but its genetic
basis is diferent from NF1. It is characterised by bilateral
vestibular schwannomas (acoustic neuromas) and other tumours
of the central and peripheral nervous systems (including
schwannomas and meningiomas). It is much rarer than NF1
(frequency about 1in 30000), and is not described further.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 315
CAUSE
NF1 arises from autosomal dominant mutations within the
NF1 gene. Tese mutations may be inherited from an afected
parent (about 50% of patients) or due to a new dominant
(sporadic) mutation (about 50% of patients). Te NF1 gene
encodes neurofbromin, an important regulator of cell growth
and diferentiation through the rasMAPK pathway.
DIAGNOSIS
Diagnosis of NF1 is based on clinical fndings, using criteria
established by the National Institutes of Health. Te main dis-
ease manifestations of NF1 (ie caf au lait spots, axillary
freckling, neurofbromas, Lisch nodules) occur in most patients.
Tey are invaluable for making or excluding the diagnosis. In
people older than 5years, if all the main disease manifestations
are absent on screening, a diagnosis of NF1 can be excluded
with more than95% certainty. Te level of certainty is higher for
adults. Tis clinical screening protocol is important for:
excluding or establishing the diagnosis in parents of afected
children
enabling genetic counselling on the risk of NF1 recurring in
a family.
Sometimes patients have features of NF1 in only one part of the
body. Tis is segmental neurofbromatosis. It is probably due to
mosaicism for an NF1gene mutation in a subset of cells or tissues.
Molecular genetic testing is rarely necessary for diagnosing NF1,
since the clinical criteria are sensitive and specifc. Identifying
the NF1gene mutation afer the clinical diagnosis can be useful
for prenatal testing.
CHARACTERISTICS
Te most common features of NF1 are changes in skin pigment
(ie caf au lait spots, axillary and inguinal freckling). Tese ofen
bring the patient to medical attention and diagnosis. Once the
diagnosis is made, patients need regular review to monitor for
possible disease complications.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 316
NF1 is a multisystem disorder and has many complications.
Te more common complications (eg plexiform neurofbromas,
learning disability, optic gliomas, scoliosis) occur in 15%to 50%
of patients. Te more rare complications usually afect fewer
than5% of patients with NF1, but cumulatively cause signifcant
morbidity. NF1 ranges widely in severity. About 40%of people
with NF1 will have medical problems related to the disorder at
some time during their life.
Tumours
Benign neurofbromas may afect almost any organ in the body.
Adults with NF1 usually have numerous benign cutaneous
neurofbromas and Lisch nodules.
Superfcial or internal plexiform neurofbromas are congenital.
Tey occur in about 50% of patients, but usually only half of
them are obvious on clinical examination. Superfcial plexiform
neurofbromas may cause disfgurement. Tose that may
become cosmetically disfguring are usually evident by the
age of 2 years. Parents can be reassured that their child is at
low risk of disfgurement if no such lesions are evident by this
age. Internal tumours can compromise function by exerting
pressure on internal nerves or organs. Plexiform neurofbromas
(but not cutaneous neurofbromas) may undergo malignant
transformation in adults. Tis may be heralded by rapid growth,
pain or a focal neurological defcit.
Te main ocular complications of NF1 are optic gliomas, which
occur in 15% of patients and are symptomatic in 5% to 7%.
Tey may cause decreased visual acuity and/or hypothalamic
dysfunction and precocious puberty. Increased height velocity
may be an early sign of precocious puberty. Te risk of optic
pathway tumours is highest in children younger than 6years.
Other associated conditions
Skeletal manifestations of NF1 include:
congenital pseudoarthrosis (which is usually evident once
the child is weight-bearing)
scoliosis (which may be associated with vertebral dysplasia).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 317
Te frequency of elevated blood pressure increases with
age in people with NF1. In most cases no specifc cause is
found. A minority of patients have renal artery stenosis or
phaeochromocytoma associated with NF1these conditions
need to be excluded. Structural cardiac complications of NF1
are rare, and include pulmonary valvular stenosis.
Other medical concerns in people with NF1 include
vasculopathy, intracranial tumours and malignant peripheral
nerve sheath tumours (MPNST). Tey increase in frequency
with age. MPNST are rare in the general population, but afect
5.9% to 15% of people with NF1. Te onset of malignancy is
highest between the ages of 20and 35years.
Many adults with NF1 experience pain, particularly back pain
and headaches. Pain should be investigated to:
look for an underlying cause
exclude pressure efects from a tumour or malignant
transformation.
Patients ofen beneft from referral to a pain management team,
since nerve pain does not ofen respond to standard analgesia.
Anxiety and depression are more common in patients with NF1,
and need to be actively managed as for the general population
(see eTGcomplete).
MANAGEMENT
Te mainstays of care for patients with NF1 are anticipatory
guidance and early detection and symptomatic treatment of
disease complications. Tis is achieved through regular medical
review, at least once a year for children younger than 18years,
and every second year for adults. Review should be more
frequent if the patient has active medical complications.
Patients with NF1 receive optimal care if they see the same
clinician regularly, and if that clinician has expertise in disease
surveillance for NF1. In Australia, children with NF1 are usually
managed in a clinic at a childrens hospital by a neurologist
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 318
or geneticist, in conjunction with a general paediatrician. For
adults, their general practitioner (GP) is ofen the primary
coordinating clinician. Te GP should refer them to a relevant
specialist if new problems arise.
Genetic counselling
When a diagnosis of NF1 is made, a family history of NF1
should be sought. All available frst-degree relatives should
be screened (by skin and slit lamp examination) to determine
whether the case is familial or sporadic. Afected families should
be seen by a genetics counsellor or a clinical geneticist, to discuss
recurrence risk and options for prenatal diagnosis. Most women
with NF1 have normal pregnancies. Te number and size of
their cutaneous neurofbromas may increase during pregnancy.
When one parent has NF1, each pregnancy has a 50% risk of an
afected child. Te disorder does not run true within the family,
and a mildly afected parent can have a severely afected child. It
is not possible to predict the severity of a persons disease.
Regular medical review
Each regular medical review of a person with NF1 should
include:
a medical history, with a focus on symptoms associated with
NF1 (eg pain, visual complaints, progressive neurological
defcits, seizures, headaches)
physical examination (especially cutaneous, skeletal and
neurological systems):
manifestations of NF1 diagnostic criteria
other medical complications associated with NF1 (eg
elevated blood pressure, scoliosis, focal neurological
defcits, visual loss or feld defects, short stature, signs of
precocious puberty)
ophthalmological evaluation (including slit lamp examin-
ation of the irises):
at least once a year for all children with NF1, up to the age
of 12years
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 319
detailed developmental assessment (if the patient is a child):
yearly review should include a developmental history and
review of school progress
if any areas of concern are identifed, a formal educational
assessment is indicated
other investigations, as dictated by the fndings on history
and clinical examination:
routine screening with magnetic resonance imaging
(MRI) or audiology is not indicated
new or worsening pain should be investigated by imaging
(MRI+/positron emission tomography [PET] scan).
Natural history of neurobromatosis type 1
Input from specialist clinicians familiar with NF1 is helpful
when interpreting neuroimages (eg MRIs) from patients. Tis is
especially so when considering the need for medical or surgical
intervention. For example, even when optic nerve tumours are
detected in patients with NF1, 50% of patients do not develop
symptoms. Furthermore, symptomatic optic nerve lesions are
usually stable for many years, or only progress slowly. Some
lesions may even regress spontaneously.
Discussion of the risk of disease complications with a patient
or parent of a child with NF1 can be helpful. It ofen relieves
unwarranted anxiety, and gives the patient or parent some
perspective on the disorder. As part of this discussion, the risk
of complications at diferent ages is important. For example, a
child aged 10 years is unlikely to develop signifcant cosmetic
disfgurement from a plexiform neurofbroma, or visual loss
from an optic glioma. However, their spine must be closely
watched during puberty for evidence of scoliosis, and cutaneous
neurofbromas are likely to appear during adolescence.
RESOURCES
Te following organisations provide information on neuro-
fbromatosis.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Neurobromatosis type 1 320
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
NF Australia
Childrens Tumor Foundation (USA)
REFERENCES AND FURTHER READING
Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, et al. Neurological
complications of neurobromatosis type 1 in adulthood. Brain 1999;122 (Pt 3):473-81.
DeBella K, Szudek J, Friedman JM. Use of the National Institutes of Health criteria for
diagnosis of neurobromatosis 1 in children. Pediatrics 2000;105(3 Pt 1):608-14.
Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, et al. Mortality
associated with neurobromatosis 1: a cohort study of 1895 patients in 1980-2006 in
France. Orphanet J Rare Dis 2011;6:18.
Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve
sheath tumors in neurobromatosis. Cancer Res 2002;62(5):1573-7.
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for
the diagnosis and management of individuals with neurobromatosis 1. J Med Genet
2007;44(2):81-8.
Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic
evaluation and multidisciplinary management of neurobromatosis 1 and neuro-
bromatosis 2. JAMA 1997;278(1):51-7.
Huson SM. Neurobromatosis 1: A clinical and genetic overview. In: Huson SM, Hughes
RAC, editors. The neurobromatoses: A pathogenetic and clinical overview. London:
Chapman and Hall Medical; 1994. p.160-203.
Hyman SL, Shores EA, North KN. Learning disabilities in children with neurobromatosis
type 1: subtypes, cognitive prole, and attention-decit-hyperactivity disorder. Dev Med
Child Neurol 2006;48(12):973-7.
Hyman SL, Shores A, North KN. The nature and frequency of cognitive decits in children
with neurobromatosis type 1. Neurology 2005;65(7):1037-44.
Mautner VF, Asuagbor FA, Dombi E, Funsterer C, Kluwe L, Wenzel R, et al. Assessment
of benign tumor burden by whole-body MRI in patients with neurobromatosis 1. Neuro
Oncol 2008;10(4):593-8.
Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with
neurobromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J
Surg Pathol 2006;30(1):90-6.
North K. Cognitive function and academic performance. In: Friedman JM, Riccardi
VM, editors. Neurobromatosis: phenotype, natural history, and pathogenesis. 3rd ed.
Baltimore: Johns Hopkins University Press; 1999. p.162-89.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Noonan syndrome 321
Noonan syndrome
Noonan syndrome varies in expression, and its phenotype
changes with age. A child or adult with Noonan syndrome may
have:
short stature
congenital heart disease (mainly valvular pulmonary stenosis)
mild intellectual disability
characteristic facial features and a broad or webbed neck.
Te epidemiology of Noonan syndrome remains poorly defned.
It has been estimated that Noonan syndrome with intellectual
disability accounts for fewer than 1in 10000 births (1in33000
births in Western Australia).
*
As Noonan syndrome is not always
associated with intellectual disability, its true incidence may be
much higher.
CAUSE
Noonan syndrome is genetically heterogeneous. Mutations in the
PTPN11, SOS1, RAF1, KRAS, NRAS and BRAF genes have been
found in approximately 75% of cases. PTPN11gene mutations are
most common. Tese genes encode functionally related proteins
that are implicated in a common signal transduction pathway.
Genetic testing for Noonan syndrome involves sequencing the
most common causal genes. It is normally performed in a tiered
order, starting with the PTPN11gene.
Although the pattern of transmission of Noonan syndrome
in families suggests inheritance is autosomal dominant, a
signifcant proportion of cases is sporadic.
*
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report
of the idEA database: intellectual disability in Western Australia. Perth, WA: Telethon
Institute for Child Health Research; 2004.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Noonan syndrome 322
DIAGNOSIS
Noonan syndrome is usually diagnosed by a clinical geneticist
or experienced paediatrician, based on clinical fndings (see
below). Several other developmental disorders are clinically
(and genetically) related. Tese include LEOPARD syndrome,
neurofbromatosis-Noonan syndrome and cardiofaciocutaneous
syndrome. Te phenotype of Noonan syndrome has some overlap
with neurofbromatosis, as caf au lait spots are common. Also,
some people with neurofbromatosis have facial and cardiac
features similar to people with Noonan syndrome.
Other disorders that share features with Noonan syndrome and
may be confused with it are Costello, Aarskog, Turner and fetal
alcohol syndromes.
If a pathogenic mutation in the PTPN11 gene is detected, this
is useful to confrm the diagnosis, particularly in atypical cases.
CHARACTERISTICS
People with Noonan syndrome have a range of physical features
and medical, cognitive and behavioural problems.
Facial features
People with Noonan syndrome have characteristic facial features,
especially their eyes and neck. Tese include:
widely spaced eyes (hypertelorism)
drooping upper eyelids (ptosis)
downslanting eyes (downslanting palpebral fssures)
a low hairline at the nape of the neck
excess skin behind the nape of the neck at birth (excess nuchal
skin)
neck webbing, more obvious in older children.
As a child gets older, their face may develop a triangular contour.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Noonan syndrome 323
Other common features in people with Noonan syndrome
include:
visual defects, such as strabismus and refractive errors
low-set and posteriorly rotated ears
a high arched palate
a fattened nasal bridge
an unusually small jaw (micrognathia)
wispy hair in infants, more curly or woolly hair in older
children.
Growth
About 80% of people with Noonan syndrome have short stature.
Teir growth before puberty tends to follow the 3rd percentile,
but they may have some catch-up growth during adolescence.
In both sexes puberty may be normal or delayed. Over half the
males with Noonan syndrome have at least one undescended
testis. Tey may also have inadequate secondary sexual
development, associated with defcient spermatogenesis. Most
females are fertile.
Medical conditions
Many medical conditions may be associated with Noonan
syndrome.
More than 80% of people with Noonan syndrome have an
abnormality of the cardiovascular system. Ofen they have an
unusual and distinctive electrocardiographic pattern. Te most
common heart defect (about 50%) is pulmonary valvular sten-
osis. Other heart lesions include hypertrophic cardiomyopathy,
atrial septal defect, asymmetrical septal hypertrophy, ventricular
septal defect and persistent ductus arteriosus.
Some conditions in people with Noonan syndrome afect their
body structure. Chest deformities (eg pectus carinatum, pectus
excavatum) occur in 90%. Cubitus valgus and hand anomalies
are common. Scoliosis and talipes equinovarus also occur.
Hypotonia is common.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Noonan syndrome 324
Other conditions associated with Noonan syndrome are:
abnormal bleeding and bruising (approximately one-third of
people have one or more coagulation defects)
unexplained hepatosplenomegaly (in about 25% of people)
abnormalities of the lymphatic vessels, sometimes leading to
general or peripheral lymphoedema.
Seizures, vision and hearing impairments and dental problems
can also occur.
Cognitive and behavioural problems
About one-third of people with Noonan syndrome have mild
intellectual disability. Teir average IQ is approximately 10points
below that of unafected family members. Learning disability
appears to be associated with specifc visual-constructional
problems. Language delay may be secondary to articulation
problems, mild hearing loss or perceptual motor disabilities.
Behavioural and psychiatric problems may also occur.
MANAGEMENT
A person with Noonan syndrome should be referred to a clinical
geneticist to confrm the diagnosis and provide:
information about its natural course
counselling on mode of inheritance and risk of recurrence.
At the time of diagnosis, the person should:
have routine kidney ultrasound
be referred for management of cryptorchidism (if present).
Management of Noonan syndrome also involves:
specialist care and long-term monitoring of any congenital
heart disease
monitoring growth and endocrine (eg thyroid) status, and
intervening if indicated
screening for clotting abnormalities
assessing and monitoring hearing and vision (including
audiological and ophthalmological examinations)
treating epilepsy (if present)
assessing specifc learning defcits, and possibly intervening.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Noonan syndrome 325
REFERENCES AND FURTHER READING
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report of the
idEA database: intellectual disability in Western Australia. Perth, WA: Telethon Institute for
Child Health Research; 2004.
Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, et al.
Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with
Noonan syndrome and ve patients with cardio-facio-cutaneous syndrome. Eur J Hum
Genet 2003;11(2):201-6.
Noonan JA. Noonan syndrome. An update and review for the primary pediatrician. Clin
Pediatr (Phila) 1994;33(9):548-55.
Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome:
clinical features, diagnosis, and management guidelines. Pediatrics 2010;126(4):746-
59.
Sharland M, Burch M, McKenna WM, Paton MA. A clinical study of Noonan syndrome.
Arch Dis Child 1992;67(2):178-83.
Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best
Pract Res Clin Endocrinol Metab 2011;25(1):161-79.
Wood A, Massarano A, Super M, Harrington R. Behavioural aspects and psychiatric
ndings in Noonans syndrome. Arch Dis Child 1995;72(2):153-5.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 326
Prader-Willi syndrome
Prader-Willi syndrome is a complex genetic condition. It is
characterised by:
an altered pattern of growth and development
a specifc behavioural phenotype that includes hyperphagia.
Te preoccupation with food, and accompanying compulsion
to eat, can cause extreme obesity and premature death. Lifelong
interventions by a multidisciplinary team (including a dietitian)
are essential. Although people with this syndrome have been
reported to live into their eighth decade, it still causes signi-
fcantly increased morbidity and mortality. Most adults live with
family or in accommodation with formal support networks.
Te condition is mostly sporadic, afects males and females,
and is not associated with any ethnic or socioeconomic group.
Estimates of its incidence range from 1in15000 to 1in25000
live births. Probably many cases are undiagnosed.
CAUSE
Prader-Willi syndrome is associated with a lack of expression of
paternally inherited genes on chromosome15q11q13.
Te main genetic mechanisms that have been identifed are
deletions (70%), maternal uniparental disomy (20% to 30%),
translocations, inversions and duplications (5%) and imprinting
centre mutations.
PATHOLOGY
Little is known about the neurological pathology in Prader-
Willi syndrome that leads to congenital hypotonia, growth and
metabolic disorders, developmental disability and hyperphagia.
Neurotransmitters and receptors are probably impaired, causing
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 327
multisystem disorders with variable expression. Te hypo-
thalamus is involved. Having fewer specifc oxytocin neurones
(putative satiety cells) in the hypothalamic paraventricular
nucleus may impair the satiety response, and result in
hyperphagia.
PRESENTATION
Prader-Willi syndrome usually presents in:
infancy, with severe central neonatal hypotonia
early childhood, with developmental delay, hyperphagia and
obesity.
Most children with Prader-Willi syndrome are diagnosed in
their frst year of life. Te core criteria that raise suspicion at
birth result from central generalised hypotonia, and are:
extreme central foppiness
weak cry or inactivity
poor sucking ability.
In older children and adults (who dont have a reliable neonatal
or early history), suspicion may be raised when they have:
hyperphagia
a learning disability or intellectual disability, with impairments
in social cognition, fexibility, abstract ideas and concepts of
time and number
abnormal growth (short stature, small hands and feet,
hypotonia, narrow forehead).
Hypogonadism is common, and puberty is ofen delayed.
DIAGNOSIS
Prader-Willi syndrome is diagnosed by a blood test using a
specifc methylation analysis of DNA. Tis test distinguishes
between the maternal (methylated) and paternal (nonmethylated)
Prader-Willi syndrome region of chromosome15.
Further genetic investigations are required to determine the
genetic mechanism.
In Australia, analysis by comparative genomic hybridisation
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 328
(CGH) array (commonly known as microarray or molecular
karyotype) is recommended. Tis test detects deletions,
translocations with a small deletion, and maternal isodisomy. It
replaces fuorescent in situ hybridisation (FISH). If CGH array
is negative, maternal heterodisomy can be detected by DNA
polymorphism analysis (polymerase chain reaction [PCR]) of
the patient and their parents. Deletions and maternal disomy
are sporadic, with no risk of recurrence.
If all these tests are negative, referral to a geneticist is required, to
test for an imprinting centre mutation and other rare anomalies.
Prenatal diagnosis is possible. Risk of recurrence is low, except
when Prader-Willi syndrome is caused by an imprinting
anomaly.
MANAGING ASSOCIATED HEALTH PROBLEMS
Despite interventions, people with Prader-Willi syndrome have
considerable morbidity and premature mortality. Teir health
problems are related to hypotonia, altered metabolism, obesity,
psychiatric disorders, sleep disorders, scoliosis and other factors.
Regular follow-up and screening for these associated health
problems is essential.
Premature death is commonly associated with cardiorespiratory
complications of obesity. Sudden death is not uncommon. It
may be related to undiagnosed coronary artery disease or other
acute diseases (eg peritonitis secondary to a ruptured appendix).
Tese diseases may not be recognised, because people with
Prader-Willi syndrome have a high pain threshold.
Parents take time to adjust to the diagnosis of a long-term
disability in their infant or child. While doing this, they also
need to develop a healthy approach to eating for the whole
family. It is ofen challenging to maintain weight in an infant
with feeding difculties. However, this is an important time for
families to adjust their eating habits. Te onset of hyperphagia
can be subtle and may be preceded by obesity, refecting an
underlying metabolic disorder.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 329
Failure to thrive
Infants who are slow at sucking and do not wake up hungry for
feeds are at risk of failure to thrive. A Haberman teat may be help-
ful. A speech pathologist can advise on improving oral function.
A dietitian can monitor calories to avoid undernutrition.
Some infants need nasogastric feeding for several weeks or
months. Tey should be closely monitored, to avoid over-
nutrition and excessive weight gain.
Short stature
Prader-Willi syndrome is characterised by impaired linear
growth. Impaired linear growth, abnormal body composition
and hypothalamic dysfunction suggest growth hormone
defciency.
Growth hormone is available in Australia through the Pharm-
aceutical Benefts Scheme (see application and guidelines) for all
children with Prader-Willi syndrome, until the age of 18years.
Te purpose of therapy is to improve body composition
and short stature. An endocrinologist needs to apply to the
Terapeutic Goods Administration, and growth measurements
are required every 3months. Formal sleep studies are required
before commencing therapy and afer 6 weeks, to exclude any
obstructive sleep difculties.
Studies of the efect of growth hormone on quality of life,
development and physical strength are limited.
Respiratory problems
Hypotonia in the upper airways and chest wall increases the
risk of respiratory disease in young children and adults with
Prader-Willi syndrome. Minor upper respiratory infections in
young children may cause a croup-like illness with upper airway
obstruction. Tonsillectomy and adenoidectomy may be required
because of the relative narrowing of their upper airway.
People with Prader-Willi syndrome recover slowly from lower
respiratory tract infections. Recurrent respiratory infections are
common in adults.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 330
Sleep disorders
Sleep disorders in people with Prader-Willi syndrome include
excessive daytime sleeping, and are probably due to hypo-
thalamic dysfunction. Abnormal responses to hypoxia and
hypercapnia have been reported. Both can be exacerbated by
obesity, and increase the risk of obstructive sleep apnoea and
sleep-related alveolar hypoventilation.
A detailed history, with a sleep diary, helps in the diagnosis.
Formal sleep studies are recommended.
Hypogonadism
Most boys with Prader-Willi syndrome have altered
spermatogenesis, and male fertility has never been reported.
Tere are a few reports of women with this syndrome bearing
children.
Ochidopexy is recommended by the age of 2 years for boys
with undescended testes. Testosterone can be used to increase
penile size.
Afer investigation for delayed puberty in girls and boys, hor-
mone replacement therapy is recommended (see eTGcomplete).
Obesity
People with Prader-Willi syndrome are at extreme risk of obesity,
due to their:
preoccupation with food/hyperphagia
low energy expenditure
reduced activity.
Obesity increases the risk of diabetes, coronary artery disease,
cor pulmonale, sleep apnoea and premature death. Preventing
obesity is paramount for the persons physical, psychological and
social wellbeing. A person with Prader-Willi syndrome needs
support and intervention throughout their life.
All people with Prader-Willi syndrome have a preoccupation
with food with a reduced appetite controlthis is a disturbance
in satiety, and is likened to a constant state of feeling starved.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 331
People with Prader-Willi syndrome have low energy expenditure,
and require considerably fewer kilojoules than the general
population. Tis is because they have a signifcantly higher
proportion of body fat relative to lean body mass. Te efect is
more pronounced in boys than girls. It may result from androgen
defciency in early infancy, caused by hypogonadotrophic
hypogonadism.
Hypotonia, with reduced muscle bulk and strength, persists into
adult life. It contributes to the poor posture and reduced stamina
for physical activity of people with Prader-Willi syndrome.
Preventing and managing obesity
Preventing and managing obesity requires:
restricting access to food
a low kilojoule diet
modifed eating behaviours
regular physical activity.
Modifying excessive eating
Healthy eating patterns and a low kilojoule diet must be
established in the preschool years, before preoccupation with
food begins. Parents ofen need support in this. For people of all
ages with Prader-Willi syndrome, it is important to explain their
eating disorder and diet program to extended family, support
people, teachers, employers and others who have contact with
them. Written personalised information can be provided when
appropriate.
Total involvement of family and other support people is
essential to ensure a person with Prader-Willi syndrome has
restricted access to food. Parents may need support to convince
extended family and community members that it is important
this approach is applied consistently. Specifc measures include
an inaccessible pantry, and supervised snacks and meals at
school and elsewhere. Children and young adults with Prader-
Willi syndrome ofen speak about the difculty of resisting
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 332
available food. Tey comment that they can resist food if they
are supervised.
Te onset of hyperphagia can be subtle. Currently there is no
specifc drug to counteract it. Selective serotonin reuptake
inhibitors are used in obsessive compulsive disorders, and may
be helpful.
Te height and weight of children and adolescents with Prader-
Willi syndrome should be measured regularly. Results should
be plotted on growth charts to detect early weight gain. Ideally
weight should be maintained at less than the 90th percentile.
Adults should be weighed regularly (every 1 to 3 months) and
maintain their body mass index at less than25. Tey should be
weighed more ofen if they are rapidly gaining weight or are
foraging for food.
Dietary guidelines
Close involvement with a dietitian and a psychologist or social
worker helps maintain nutritional guidelines and strategies
throughout the persons life. Dietary guidelines are essential for
all settings (eg child care, kindergarten, school, work, home).
Tis is particularly important in settings where there is a high
turnover of support staf.
All people with Prader-Willi syndrome need a dietitian to help plan
their nutritional guidelines and review them regularly.
Te diet should contain a variety of healthy foods including
bread and cereals (including whole grain), vegetables, fruit,
minimum-fat milk (or alternatives for adults) and moderate
amounts of lean meat or alternatives. It is helpful to:
avoid foods and drinks high in fat and/or sugar
provide water to quench thirst
substitute fruit for fruit juice
give a list of fat-free foods (eg celery, cucumber, carrot, pickled
gherkin) to people in the persons life (eg friends, educators)
establish regular times for meals and snacks.
Generic weight loss organisations and strategies have helped
some young adults.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 333
Physical activity
Physical activity needs to be incorporated into the daily life of
people with Prader-Willi syndrome. Participation in organised
training and physical activities (eg attending a gymnasium,
organised sport) is recommended.
Other health problems
People with Prader-Willi syndrome are at a higher risk of other
health problems. Tese include:
late presentation of illness, due to an increased pain threshold,
altered temperature control or a reduced ability to vomit
cellulitis secondary to skin picking
scoliosis
hip dysplasia
reduced cortisol response with acute illness
strabismus
dental anomalies, including hypoplastic enamel
choking with binge eating.
BIOPSYCHOSOCIAL CONCERNS
People with Prader-Willi syndrome have signifcant social
handicaps, as a result of:
cognitive difculties
specifc behavioural and personality traits
hyperphagia
interventions that limit their autonomy.
Diferences in cognitive profles and psychiatric morbidities
between genetic subtypes (deletion and maternal disomy) have
been reported.
Cognitive disabilities
Specifc learning and language disorders may occur with a normal
intellect in people with Prader-Willi syndrome. However, most
people have an IQ in the range of mild intellectual disability,
the average being between 60 and 65. Ofen these people have
greater difculties in adaptive behaviour than expected.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 334
Disabilities have been described in the areas of:
speech (resulting from hypotonia and cognitive impairments)
short-term memory and sequential processing
language processing
self-refection and conceptualisation (causing reduced
capacity to self-monitor).
Several strategies may help minimise the efect of cognitive
disability in children with Prader-Willi syndrome. Tese include
early referral to a speech pathologist for assessment, advice and
(if appropriate) therapy and ongoing surveillance. Some toddlers
and preschool children with expressive language delays beneft
from Makaton sign language. Before starting school, the child
may be referred for a detailed cognitive assessment to identify
their learning profle and specifc learning disabilities.
Behavioural phenotype
People with Prader-Willi syndrome are at increased risk of
a cluster of behavioural traits. Tese may be related to specifc
cognitive impairments. Te phenotype includes a preoccupation
with food and other obsessive traits, mood lability, impulsiveness,
temper tantrums, inactivity, repetitive speech patterns, skin
picking and relative weakness in social skills and adaptive
behaviour. Some children have the triad of behaviours that
are consistent with autism spectrum disorder. Behavioural
difculties ofen increase with age.
During school years, special education and psychological
assistance are ofen required for difculties in adaptive behaviour.
Adolescence and early adulthood is ofen a time of emotional
lability, defance, socialisation difculties and depression.
Early referral to a psychologist for cognitive and clinical
assessment is recommended, with appropriate ongoing advice,
support and interventions. Long-term follow-up benefts the
patient and their family.
It is important that young people with Prader-Willi syndrome
have an opportunity to meet, to express themselves and discuss
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 335
their frustrations and difculties. Referral to a behavioural
psychologist for behavioural intervention may be required.
Psychiatric and physical illness should be excluded when serious
problems arise or their behaviour deteriorates suddenly.
Psychiatric disorders
Adults with Prader-Willi syndrome have an increased risk of
psychiatric disorders. A relationship between family stress and
behavioural symptomatology has been noted. A high risk for
obsessive compulsive disorders and an increased vulnerability
to schizophrenia and other psychoses has also been noted.
See advice on managing psychiatric disorders.
RESOURCES
Specifc clinics for Prader-Willi syndrome and support
associations (a source of information for professionals as well as
families) are listed below.
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Clinics
Multidisciplinary Prader-Willi syndrome clinics are located
in Brisbane, Melbourne and Sydney. For young people and
adults not attending a specifc Prader-Willi syndrome clinic, a
6-monthly visit to their general practitioner is recommended to
monitor weight and general health.
Brisbane
Mater Hospital (child clinic)
Raymond Terrace
South Brisbane, QLD 4101
Telephone (07) 3163 2500
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 336
Princess Alexandra Hospital
Ipswich Road
Woolloongabba, QLD 4102
Telephone (07) 3176 1080
Melbourne
Royal Childrens Hospital
Flemington Road
Parkville, VIC 3052
Telephone (03) 9345 5898
Sydney
Royal Prince Alfred Hospital
Missenden Road
Camperdown, NSW 2050
Telephone (02) 9515 4230
Sydney Childrens Hospital
High Street
Randwick, NSW 2031
Telephone (02) 9382 8189
Support associations
Prader-Willi associations provide information and support
for parents, professionals and other interested people.
Prader-Willi Syndrome Association of Australia
Telephone (02) 4946 9001
(Website has contact information for the fve incorporated
State Associations in Australia [New South Wales, Queensland,
South Australia, Victoria and Western Australia].)
Prader-Willi Syndrome Association UK
REFERENCES AND FURTHER READING
de Lind van Wijngaarden RF, Otten BJ, Festen DA, Joosten KF, de Jong FH, Sweep FC, et
al. High prevalence of central adrenal insufciency in patients with Prader-Willi syndrome.
J Clin Endocrinol Metab 2008;93(5):1649-54.
Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Recommendations
for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab
2008;93(11):4183-97.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Prader-Willi syndrome 337
James TN, Brown RI. Prader-Willi syndrome. London: Chapman & Hall; 1992.
Lionti T, Reid SM, Rowell MM. Prader-Willi syndrome in Victoria: Mortality and causes of
death. J Paediatr Child Health 2012;48(6):506-11.
McCandless SE. Clinical report-health supervision for children with Prader-Willi syndrome.
Pediatrics 2011;127(1):195-204.
Waters J. A handbook for parents and carers of adults with Prader-Willi syndrome. 2nd rev.
ed. Derby: Prader-Willi Syndrome Association (UK); 2009.
Waters J, Gellatly M. Babies and children with Prader-Willi Syndrome: a handbook for
parents and carers. Rev. ed. Derby: Prader-Willi Syndrome Association (UK); 2001.
Waters J, Mitchell K. Teenagers with Prader-Willi syndrome: a handbook for parents and
carers. Derby: Prader-Willi Syndrome Association (UK); 2005.
Whittington J, Holland A. Neurobehavioral phenotype in Prader-Willi syndrome. Am J Med
Genet C Semin Med Genet 2010;154C(4):438-47.
Whittington J, Holland T. Prader Willi Syndrome: development and manifestations.
Cambridge: Cambridge University Press; 2004.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 338
Rett syndrome
Rett syndrome is a neurodevelopmental disorder seen almost
exclusively in females. Severe intellectual and physical handicap
are dominant features, although assessing IQ by traditional
methods is difcult.
Rett syndrome is diagnosed in approximately 1 in 10 000 girls
by the age of 12 years. In Australia this is equivalent to about
15 girls for each birth year.
*
Life expectancy in Rett syndrome
has not been well studied. However, an Australian study found
that 65% of afected females survive to the age of 32years.
CAUSE
Rett syndrome is a genetic disorder. Most cases are caused by
mutations in the MECP2 gene. About 99% of these cases are
single occurrences in a family, caused by a de novo mutation
in the child. Rarely, the mother carries the mutation, but has
been protected from its efects by skewed X inactivation. Eight
common mutations account for about two-thirds of cases with
MECP2mutations. Specifc mutations are associated with both
milder and more severe presentations of the syndrome.
CLINICAL AND GENETIC DIAGNOSIS
Clinical diagnosis of Rett syndrome is challenging, because some
features necessary for diagnosis may only become apparent with
time. Despite clear criteria, children with Rett syndrome have
been misdiagnosed as having Angelman syndrome, Prader-
*
Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, de Klerk N, et al. Trends in the
diagnosis of Rett syndrome in Australia. Pediatr Res 2011;70(3):313-9.
Freilinger M, Bebbington A, Lanator I, de Klerk N, Dunkler D, Seidl R, et al. Survival
with Rett syndrome: comparing Retts original sample with data from the Australian Rett
Syndrome Database. Dev Med Child Neurol 2010;52(10):962-5.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 339
Willi syndrome, autism spectrum disorder, cerebral palsy and
other (more rare) neurodegenerative disorders.
Doctors in Australia have only known about Rett syndrome
since 1983. Terefore, it is likely that some adults with Rett
syndrome remain undiagnosed or misdiagnosed. Tis adds to
the complexity of estimating life expectancy.
Consensus criteria to help clinicians diagnose Rett syndrome
were frst formulated in 1988, but have been revised since. Te
most recent revision
*
refers to typical (or classic) and atypical
Rett syndrome. For any type of Rett syndrome to be diagnosed,
a period of regression is necessary. Te two categories of
diagnostic criteria are main and supportive. For typical Rett
syndrome, all four main criteria need to be present. For atypical
Rett syndrome, only two of the main criteria are required, as
long as at least fve of the eleven supportive criteria are present.
Atypical presentations can be either milder or more severe than
typical Rett syndrome.
See diagnostic criteria (including exclusion criteria) listed in
Characteristics below.
If genetic testing reveals a pathogenic MECP2 mutation, this
is helpful. It gives independent confrmation of a challenging
clinical diagnosis. Failure to fnd a mutation does not exclude
the diagnosis, as about 20% of cases have no apparent defect
within the gene.
CHARACTERISTICS
A child with typical Rett syndrome has the following
characteristics.
First, the child (almost invariably a girl) has had a period of
regression followed by recovery or stabilisation.
She has also experienced each of the main criteria, which are:
partial or complete loss of purposeful hand skills
*
Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N,
et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol
2010;68(6):944-50.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 340
partial or complete loss of acquired spoken language
gait abnormalities (either an impaired gait [dyspraxia] or
inability to walk)
stereotypic hand movements (eg hand wringing/squeezing,
clapping/tapping, mouthing, washing/rubbing automatisms).
A diagnosis of Rett syndrome is excluded if there has been:
brain injury secondary to trauma (perinatal or postnatal),
neurometabolic disease or severe infection causing
neurological problems
grossly abnormal psychomotor development in the frst 6
months of life.
Supportive criteria are characteristics that are not essential for a
diagnosis of typical Rett syndrome, but are ofen present. Tese
are:
breathing disturbances when awake
bruxism when awake
impaired sleep pattern
abnormal muscle tone
peripheral vasomotor disturbances
scoliosis/kyphosis
growth retardation
small cold hands and feet
inappropriate laughing/screaming spells
diminished response to pain
intense eye communication (eye pointing).
Additional features
Rett syndrome is associated with several comorbidities, and
some have been included in the supportive criteria above.
Epilepsy afects approximately 80% of patients, with a median
age of onset of 4years. Seizures generally become less frequent
in late adolescence and adulthood, but in some people they
remain difcult to control.
Gastrointestinal problems (eg constipation, gastro-oesophageal
refux) are common, as are growth problems.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 341
Rett syndrome is associated with dysfunction of the autonomic
nervous system, which may manifest as abnormal breathing (eg
hyperventilation or apnoeic episodes). Sleep problems are also
common.
Scoliosis is one of the most signifcant orthopaedic compli-
cations. About 75% of girls with Rett syndrome have scoliosis by
the age of 13years (median age of onset is 9years). Osteopenia
and fractures are also common.
MANAGEMENT
Parents and family generally value establishing a defnitive
diagnosis of Rett syndrome, because it:
provides insight into the cause of the childs clinical features
facilitates access to support services.
Management includes:
antiepileptic drugs, if the person has seizures (see diagnosis
of epilepsy)
nutrition support (sometimes a gastrostomy)
physiotherapy (to help maintain ambulation and prevent
osteopenia)
occupational therapy (to help maintain function and prevent
deformities).
Te child may also beneft from:
referral to an orthopaedic specialist:
ofen required, particularly for monitoring and managing
scoliosis (see guidelines
*
)
scoliosis ofen improved by surgery
active management of constipation (most girls and women
need this)
music therapy and hydrotherapy (girls generally respond
well)
communication aids (simple and more sophisticated).
*
Downs J, Bergman A, Carter P, Anderson A, Palmer GM, Roye D, et al. Guidelines for
management of scoliosis in Rett syndrome patients based on expert consensus and
clinical evidence. Spine (Phila Pa 1976) 2009;34(17):E607-17.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 342
RESOURCES
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
With the help of clinicians and families in Australia who have
children with Rett syndrome, the Australian Rett syndrome
study (AussieRett) aims to improve understanding of this
syndrome, improve the clinical care of people with it, and help
fnd its cause and cure.
Australian Rett syndrome study
Telephone (08) 9489 7790
Te Rett Syndrome Association of Australia provides support
and resources to families.
Rett Syndrome Association of Australia
GPO Box 3497
Melbourne VIC 3001
Telephone 0418 561 796
Email rettaust@bigpond.com.au
REFERENCES AND FURTHER READING
Amir RE, Zoghbi HY. Rett syndrome: methyl-CpG-binding protein 2 mutations and
phenotype-genotype correlations. Am J Med Genet 2000;97(2):147-52.
Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, et al. Investigating
genotype-phenotype relationships in Rett syndrome using an international data set.
Neurology 2008;70(11):868-75.
Colvin L, Fyfe S, Leonard S, Schiavello T, Ellaway C, de Klerk N, et al. Describing the
phenotype in Rett syndrome using a population database. Arch Dis Child 2003;88(1):38-
43.
Downs J, Bebbington A, Woodhead H, Jacoby P, Jian L, Jefferson A, et al. Early determinants
of fractures in Rett syndrome. Pediatrics 2008;121(3):540-6.
Downs J, Bergman A, Carter P, Anderson A, Palmer GM, Roye D, et al. Guidelines for
management of scoliosis in Rett syndrome patients based on expert consensus and
clinical evidence. Spine (Phila Pa 1976) 2009;34(17):E607-17.
Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, de Klerk N, et al. Trends in the
diagnosis of Rett syndrome in Australia. Pediatr Res 2011;70(3):313-9.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Rett syndrome 343
Freilinger M, Bebbington A, Lanator I, de Klerk N, Dunkler D, Seidl R, et al. Survival
with Rett syndrome: comparing Retts original sample with data from the Australian Rett
Syndrome Database. Dev Med Child Neurol 2010;52(10):962-5.
Habgberg B. Clinical criteria, stages and natural history. In: Hagberg B, Anvret M, Wahlstrom
J, editors. Rett syndrome: clinical and biological aspects. London: Mac Keith Press; 1993.
p.4-20.
Hagberg B. Clinical criteria, stages and natural history. In: Hagberg B, Wahlstrom J, editors.
Rett syndrome: clinical and biological aspects. London: Mac Keith Press; 1993.
Hagberg B, Hanefeld F, Percy A, Skjeldal O. An update on clinically applicable diagnostic
criteria in Rett syndrome. Comments to Rett Syndrome Clinical Criteria Consensus Panel
Satellite to European Paediatric Neurology Society Meeting, Baden Baden, Germany, 11
September 2001. Eur J Paediatr Neurol 2002;6(5):293-7.
Jefferson AL, Woodhead HJ, Fyfe S, Briody J, Bebbington A, Strauss BJ, et al. Bone
mineral content and density in Rett syndrome and their contributing factors. Pediatr Res
2011;69(4):293-8.
Jian L, Nagarajan L, de Klerk N, Ravine D, Christodoulou J, Leonard H. Seizures
in Rett syndrome: an overview from a one-year calendar study. Eur J Paediatr Neurol
2007;11(5):310-7.
Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, et al. Rett syndrome
in Australia: a review of the epidemiology. J Pediatr 2006;148(3):347-52.
Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in
Australia. Eur Child Adolesc Psychiatry 1997;6(Suppl 1):8-10.
Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett
syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010;68(6):944-50.
Oddy WH, Webb KG, Baikie G, Thompson SM, Reilly S, Fyfe SD, et al. Feeding
experiences and growth status in a Rett syndrome population. J Pediatr Gastroenterol Nutr
2007;45(5):582-90.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 344
Tuberous sclerosis
Clinically, tuberous sclerosis has three classical features
intellectual disability, epilepsy and a butterfy-shaped facial
rash of angiofbromas (also known as adenoma sebaceum). It
is a genetic disease that afects many body systems. Tuber-like
growths occur in the brain and other major organs (including
heart and kidneys). Te spectrum and severity of its efects
varies widely, and some people with this condition have no
obvious signs.
Te prevalence of tuberous sclerosis is not clear. In Caucasian
populations it is estimated to occur in 1in 25000 children.
CAUSE
Most cases of tuberous sclerosis arise from mutations in the
TSC1 or TSC2 genes. Te TSC1gene is at chromosome 9q34 and
encodes the protein hamartin. Te TSC2gene is at chromosome
16p13.3 and encodes the protein tuberin. Other genetic and
environmental factors infuence clinical severity.
Inheritance of tuberous sclerosis is autosomal dominant.
Sporadic new mutations (more commonly in the TSC2 gene)
are responsible for up to two-thirds of cases. In general, patients
with TSC2 mutations have more severe symptoms.
DIAGNOSIS
Standardised diagnostic criteria for tuberous sclerosis are shown
in Table 19. A neurologist, paediatrician or clinical geneticist
usually assesses the patient. Diagnosis is clinical, and is based on
imaging (brain, cardiac and renal) and specialised assessments
(ophthalmological, dental and skeletal). Genetic testing is
positive in 75% to 85% of cases that meet the clinical criteria.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 345
It is recommended, because it helps give families accurate
genetic counselling and access to prenatal or preimplantation
genetic diagnosis.
Table 19. Diagnosis of tuberous sclerosis
*
Diagnosis of tuberous sclerosis
denite: 2 major features, or 1 major feature plus 2 minor features
probable: 1 major feature plus 1 minor feature
possible: 1 major feature, or 2 or more minor features
Major features
facial angiobromas or forehead
plaque
nontraumatic ungual or periungual
bromas
hypomelanotic patches, three or
more
shagreen patch (connective tissue
naevus)
multiple retinal nodular hamartomas
cortical tuber
subependymal nodule
subependymal giant cell astrocytoma
cardiac rhabdomyoma, single or
multiple
lymphangiomyomatosis
renal angiomyolipoma
Minor features
multiple randomly distributed pits in
dental enamel
hamartomatous rectal polyps
bone cysts
cerebral white matter radial migration
lines
gingival bromas
nonrenal hamartomas
retinal achromic patch
confetti skin lesions
multiple kidney cysts
* Source: Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus
conference: revised clinical diagnostic criteria. J Child Neurol 1998;13(12):624-8.
When cerebral cortical dysplasia and white matter migration lines occur together,
they count as one feature, not two.
When lymphangiomyomatosis and renal angiomyolipomas are both present, this
is not sufcient for a diagnosis of tuberous sclerosis. Other features of tuberous
sclerosis must be present to complete the diagnosis.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 346
CHARACTERISTICS
Te classical features of tuberous sclerosis are:
intellectual disability
epilepsy
skin lesions.
About half the people with tuberous sclerosis have associated
intellectual disability. Te severity of intellectual disability is
related to the severity of epilepsy.
Seizures occur in 70% to 80% of people with tuberous sclerosis,
and range from subtle to severe. Te most common types are
infantile spasms (jackknife or salaam seizures), complex partial
seizures and myoclonic seizures. Infantile spasms may be the
frst sign of this condition. Seizures can be difcult to control.
On occasion, seizure control has been obtained by surgical
excision of a single tuber.
Skin lesions
Tuberous sclerosis causes several types of skin lesions, including:
angiofbromas
hypomelanotic patches
shagreen patches (French: chagringrained skin)
subungual or periungual fbromas.
Angiofbromas are rarely obvious before the age of 2 years,
and frst appear as small erythematous lesions. Tey ofen
proliferate during puberty and can be confused with acne.
Typically, angiofbromas are found on the face. Forehead fbrous
plaques that also occur in tuberous sclerosis are clinically
indistinguishable.
Patches of depigmented skin (also known as ash leaf or
Fitzpatrick patches) are a common sign, and occur in 60% of
people with tuberous sclerosis. Tese white patches are the
frst skin abnormality to appear, and can usually be detected in
infancy and early childhood. A Woods light is ofen needed to
identify them, especially in people with fair skin.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 347
Shagreen patches are thickened and raised yellowish areas of
skin on the lower back. Tey occur in approximately half the
people with tuberous sclerosis.
Subungual or periungual fbromas occur under and around the
fngernails and are associated with grooves in the nail. Tey
become more prevalent with age, and occasionally are the only
signs of tuberous sclerosis.
Other characteristics
Te presence of cortical tubers (in terms of number and location)
is usually related to the severity of epilepsy and intellectual
disability in a person with tuberous sclerosis. Rarely, a cortical
tuber may become malignant.
Subependymal nodules are markers for tuberous sclerosis, but
do not usually cause complications.
Cystic kidney disease in tuberous sclerosis can be
indistinguishable from autosomal dominant polycystic kidney
disease, and usually presents in infancy. Renal angiomyolipomas
tend to present afer puberty.
Rhabdomyomas of the heart are ofen identifed antenatally. Tey
rarely cause any symptoms, but suggest that tuberous sclerosis is
highly probable and that further investigations are needed afer
birth. Tese benign muscle tumours (ie rhabdomyomas) may
also occur in the eyes, bones, lungs and liver. Teir prevalence
ranges from 47% to 60%. Surgery is only recommended for life-
threatening situations.
Te most common ocular abnormalities are retinal hamartomas,
found in 40% to 50% of patients.
Sleeping problems are common in children.
Behavioural difculties are common, and include hyperactivity
(59% of cases), aggressive behaviour (13%) and autism spectrum
disorder (50%).
Dental abnormalities (eg multiple enamel pits) may occur, and
sometimes assist diagnosis.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 348
MANAGEMENT
It is recommended that people with tuberous sclerosis are
seen periodically by a clinician with experience in managing
this condition. Te clinician can ofer management advice,
surveillance suggestions and treatment options.
Management of tuberous sclerosis also involves:
genetic counselling for the family (if the TCS1 and TCS2 gene
mutations that cause tuberous sclerosis are found, prenatal
diagnosis for future children becomes an option)
epilepsy management, which is particularly important as
developmental progress may be severely restricted by poorly
controlled seizures (occasionally, focal seizures arising from
hamartomas in the central nervous system can be improved
by neurosurgery)
brain scans (magnetic resonance imaging or computerised
tomography) if the person develops:
signs and symptoms of raised intracranial pressure
new focal neurological signs or symptoms
regular assessment of cognitive development and behaviour,
to identify and treat emerging difculties
skin lesion treatment (laser therapy, dermabrasion and
cautery)
behaviour management (as required)
dental care (regular)
kidney ultrasound scans (every 5years).
Cardiac outfow obstruction or arrhythmias may occur in
association with rhabdomyomas (particularly in infancy), and
may need treatment.
Sirolimus, an immunosuppressant drug, has been approved
by the Terapeutic Goods Administration for the medical
treatment of subependymal giant cell astrocytomas. Tis ofers
an alternative to surgery. Other studies have shown that drugs
like sirolimus may have a role in treating renal angiomyolipomas
and lymphangiomyomatosis.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Tuberous sclerosis 349
RESOURCES
Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Te Australasian Tuberous Sclerosis Society provides
information and support for parents, professionals and other
interested people.
Australasian Tuberous Sclerosis Society
Telephone 1300 733 435
REFERENCES AND FURTHER READING
Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;
355(13):1345-56.
Hunt A. Tuberous sclerosis: a survey of 97 cases. I: Seizures, pertussis immunisation and
handicap. Dev Med Child Neurol 1983;25(3):346-9.
Kandt RS. Tuberous sclerosis: the next step. J Child Neurol 1993;8(2):107-10.
Morrison PJ. Tuberous sclerosis: epidemiology, genetics and progress towards treatment.
Neuroepidemiology 2009;33(4):342-3.
OCallaghan FJ. Tuberous sclerosis. BMJ 1999;318(7190):1019-20.
OCallaghan FJ, Martyn CN, Renowden S, Noakes M, Presdee D, Osborne JP. Sub-
ependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a
population-based study. Arch Dis Child 2008;93(9):751-4.
Osborne JP, Merrield J, OCallaghan FJ. Tuberous sclerosis whats new? Arch Dis Child
2008;93(9):728-31.
Petrova LD. Tuberous sclerosis and epilepsy. Am J Electroneurodiagnostic Technol 2011;
51(1):5-15.
Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference:
revised clinical diagnostic criteria. J Child Neurol 1998;13(12):624-8.
Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: advances
in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57(2):189-202.
Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a
population study. Br J Dermatol 1996;135(1):1-5.
Webb DW, Osborne JP. Tuberous sclerosis. Arch Dis Child 1995;72(6):471-4.
Yates JR, Maclean C, Higgins JN, Humphrey A, le Marechal K, Clifford M, et al. The
Tuberous Sclerosis 2000 Study: presentation, initial assessments and implications for
diagnosis and management. Arch Dis Child 2011;96(11):1020-5.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Williams syndrome 350
Williams syndrome
People with Williams syndrome have characteristic facial
features and medical problems (eg cardiovascular disease).
Intellectual disability (which varies in severity) may be masked
by an unusually friendly outgoing personality.
Te epidemiology of Williams syndrome is not well studied. A
Norwegian study estimated a birth prevalence of 1in7500.
*
In
Western Australia, the estimated birth prevalence is 1in16000
births.
CAUSE
Williams syndrome is caused by a hemizygous microdeletion
of 26to 28 genes (the Williams-Beuren syndrome chromosome
region) on the long arm of chromosome7. One of these genes
is the elastin gene (ELN). It is deleted in approximately 95% of
people with Williams syndrome, and so is used for molecular
diagnosis.
An elastin defect may account for the abnormalities in connective
tissue in the aorta and larynx of people with Williams syndrome.
Te basis for their cognitive and behavioural problems has not
been fully explained.
DIAGNOSIS
Typically, infants with Williams syndrome have a characteristic
facial appearance, supravalvular aortic stenosis and intellectual
disability.
*
Stromme P, Bjornstad PG, Ramstad K. Prevalence estimation of Williams syndrome. J
Child Neurol 2002;17(4):269-71.
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report
of the idEA database: intellectual disability in Western Australia. Perth, WA: Telethon
Institute for Child Health Research; 2004.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Williams syndrome 351
Presentation in infancy can include:
failure to thrive
vomiting and colic
constipation
recurrent ear infections
sleep dysregulation.
At the time of initial diagnosis, a series of specialised evaluations
is recommended. Tese include:
complex physical and neurological examinations
cardiology, urinary system and ophthalmic evaluation
genetics consultation
growth parameter plots (using Williams syndrome growth
charts)
serum calcium concentration
thyroid function.
Molecular karyotype tests and fuorescent in situ hybridisation
identify a submicroscopic deletion on chromosome7 (at 7q11.23
ie the elastin gene) in approximately 95% of cases.
CHARACTERISTICS
Children and adults with Williams syndrome have a range
of physical features and medical, cognitive, behavioural and
neurological problems.
Facial features
Common facial features in people with Williams syndrome
include:
pufness around the eyes (periorbital fullness)
a star-shaped pattern in their irises (stellate irides)
incomplete development of cheeks or cheekbones, so they
dont reach adult size (malar hypoplasia)
an upturned nose and fattened nose bridge and a full lower
lip, ofen with an open mouth appearance
sagging cheeks in infancy and childhood, with cheeks be-
coming thin in adolescence or early adulthood
strabismus.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Williams syndrome 352
Characteristic dental anomalies may also occur (eg small or
unusually shaped primary teeth).
Growth
Williams syndrome may be associated with intrauterine growth
retardation. Children and adults may be short, and ofen have
microcephaly. Girls may have early menarche.
Medical concerns
Williams syndrome has many associated medical conditions.
Tese include:
cardiac abnormalities (about 75% of cases; supravalvular
aortic stenosis and peripheral pulmonary artery stenosis are
most commonly reported)
elevated blood pressure (frequent in adults)
myocardial ischaemia (associated with stenosis of the lef
coronary artery)
strokes and chronic hemiparesis (rare; associated with
stenosis of the cerebral arteries).
Other medical conditions that may occur in people with
Williams syndrome are:
kidney abnormalities (approximately 20% of cases; eg bladder
diverticulae, renal hypoplasia and duplicated kidneys) and
urinary tract infections
gastrointestinal problems (eg gastro-oesophageal refux,
chronic constipation, diverticulosis)
endocrine abnormalities (eg calcium abnormalities [infantile
hypercalcaemia may present as constipation], impaired
glucose tolerance, early puberty)
ear, nose and throat anomalies (eg hoarse voice, hyperacusis
[increased sensitivity to noise], hearing loss)
eye problems (eg strabismus, altered visual acuity)
inguinal hernia (common in children)
orthopaedic problems (eg joint laxity, contractures, scoliosis).
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Williams syndrome 353
Cognitive, behavioural and neurological problems
Cognitive defcits in people with Williams syndrome range from
mild to moderate intellectual disability. Perceptual and motor
functions are reduced more than verbal skills and memory.
Infants with Williams syndrome may be irritable and feed
poorly. Older children tend to be friendly and talkative, and
may be socially uninhibited. Teir intellectual ability may be
overestimated because of their apparently good verbal skills.
Emotional and behavioural disturbances (including generalised
anxiety and attention defcit problems) are common in children.
Tey may improve in adolescence and adulthood.
Parents report a high prevalence of sleep difculties. Tese
include bedtime resistance, sleep anxiety, night waking and
daytime sleepiness. Hypotonia is frequent in younger years, but
progresses to hypertonia.
MANAGEMENT
Management of a person with Williams syndrome involves:
screening for congenital heart disease (and if identifed,
subsequent management)
regular checks for elevated blood pressure in adults (and if
identifed, antihypertensive treatment)
urinary system evaluation (including ultrasound screening of
the renal system)
surveillance for endocrine abnormalities (and if identifed,
subsequent management)
ophthalmological review
regular dental care
physiotherapy for children with musculoskeletal and
neurological problems.
Feeding, gastrointestinal and urinary problems may also need to
be managed. Behavioural difculties may require psychological
intervention.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Williams syndrome 354
RESOURCES
Te following organisations provide information about Williams
syndrome and support for parents, professionals and other
interested people.
Users should be aware that websites are not vetted for the quality
of their information. Some may be sponsored by the pharma-
ceutical industry or other commercial organisations. Terapeutic
Guidelines Limited accepts no responsibility for the currency or
accuracy of the information found at these or linked websites.
Williams Syndrome Association of South Australia
Williams Syndrome Family Support Group (Victoria)
Williams Syndrome Association (USA)
Williams Syndrome Foundation (UK)
REFERENCES AND FURTHER READING
I am a doctor. What should I know? [Doctors resources for Williams syndrome. Website].
Troy, Michigan: Williams Syndrome Association. Accessed July 2012.
Annaz D, Hill CM, Ashworth A, Holley S, Karmiloff-Smith A. Characterisation of sleep
problems in children with Williams syndrome. Res Dev Disabil 2011;32(1):164-9.
Ashkenas J. Williams syndrome starts making sense. Am J Hum Genet 1996;59(4):
756-61.
Burn J. Williams syndrome. J Med Genet 1986;23(5):389-95.
Ewart AK, Morris CA, Atkinson D, Jin W, Sternes K, Spallone P, et al. Hemizygosity at the
elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993;5(1):11-6.
Gosch A, Pankau R. Personality characteristics and behaviour problems in individuals of
different ages with Williams syndrome. Dev Med Child Neurol 1997;39(8):527-33.
Leonard H, Petterson B, Bourke J, Glasson E, Morgan V, Bower C. Inaugural report of the
idEA database: intellectual disability in Western Australia. Perth, WA: Telethon Institute for
Child Health Research; 2004.
Lopez-Rangel E, Maurice M, McGillivray B, Friedman JM. Williams syndrome in adults. Am
J Med Genet 1992;44(6):720-9.
Martens MA, Wilson SJ, Reutens DC. Research Review: Williams syndrome: a critical
review of the cognitive, behavioral, and neuroanatomical phenotype. J Child Psychol
Psychiatry 2008;49(6):576-608.
Morris CA, Leonard CO, Dilts C, Demsey SA. Adults with Williams syndrome. Am J Med
Genet Suppl 1990;6:102-7.
Pober BR. Williams-Beuren syndrome. N Engl J Med 2010;362(3):239-52.
Stromme P, Bjornstad PG, Ramstad K. Prevalence estimation of Williams syndrome. J Child
Neurol 2002;17(4):269-71.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 355
Disability resources
People with disability need opportunities and choices in all areas
of life, including education, employment, housing and social
and leisure activities. A range of community support services
(both generic and specifc for disability) is available. Services
vary between states and regions.
Listed below is information for practitioners, people with
developmental disability, their parents and other support
people. Users should be aware that websites are not vetted for the
quality of their information. Also, some may be sponsored by
the pharmaceutical industry or other commercial organisations.
Terapeutic Guidelines Limited accepts no responsibility for the
currency or accuracy of the information found at these or linked
websites.
Resources for specifc syndromes and disorders are listed at the
end of the relevant chapters.
COMMONWEALTH
Carers Australia
Works with the carers associations in each of the states and
territories to deliver programs and services for carers and
advocate on their behalf.
Telephone 1800 242 636
Centrelink
Access point for payments and services for people with dis-
ability and their families (eg Assistance for Isolated Children
Scheme; Carer Allowance, Payment and Supplement; Child
Disability Assistance Payment; Disability Support Pension;
Mobility Allowance; Pensioner Education Supplement; Youth
Disability Supplement). Assistance fnding a job available
through Disability Employment Services.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 356
Commonwealth Respite and Carelink Centres
Information centres for older people, people with disabilities
and those who provide care and services. Free and confdential
information on community aged care, disability and other
support services available locally or interstate.
Telephone 1800 052 222
National Council on Intellectual Disability (NCID)
Advocacy and consultative services for people with intellectual
disability and their families.
Telephone (02) 6296 4400
STATES AND TERRITORIES
Australian Capital Territory
Access City Hotline
Referral service for solving or easing access problems in the ACT.
Contact point for people requiring information and referrals to
other services.
Telephone (02) 6257 3077
Citizens Advice Bureau ACT
Information, referral and support to all ACT residents by
educating them about their options, rights and responsibilities.
Telephone (02) 6248 7988
Disability ACT
Services for people with disability in the ACT and their families,
carers and friends.
Telephone (02) 6207 1086 or TTY (02) 6205 0888
New South Wales
Centre for Disability Studies (CDS)
Academic centre with an international focus. Clinical, educa-
tional and research activities aimed at improving health services
for adults with disability. Supports generic medical practitioners
caring for the developmental disability population. Can be
contacted for advice or referral.
Telephone (02) 9036 3600
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 357
Disability & Aged Information Service (DAISI)
Free and confdential service giving information on services
and supports for people with disability, aged people and their
families, carers and advocates. Based on far north coast of NSW.
Telephone 1800 800 340
Family and Community Services Ageing, Disability and
Home Care
Services and support to people with a disability, and their
families and carers in NSW.
Telephone (02) 8270 2000
TTY (02) 8270 2167
Information on Disability & Education Awareness Services
(IDEAS)
Information about, and referrals for, services and resources.
Telephone 1800 029 904
TTY (02) 6947 3377
NSW Council for Intellectual Disability (NSW CID)
Represents the interests of people with intellectual disability.
Information about, and referrals for, services and resources.
Health fact sheets available in standard and easy English.
Telephone (02) 9211 1611
Telephone 1800 424 065
Northern Territory
Aged and Disability Services
Information about disability services in the Northern Territory.
Telephone 1800 139 656
Carpentaria Disability Services (CDS)
Inclusive opportunities for people with disability in employment,
training, accommodation and leisure.
Telephone (08) 8945 4977
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 358
Queensland
Department of Communities, Child Safety and Disability
Services (Disability Services)
Help for people with a disability and their families to access
the support and services they need as they move through the
diferent stages of their life.
Telephone 1800 177 120
TTY 1800 010 222
People with Disability
Information about disability services in Queensland.
Telephone 13 74 68
Queensland Centre for Intellectual and Developmental
Disability (QCIDD)
Academic centre that supports people with intellectual disability
via research, teaching and clinical activities.
Telephone (07) 3163 2412
South Australia
Centre for Disability Health, South Australia
Tree clinics in Adelaide developed for clients of Disability SA.
Disability Information and Resource Centre (DIRC)
Information about services, advocacy and support groups.
Telephone (08) 8236 0555
Community Support (Disability)
Information about disability services in South Australia.
Telephone 1300 786 117
Tasmania
Disability and Community Services
Information about disability services in Tasmania.
Telephone 1300 135 513
Advocacy Tasmania Inc.
Advocacy services for people with disabilities.
Telephone 1800 005 131
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 359
Association for Children with Disability (Tas) Inc.
Information, advocacy, and support for Tasmanian families of
children with disability.
Telephone (03) 6231 2466
Telephone 1800 244 742
Shaid (Specialist health care for adults with intellectual
disability) clinic
Calvary Hospital (Hobart). Tertiary-level comprehensive
medical care for adults (18years of age and over) with intellectual
disability.
Telephone (03) 6278 5359
Email r.wallace@calvarytas.com.au
Victoria
Centre for Developmental Disability Health Victoria
(CDDHV)
Academic centre. Clinical, educational and research activities
aimed at improving health outcomes for people with devel-
opmental disability. Supports generic medical practitioners
caring for the developmental disability population. Can be
contacted for advice or referral.
Telephone (03) 9902 4467
Department of Human Services
Financial assistance, accommodation options, community
involvement and other supports and services for people with a
disability, their families and carers.
DiVine
Online community for and by people with a disability.
Victorian Dual Disability Service
Statewide mental health service for people with an intellectual
disability.
Telephone (03) 9288 2950
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 360
Western Australia
People with Disabilities Western Australia (PWdWA)
Peak disability consumer organisation representing the rights,
needs and equity of all Western Australians with physical,
intellectual, psychiatric or sensory disability via individual and
systemic advocacy.
Telephone (08) 9485 8900 or 1800 193 331
Disability Services Commission
Information about disability services in Western Australia.
Telephone (08) 9426 9200 or 1800 998 214
TTY (08) 9426 9315
LOCAL GOVERNMENT
Local councils provide a range of services including home help,
respite care, disabled persons parking permits and recreation.
For information, contact health and aged services at your local
council.
OTHER RESOURCES
Disability aids, products and equipment
Community Equipment Scheme (Tasmania)
Equipment to assist people with a temporary or permanent
disability to live independently and safely in the community.
Continence Aids Payment Scheme (Commonwealth)
Funding to help people with permanent and severe incontinence
pay for continence products.
Individual Support Packages (Victoria)
Funds available to a person to meet their disability-related
support needs.
Technical Aid to the Disabled (TAD) Australia
Not-for-proft voluntary cooperative providing personalised
equipment and advice to people with disability and their carers.
Telephone 1300 663 243
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 361
Genetics information
Te Association of Genetic Support of Australasia Inc
(AGSA)
Support and information for individuals and families afected by
a genetic condition/rare disease.
Centre for Genetics Education
Genetics information for afected people, their family members
and the professionals who work with them.
Genetic Metabolic Disorders Service (GMDS)
New South Wales multidisciplinary consultative diagnostic ser-
vice and clinical care for children and adolescents with inborn
errors of metabolism.
Telephone (02) 9845 3452
Genetics clinics (Te Childrens Hospital at Westmead)
Diagnosis, assessment and genetic counselling of children with
single or multiple congenital anomalies, dysmorphic features,
syndromes, chromosomal disorders, disorders of special senses
or of organ systems, serious developmental delay or unexplained
abnormalities of growth. Adult and prenatal genetics clinics also
held here (same contact details).
Telephone (02) 9845 3273 (initial visit)
Telephone (02) 9845 3205 (subsequent visits)
Genetics in family medicine: the Australian handbook for
general practitioners
Educational resource on genetic medicine for Australian gen-
eral practitioners. Includes patient and family fact sheets to
download.
Genetic Support Council WA (GSCWA)
Peak body for genetic support groups in Western Australia.
Metabolic Dietary Disorders Association
Not-for-proft family support group to help members and
their families manage the complex problems associated with
metabolic dietary disorders.
Telephone (03) 9723 0600 or 1800 288 460
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 362
Online Mendelian Inheritance in Man (OMIM)
Comprehensive website with a focus on genetic conditions.
Victorian Clinical Genetics Services
Diagnosis, risk assessment, management and counselling for
people with genetic conditions in Victoria and Tasmania.
Telephone (03) 8341 6201
Associations
Australian Association of Developmental Disability
Medicine (AADDM)
Network of doctors with an interest in improving the health
status of people with intellectual and developmental disability.
Australasian Society for Intellectual Disability (ASID)
Promotes research and understanding of intellectual disability
and high standards of practice in this feld.
Telephone 1800 644 741
International Association for the Scientifc Study of
Intellectual Disabilities (IASSID)
International and interdisciplinary scientifc nongovernment
organisation, ofcially related to the World Health Organ-
ization. Promotes worldwide research and exchange of infor-
mation on intellectual disability.
National Disability Services
Australian peak body for nongovernment disability services.
Professional Association of Nurses in Developmental
Disability Australia (PANDDA)
National networking and support for nurses working with
people who have developmental disabilities.
Rare diseases
Orphanet
Information about rare diseases.
Ofce of Rare Diseases Research
Website links to a broad range of information about rare diseases,
including defnitions, causes, treatments and publications.
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Disability resources 363
Te National Organization for Rare Disorders
A federation of voluntary health organisations in the US,
dedicated to helping people with rare orphan diseases and
assisting the organisations that serve them.
Transport
Road transport schemes may provide subsidised transport,
including reduced taxi fares for people with disability. Tese
schemes difer from state to state.
New South Wales
Taxi Transport Subsidy Scheme
Provides subsidised travel by taxi at half fare for NSW residents
who are unable to use public transport because of a qualifying
severe and permanent disability.
Telephone 1800 623 724
Disability Hire Vehicles (Sydney)
Provides adapted vans to carry people with wheelchairs, and
cars with radial hand controls, lef foot accelerators and other
adaptions.
Telephone (02) 4577 2225
Victoria
Multi Purpose Taxi Program
Provides subsidised travel by taxi at half fare for Victorians with
a severe and permanent disability.
Telephone 1800 638 802
TTY 133 677
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
Index
A
AAC see augmentative and
alternative communication
ABA see applied behaviour analysis
Aberrant Behaviour Checklist 159
abuse 44
of adolescent 85
adolescents with
developmental disability 7994
challenging behaviour 90
Down syndrome 291
health and social concerns 816
checklist (table) 81
leaving
home 93
school 92
psychosocial changes 87
pubertal disorders (table) 84
role of general practitioner 79
adults with developmental
disability
health care 95111
checklist (table) 9799
disorders
cardiovascular 117
endocrine 107
epilepsy 21019
gastrointestinal 102
genitourinary 105
musculoskeletal 110
psychiatric 175209
respiratory 101
skin 110
vision and hearing 100
genetic review 96
advance health directives 46
advocacy
doctors role 1014
family and other support people 11
government departments 12
public hospital system 12
case example 13
investigations 35
aged care see older people with
developmental disability
Ages and Stages Questionnaire 58
aggression 170
agitation 173
aided communication systems 23
alcohol-related
neurodevelopmental disorder 297
Alcohol Use Disorders
Identication Test 297
alternative therapies 7
Alzheimer disease 120
androgen deciency 142
Angelman syndrome 2504
cause 250
characteristics (table) 252
diagnosis 251
management 253
resources 253
antiepileptic drugs 214219
adverse effects 217
aggression 172
bipolar disorder 203
oral contraceptive pill 133, 134
antipsychotic drugs see also
psychotropic drugs
bipolar disorder 203
challenging behaviour
outward 171, 173
self-directed 170
schizophrenia and related
psychoses 207
anxiety and associated disorders
assessment 179
management 194
applied behaviour analysis 159
anxiety 196
autism spectrum disorder 261
ARND see alcohol-related
neurodevelopmental disorder
ASD see autism spectrum disorder
Asperger disorder 258
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
bipolar disorder (cont.)
management
acute mania 202
bipolar depression 204
maintenance therapy 204
mixed episodes and rapid
cycling bipolar disorder 204
Brigance Developmental
Screening Tool 58
C
cardiovascular disease 117
CBT see cognitive
behavioural therapy
cerebral palsy 26682
ageing 280
associated
health problems 27380
musculoskeletal effects 276
impairments 271
resources 281
role of general practitioner 270
CGH array see comparative
genomic hybridisation array
challenging behaviour
adolescent 90
assessment and
management 148164
causes 149
checklist (table) 153
data sheet for monitoring (table) 159
history taking (table) 155
safety 153
child 77
drug therapy 16574
aggression 170
agitation 173
behavioural emergencies 168
drug treatment plan 167
questions before prescribing (box) 166
self-injury 169
stereotyped behaviour 170
CHAP see Comprehensive
Health Assessment Program
children with developmental
disability
assessment 5769
ASQ see Ages and
Stages Questionnaire
assessment, developmental
delay and disability 5769
assessment approach 62
history information (table) 64
causes (table) 60
manifestation 60
delayed development (table) 62
normal development (table) 61
referrals (table) 67
atlantoaxial instability 287
AUDIT see Alcohol Use
Disorders Identication Test
augmentative and alternative
communication 22
autism, atypical 258
autism spectrum disorder 25565
Asperger disorder 258
atypical autism 258
autistic disorder 258
characteristics 256
diagnosis 260
management 260
prevalence 255
resources 263
role of general practitioner 262
autistic disorder 258
B
Bayley Scales of Infant
Development 65
behaviour, challenging see
challenging behaviour
behavioural assessment interview
form 155
behavioural emergencies 168
behavioural therapy 189
benzodiazepines
anxiety and associated disorders 197
bereavement 123
beta blockers
aggression 172
bipolar disorder
assessment 183
observable features of hypomania
and mania (table) 184
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
constipation 104
older people 118
consultation (general practice) 2937
case example 36
communication 17
history taking 31
information needed (box) 33
investigations 35
legal concerns 3849
medications 35
physical examination 34
reception and booking 29
consumer support groups 74
additional information 355363
Contextual Assessment
Inventory 159
contraception 247
female 133
antiepileptic drugs 133, 134
emergency 136
hormonal 133
sterilisation 135
male 248
cryptorchidism 143
D
DC-LD 175
decision-making
for adults 39
for children 38
delayed puberty
boys 142
girls 131
delirium 119
delusions 184
dementia 120
dental problems 2403
depot medroxyprogesterone
acetate
contraception 134
menstrual suppression 139
depression
assessment 180
observable features (table) 182
management 198
older people 123
children with developmental
disability (cont.)
assessment (cont.)
approach 62
history information (table) 64
causes (table) 60
manifestation 60
delayed development (table) 62
normal development (table) 61
referrals (table) 67
health problems 76
Down syndrome, monitoring
(table) 292-3
management 708
interventions (table) 72
role of general practitioner 77
support services 72
clomipramine
agitation 173
clozapine
psychosis therapy 208
COCP see oral contraceptive pill
cognition
antiepileptic drugs 218
assessment tools 65
cognitive behavioural therapy 189
communication 1528
at a consultation 17
augmentative and alternative 22
complex needs 227
facilitated 24
optimal 20
resources 27
skills of people with
developmental disability 16
comparative genomic hybridisation
array 66
complex communication needs 22
Comprehensive Health
Assessment Program 34
congenital heart disease
child 77
Down syndrome 286
Noonan syndrome 323
consent to medical treatment
adult 41
child 38
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
education see school
elderly people see older people with
developmental disability
electroconvulsive therapy 201
emergencies, behavioural 168
emergency contraception 136
endometrial ablation 140
enduring guardianship and
power of attorney 46
enteral nutrition
dysphagia 237
underweight 225
epilepsy 21019
contraception 133, 134
diagnosis 210
Lennox Gastaut syndrome
indicators (box) 213
management 213
antiepileptic drug therapy 214
adverse effects 217
status epilepticus 219
sudden unexpected death in 214, 215
equipment, special 74
erectile dysfunction 144
ethical decision-making
framework for dysphagia (box) 238
etonogestrel implant 135
exercise 145
older people 114
F
facilitated communication 24
family support services 72
family systems therapy 190
FASD see fetal alcohol
spectrum disorder
FAS see fetal alcohol syndrome
fetal alcohol spectrum disorder 295
fetal alcohol syndrome 295300
cause 295
diagnosis 296
management 297
resources 299
nancial support 73
fragile X premature ovarian
insufciency 304
development
normal (table) 61
delayed (table) 62
Developmental Behaviour
Checklist 159
developmental disability
health care 6
assessment 5769
causes 58
denition 1
population characteristics 3
resources 35563
diabetes 109
Down syndrome, monitoring
(table) 98
dialectical behaviour therapy 189
dignity of risk 5
disability
developmental see developmental
disability
intellectual (denition) 2
discrimination 45
DM-ID 175
DMPA see depot
medroxyprogesterone acetate
DNA studies
fragile X syndrome 305
Down syndrome 28394
cardiovascular disease 117
functional decline 290
dementia 120
differential diagnosis (table) 121
health care and concerns 28491
monitoring child (table) 292
resources 293
Dravet syndrome 213
DSM-IV-TR 175
duty of care 45
dysphagia 2309
assessment 232
management 235
decision-making framework (box) 238
presentation 231
E
early intervention 75
ECT see electroconvulsive therapy
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
genetic testing
adult review 96
child 66
fragile X syndrome 305
genitourinary disorders 105
cerebral palsy 275
genome-wide microarray 66
gestures 22
GMFCS see Gross Motor Function
Classication System
GORD see gastro-oesophageal
reux disease
GP see general practitioner
Grifths Mental Development
Scales 65
Gross Motor Function
Classication System 268
growth hormone 329
guardian for adult 43
gum disease 242
gynaecological disorders 137
H
hallucinations 185
health care 6
adolescent 8186
checklist (table) 81
adult 9599
checklist (table) 97
child 76
checklist, Down syndrome
(table) 292
key principles 4
men 1427
older people 11525
oral 2403
preventive 1457
older people 114
women 136
women 13041
health record, personal 34
hearing
adult 100
older people 116
child 76
Down syndrome 288
Helicobacter pylori 104
hernia, inguinal 106
fragile X syndrome 30113
management 307
presentation
full mutation 302
premutation 304
resources 312
strengths of people with syndrome 311
testing 305
fragile X tremor ataxia syndrome 304
frailty 113
functional decline 120
cerebral palsy 280
Down syndrome 290
differential diagnosis (table) 121
FXPOI see fragile X
premature ovarian insufciency
FXTAS see fragile X
tremor ataxia syndrome
G
gastro-oesophageal reux
disease 103
dental erosion 242
gastrointestinal disorders 102
cerebral palsy 274
Down syndrome 286
generalised anxiety disorder 179
general practitioner
advocacy 1014
consultation 2937
case example 36
communication 17
history taking 31
information needed (box) 33
investigations 35
legal concerns 3849
medications 35
physical examination 34
reception and booking 29
role in health care 6
adolescent 79
adult 96
autism spectrum disorder 262
cerebral palsy 270
child 77
dysphagia 233
older people 112
sex education 244
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
lithium
aggression 172
agitation 173
bipolar disorder 203
lng IUS see intrauterine contraceptive
device (levonorgestrel-releasing)
lower urinary tract symptoms (men)
106
M
Makaton see signs, word
mania, acute
management 202
masturbation 245
medication 35
review 146
older people 115
medroxyprogesterone acetate,
depot see depot
medroxyprogesterone acetate
men with developmental
disability
health care 1427
androgen deciency 142
cryptorchidism 143
delayed puberty 142
erectile dysfunction 144
inguinal hernia 106
testicular surveillance 143
menopause 141
menstrual
disorders 137
education 131
suppression 138
mental health see psychiatric
disorders
microarray, genome-wide 66
mineral deciency 228
Mini-Mental State Examination 120
mixed episodes 183
MMSE see Mini-Mental
State Examination
mood disorders
assessment 180
management 198
homosexuality 247
hysterectomy 140
I
ICD-10 175
ICF see International Classication of
Functioning, Disability and Health
immunisation 146
implant, etonogestrel 135
incontinence, urinary
adult 105
older people 118
informing parents of childs
disability 506
childs age at diagnosis
birth 53
later in life 55
general principles 50
inguinal hernia 106
intellectual disability
denition 2
International Classication of
Functioning, Disability and Health 3
intrauterine contraceptive device
(levonorgestrel-releasing) 135
IUCD see intrauterine contraceptive
device (levonorgestrel-releasing)
L
least restrictive alternative 5
legal concerns 3849
abuse 44
advance health directives 46
decision-making for
adults with impaired capacity 39
children 38
discrimination 45
duty of care 45
enduring guardianships and
powers of attorney 46
resources (contact information) 4749
sexual offending behaviour 46
Lennox Gastaut syndrome
indicators (box) 213
life expectancy
Down syndrome 283
intellectual disability 4
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
oral contraceptive pill 134
antiepileptic drugs 133, 134
menstrual suppression 139
oral health 2403
cerebral palsy 273
dental
caries 241
erosion 242
malocclusion 242
dysphagia 236
periodontal disease 242
resources 243
tooth cleaning 240
osteoarthritis
older people 124
osteomalacia 108
osteoporosis 107
Down syndrome 287
older people 124
progestins (long-term) 139
overweight see obesity
P
panic disorder 179
Papanicolaou (Pap) smear 136
parents
approach during childs
assessment 63
informing of childs disability 507
legal concerns 38
support groups 74
additional information 35563
Parents Evaluation of
Developmental Status 578
Parkinsons disease 119
PDDNOS see pervasive developmental
disorder not otherwise specied
PEDS see Parents Evaluation of
Developmental Status
periodontal disease 242
pervasive developmental
disorder not otherwise specied 259
phobic disorders 180
physical examination 345
Prader-Willi syndrome 32637
biopsychosocial concerns 333
musculoskeletal disorders 110
cerebral palsy 276
Down syndrome 287
older people 124
N
neurobromatosis type 1 31420
cause 315
characteristics 315
diagnosis 315
management 317
resources 320
NF1 see neurobromatosis type 1
Noonan syndrome 3215
cause 321
characteristics 322
diagnosis 322
management 324
normalisation 4
nutritional disorders 2209
celebral palsy 275
deciencies, vitamin and mineral 228
overweight or obesity 225
Prader-Willi syndrome 330
underweight 221
enteral nutrition 225, 237
weight assessment 221
O
obesity 225
Prader-Willi syndrome 330
obsessive compulsive disorder 180
older people with
developmental disability 11229
cerebral palsy 280
clinical assessment 112
Down syndrome 290
health concerns 11525
common conditions (box) 115
mental health 11923
skin and temperature
homeostasis 1245
swallowing ability 118
living
at home 125
in aged care facilities 127
preventive health 114
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
psychiatric disorders (cont.)
older people 119
risk factors (table) 176
psychological therapies see therapy,
psychological
psychosis see schizophrenia and
related psychoses
psychotherapy see also therapy,
psychological
psychodynamic 190
supportive 190
psychotropic drugs
investigations before starting
treatment 191
key points (box) 192
precautions in prescribing 193
withdrawing treatment 194
puberty 84
associated disorders (table) 84
delayed
boys 142
girls 131
R
reception and booking
procedures 29
resources, disability 35563
Commonwealth 355
local government 360
other
associations 362
disability aids and equipment 360
genetics information 361
legal 47
rare diseases 362
transport 363
states and territories
Australian Capital Territory 356
New South Wales 356
Northern Territory 357
Queensland 358
South Australia 358
Tasmania 358
Victoria 359
Western Australia 360
Prader-Willi syndrome (cont.)
health problems 32833
growth hormone 329
obesity 330
resources 335
pregnancy 140
Down syndrome 290
preventive health care 1457
checklist (table) 979
exercise 145
immunisation 146
medication review 146
nutrition 147
older people 114
smoking 147
women 136
progestins
contraception 1336
menstrual suppression 139
psychiatric disorders
adolescent 85
assessment 17586
anxiety and associated
disorders 179
collateral information (box) 178
diagnostic criteria 175
history taking (box) 179
investigations (box) 177
mood disorders 180
depression features (table) 182
hypomania and mania
features
(table) 184
schizophrenia and related
psychoses 184
management 187209
anxiety and associated
disorders 194
key points 187
mood disorders
bipolar disorder 202
depression 198
psychological interventions 188
psychotropic drug use 191
key points (box) 192
schizophrenia and related
psychoses 206
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
respiratory disorders
adult 101
cerebral palsy 273
Down syndrome 288
Prader-Willi syndrome 329
Rett syndrome 33843
cause 338
characteristics 339
diagnosis 338
management 341
resources 342
S
saliva control 236
schizophrenia and related
psychoses
assessment 184
management 206
acute psychotic episode 206
maintenance therapy 208
school
adolescent 91
choice of 76
fragile X syndrome 310
leaving 92
seizures see epilepsy
selective serotonin reuptake
inhibitors
aggression 171
agitation 173
anxiety and associated disorders 197
depression 200
self-injury 169
sexual behaviour
inappropriate 245
offending 46
sexual expression 2449
adolescent 88
contraception 247
homosexuality 247
inappropriate behaviour 245
masturbation 245
preventive health 248
resources 248
signs, word 23
skin
cerebral palsy 273
neurobromatosis 315
older people 1245
tuberous sclerosis 346
smoking 147
social role valorisation 4
SSRIs see selective serotonin
reuptake inhibitors
Stanford Binet Intelligence Scales 65
status epilepticus 219
stereotyped behaviour 170
sterilisation (female) 135
substitute decision-maker 39
sudden unexpected death
in epilepsy 214, 215
SUDEP see sudden unexpected
death in epilepsy
support
contact information 35563
equipment 74
nancial 73
groups 74
support person (denition) 2
T
T-ACE see Alcohol Use Disorders
Identication Test
tardive dyskinesia
(psychosis therapy) 208
TEACCH program 261
teenagers see adolescents with
developmental disability
testes
surveillance 143
undescended 143
therapy, psychological 188
anxiety 195
depression 199
thought disorder 185
thyroid disorders 109
Down syndrome, monitoring in
(table) 98
hypothyroidism in older people 123
tooth care 2403
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Index
tuberous sclerosis 3449
cause 344
characteristics 346
diagnosis (table) 345
management 348
resources 349
U
unaided communication
systems 22
underweight 221
enteral nutrition 225, 237
undescended testes 143
urinary
incontinence 105
older people 118
tract
infection 105
lower, symptoms in males 106
V
valorisation, social role 4
Vineland Adaptive Behaviour
Scale 120
vision
adult 100
older people 116
child 76
Down syndrome 288
vitamin deciency 228
W
Wechsler Intelligence Scales 65
weight
assessment 221
over- 225
under- 221
Williams syndrome 3504
cause 350
characteristics 351
diagnosis 350
management 353
resources 354
women with developmental
disability
health care 13041
contraception 133
women with developmental
disability (cont.)
health care (cont.)
gynaecological disorders 137
menopause 141
menstrual
disorders 137
education 131
suppression 138
pregnancy 140
Down syndrome 290
preventive health 136
puberty, time of onset 131
word signs see signs, word
Back Index Contents
M
a
n
a
g
e
m
e
n
t
G
u
i
d
e
l
i
n
e
s
:
D
e
v
e
l
o
p
m
e
n
t
a
l
D
i
s
a
b
i
l
i
t
y
Request for comment on guidelines
Request for comment
on guidelines
Management Guidelines: Developmental Disability,
version 3, 2012
Help us to help you
We value your comments on the content of this ebook, its layout
and how easy it is to use. Well consider them when preparing
the next version.
Please email feedback@tg.org.au.
If you prefer contacting Terapeutic Guidelines Limited by
telephone, call 1800 061 260 (within Australia).
Back Index Contents